Technological University Dublin

ARROW@TU Dublin
Doctoral

Science

2018

Formulation and in Vitro Characterisation of Fungal Chitosan
Nanoparticles Coated With Zein for Improved Oral Delivery of
Selenoamino Acids
Giuliana Vozza
Technological University Dublin, giuliana.vozza@tudublin.ie

Follow this and additional works at: https://arrow.tudublin.ie/sciendoc
Part of the Environmental Health Commons, and the Food Science Commons

Recommended Citation
Vozza, G. (2018) Formulation and in vitro characterisation of fungal chitosan nanoparticles coated with
zein for improved oral delivery of selenoamino acids. Doctoral theses, DIT, 2018. doi.org/10.21427/414kch16

This Theses, Ph.D is brought to you for free and open
access by the Science at ARROW@TU Dublin. It has been
accepted for inclusion in Doctoral by an authorized
administrator of ARROW@TU Dublin. For more
information, please contact arrow.admin@tudublin.ie,
aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Formulation and in vitro characterisation
of fungal chitosan nanoparticles coated
with zein for improved oral delivery of
selenoamino acids
Giuliana Vozza BSc (Hons)
A thesis submitted to the Dublin Institute of Technology for the
Award of Doctor of Philosophy (PhD)
Supervisors:
Prof. Jésus Frías, Dr Sinéad Ryan and Prof. Hugh J Byrne

FOCAS Research Institute
School of Food Science and Environmental Health
Dublin Institute of Technology

Submission Date: May 2018

Declaration

I certify that this thesis which I now submit for examination for the award Doctor of
Philosophy (PhD), is entirely my own work and has not been taken from the work of
others, save and to the extent that such work has been cited and acknowledged within the
text of my work.
This thesis was prepared according to the regulations for postgraduate study by research
of the Dublin Institute of Technology and has not been submitted in whole or in part for
another award in any other third level institution. The work reported on in this thesis
conforms to the principles and requirements of the DIT's guidelines for ethics in research.
DIT has permission to keep, lend or copy this thesis in whole or in part, on condition that
any such use of the material of the thesis be duly acknowledged.

Candidate Signature _________________________________Date _______________

i

Abstract

Selenium (Se) is an essential micronutrient in both human and animal nutrition that exists
in a wide array of different forms, both organic and inorganic. Selenoamino acids
(SeAAs),

such

as

selenocystine

(SeCys2),

selenomethionine

(SeMet),

and

methylselenocysteine (MSC) are organic species with reported health benefits of cancer
prevention, increased fertility and improved immunological status. However,
supplementation of SeAAs can be challenging, due to their reported narrow therapeutic
range of indices, low bioavailability and increased susceptibility to oxidation. To address
this, SeAAs were encapsulated into nanoparticles (NPs) to lower their toxicity profiles in
comparison to their native form, in addition to offering them protection from the harsh
conditions present in the gastrointestinal tract. The ionotropic gelation method was
employed to produce NPs, using the cationic polyelectrolyte chitosan (Cs) crosslinked
with the polyanion tripolyphosphate (TPP). The NP physicochemical properties were
optimised using a Design of Experiments (DoE) and mathematical modelling approach.
First, a central composite design (CCD) was used to identify a feasible region in which
unloaded NPs with target properties for oral delivery (size~300 nm, PDI < 0.5 and ZP >
30 mV) could be achieved, indicating that optimum conditions to be 6:1 mass ratios of
Cs:TPP. Following that, SeMet was used as a prototype encapsulant and a second DoE
approach was employed, namely a Box Behnken design (BBD). In that study, Cs:TPP
ratio, Cs solvent pH, and drug load concentration were independently varied and the
dependent variables assessed were encapsulation efficiency (EE%), particle size, PDI and
ZP. The BBD highlighted the optimum conditions for NP production, although EE%
remained relatively low (≈40 %). By varying the pH of the ionotropic solution
components and coating the NPs with zein (a prolamine rich protein), EE% was doubled
ii

(≈80 %), diameters increased from 187±58nm to 377±47nm and PDI and ZP values were
maintained. The formulation performed well indicating good suitability for oral delivery,
in terms of stability, cytotoxicity (intestinal and liver cell lines) and release profiles, as
determined by in vitro techniques. The models generated from the BBD were then applied
to the SeAAs, SeCys2 and MSC and further refinement of the zein coating was
investigated. NPs with similar physicochemical properties to those of SeMet loaded Cs
were produced, indicating the strength of the DoE models and their usefulness in
formulation design. These NPs also performed well in in vitro assessments for stability
and release profiles. However, SeCys2 showed cytotoxicity to liver cell lines which was
reduced after encapsulation within the NP matrix, inferring its protective effects and thus
use as a delivery system.
Chitin was extracted from the cultivated mushroom Agaricus bisporus in order to derive
fungal Cs (fCs) with equivalent physicochemical properties to the commercial Cs
(CL113) that had been employed for NP production. fCs with comparable properties to
CL113 were produced, although fCs possessed a higher molecular weight (MW) (180±19
vs 110±4 kDa). Trimethyl chitosan was then synthesised from the fCs and assessed for
permeation enhancing capabilities on intestinal cell monolayer models, which implicated
its potential application as a permeation enhancer.
fCs was used for the production of synthetic SeCys2 loaded NPs using the knowledge
gained from the previously developed DoE models and in vitro methodologies. Lastly, a
preliminary study to assess the feasibility of Irish mushrooms providing Se species for
supplementation purposes was conducted, implicating them as a viable source for SeCys2.
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1 INTRODUCTION

1

1.1 Background

Drug discovery and development involves highly challenging, laborious, and
expensive processes. On average, it can take 15 years, with an estimated cost of US
$802 million, for the development of a new drug, from bench to bedside, which is
markedly increasing at an annual rate of 7.4 % above general price inflation (Cousin
et al., 2016). Technological advances such as quantitative structure activity
relationships (QSAR) and high throughput screening (HTS) have assisted in the
identification, synthesis and activity assessment of new bioactive (BA) compounds,
more rapidly than that of conventional discovery (Park, 2014). However, in spite of
QSAR and HTS techniques, most drugs fail to achieve favourable clinical outcomes
in the clinical phase, due to their inability to reach the target site of action (Park et al.,
2010, Estanqueiro et al., 2015). Although BAs may show high potency for target sites
in vitro, the oral delivery of such compounds in vivo can often raise a challenge, for
example:
•

Stability in the gastrointestinal tract (GIT) -reducing bio-accessibility

•

Low permeability through intestinal epithelial and/or transporter restrictions

•

Instability under processing conditions (temperature, oxygen, light)

•

Degradation in the GIT by pH, enzymes or presence of other nutrients

all of which may limit the activity and potential health benefits of nutraceutical
molecules (Agrawal et al., 2014, Gleeson, Ryan and Brayden, 2016).
Targeted drug delivery systems, that release drugs or BA agents at the desired site of
action, are an effective approach to overcome these critical issues, as they can improve
therapeutic efficacy through the modulation of pharmacokinetic and biodistribution
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fate (Hagens et al., 2007). In this context, nanoparticle (NP) delivery systems have
been investigated, as they have been shown to be more biologically active, due to their
enhanced surface area per mass compared with larger-sized particles of the same
chemistry (Oberdörster et al., 2005). By using NPs as a drug delivery vehicle, it might
be possible to enhance a range of characteristics for a given BA, such as increased
protection ensuring stability and better oral uptake (Nair et al., 2010).
The gold standard for BA delivery is considered the oral route, due to ease of dosing,
patient acceptance and compliance. Because of this, encapsulation systems now are
of the upmost importance (Benshitrit et al., 2012). Recently, consumers, industry and
researchers alike are recognising the potential of BA compounds naturally present in
common food stuffs (Vattem and Maitin, 2016). There is a consumer perception on
the need to reduce animal testing for everyday products and dietary supplements,
favouring “naturally derived” BAs (Vanhonacker and Verbeke, 2014). Chitosan (Cs),
a biocompatible, mucopolysaccharide, typically derived from crustaceans, has been
investigated as a system for cargo delivery to the colon, due to its capacity to protect
therapeutic agents from the hostile conditions of the upper gastrointestinal tract
(Benshitrit et al., 2012) and to facilitate release of entrapped agents (Chen et al.,
2013), whilst its glycosidic linkages undergo degradation by colonic microflora
(Amidon, Brown and Dave, 2015). Improving the bioavailability of drugs through NP
drug delivery systems is possible using Cs prepared either as a hydrogel or as NPs,
whereby its polycationic amino groups interact with the drug’s anionic groups, in the
presence of an anionic crosslinker (Janes, Calvo and Alonso, 2001). However,
because of its high solubility in acid gastric fluids (such as the stomach environment
(pH 1.2)), Cs has limited suitability in colonic targeting of drugs, sometimes resulting
in a burst release of the drug in this environment (Garapati et al., 2015). To alleviate
3

this problem, the coating of Cs NPs has been proposed, whereby an improved
controlled release of encapsulated BA can be achieved, as the coating serves as a rate
limiting barrier (Katouzian and Jafari, 2016). It is worth noting however, that the
release from these NPs is strongly dependent on the chemical nature and physical
structure of the coating material and its interaction with Cs. Zein, a prolamine rich
protein derived from maize, has been employed for the formulation and coating of
Cs:NP oral delivery systems, due to its ability to increase the encapsulation efficiency
(EE%) of BAs and to improve their controlled release in the GIT (Luo et al., 2010;
Luo and Wang, 2014; Paliwal and Palakurthi, 2014). This coating strategy harnesses
both the protein (zein) and polysaccharide (Cs) properties in a NP delivery system in
which a broader range of physical, chemical and colloidal stability can be achieved
(Benshitrit et al., 2012).
Selenium (Se) is an essential micronutrient that exists in different forms, both
inorganic and organic and exerts its biological functions through >25 selenoproteins
(Xia et al., 2005). Nutritional deficiency of the element decreases the expression of
selenoproteins and thereby impairs selenium’s biological functions. Selenoamino
acids (SeAAs) have attracted attention as Se supplements due to their potential
immune enhancing, fertility improving and anti-cancer properties (El-Bayoumy,
Sinha and Richie Jr, 2015; Kamwesiga et al., 2015; Shanmugam et al., 2015).
However, Se from A. bisporus has been reported to have poor bioavailability (Thiry
et al., 2012), which is further reduced upon cooking (Khanam and Platel, 2016). As
such, there is substantial interest in developing an oral formulation of Se, although,
due to its susceptibility to oxidation, this has not proved possible to date.
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As a consequence of depleting finite resources, food shortages, and climate change,
the concept of a circular economy and the importance of obtaining maximum value
from organic resources have been highlighted (Walsh et al., 2017). A. bisporus offers
a renewable source for Cs which is more sustainable than that of crustacean sources
and can potentially contribute to the creation of a circular economy for the mushroom
industry (Kaur et al., 2014). More specifically, estimations of by-products produced
globally from industrial mushroom cultivation per annum have been reported to be in
excess of 50,000 tonnes (Wu et al., 2004) and as such may offer an opportunity to
acquire high purity products such as fungal-derived Cs (fCs) and SeAAs. Within this
sustainability view-point, fCs, due to the controlled environments in which the
mushrooms are cultivated may produce Cs with greater reproducible properties than
those derived from crustaceans (Muzzarelli et al., 2012). Whereas Se-fortified A.
bisporus have demonstrated the ability to assimilate inorganic Se (such as sodium
selenite) from the growth substrate and convert it to organic Se, such as SeAAs
(Maseko et al., 2013).
This project aims to develop a robust formulation for SeAA loaded fCs NPs intended
for oral delivery, using a systematic approach to design and extensive in vitro analysis.
Additionally, the extraction and characterisation of SeAAs from Se supplemented A.
bisporus will be conducted with the objective of demonstrating the feasibility of
obtaining these compounds for supplement production.

1.2 Delivery of bioactive peptides

Bioactive peptides and proteins have garnered much interest in the nutraceutical and
pharmaceutical industry over the last decade. This interest has been attributed to
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several factors such as: selectivity (Arkin, 2005; Soudy et al., 2016), effective and
potent actions (Frokjaer and Otzen, 2005; Elzoghby, Samy and Elgindy, 2012) and
reduced side effects (Morishita and Peppas, 2006). Ophthalmic, dermatological and
oral are delivery routes that have been investigated for peptides and proteins over the
last few years (Van Der Walle, 2011), the latter typically identified as the most
convenient and desired mode of delivery, due to its ease of administration and reported
patient compliance, particularly when repeat administration is required (Mahato et al.,
2003).
The oral delivery of peptides and proteins has proven challenging to date, due to their
susceptibility to enzymatic degradation (Woodley, 1993) and poor intestinal
absorption across epithelial cells found in the GIT (Hamman, Enslin and Kotzé, 2005).
Several approaches to overcoming these limitations have been investigated, for
example: enteric coatings (Toorisaka et al., 2005), permeation enhancers (Karavasili
et al., 2015), protease inhibitors (Chuang et al., 2015) and the employment of carrier
systems (Jain et al., 2013). Amongst these, the latter has shown particular promise in
the form of NP delivery systems, particularly with regards to polymers that possess
mucoadhesive properties and have the ability to protect molecules from the harsh
conditions that are found in the GIT (Ensign, Cone and Hanes, 2012). Furthermore,
NPs have been shown to possess the ability to be absorbed into mucosal tissue,
although this has also been shown to be related to the size and surface charge, manifest
as zeta potential (ZP), of the NP. In terms of oral delivery, optimum sizes for NPs
have been reported as 100 – 500 nm, with ZP of approximately +30 mV being reported
as a good indication of NP dispersibility (He et al., 2010). Additionally, the
polydispersity index (PDI) of a NP suspension should be as close to zero as possible,
a value of 0.5 generally accepted as the upper limit for PDI (Gaumet et al., 2008).
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1.3 Selenium

Selenium is a chemical element with the symbol Se and atomic number 34. Many
health benefits of Se, such as cancer prevention (Abdulah et al., 2005; Nie et al., 2016)
increased immunological status (Narayan et al., 2015) and increased fertility
(Aréchiga et al., 1998; Shanmugam et al., 2015) have been identified in recent years.
However, as a result of diverse geological conditions, the Se status of humans, plants
and animals can differ significantly. Most rock types contain very low concentrations
of Se, although high concentrations are associated with some phosphatic rocks,
organic rich black shales, coals and sulphide mineralisation, which has led to more Se
deficient soils than there are seleniferous ones, worldwide (Khanal and Knight, 2010).
Soils containing > 0.5 mg Se kg-1 are considered to be seleniferous and the forages
produced on such soils absorb Se to levels in excess of what is permissible for animal
consumption (Fordyce, 2013). In seleniferous parts of the world, such as parts of
Ireland, Canada, western USA and some zones in China, adverse effects on Se toxicity
in livestock have been reported (Navarro-Alarcon and López-Martınez, 2000).
The physical and chemical form of an element is referred to as speciation, meaning
its oxidation state, stoichiometry or possible presence of various ligands (Reeder,
Schoonen and Lanzirotti, 2006). Selenium is typically present as Se2-, Se2+, Se4+, or
Se6+, associated with organic and inorganic species. The oxyanions selenite (SeO32or Se(IV)) and selenate (SeO42- or Se(VI)) are some of the best-known inorganic
species of Se, while selenomethionine (SeMet), selenocystine (SeCys2) and
methylselenocysteine (MSC) are some of the best-known organic Se species (Uden et
al., 2004). In amino acids, when an atom of Se replaces the atom of sulphur (S), such
as methionine and cysteine, Se analogues are produced and referred to as selenoamino
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acids (SeAAs). As the bioactivity of Se is highly dependent on its chemical form
(Rayman, 2000), it is an important consideration when proposing a health supplement.
Organic forms of Se, such as SeMet, SeCys2 and MSC, have been found to be more
bioavailable than inorganic forms (Zeng et al., 2011) and several human health studies
have shown their antioxidant and anticancer activity (Abdulah et al., 2005; Thiry et
al., 2012). Health benefits of MSC and SeCys2 have been linked to the body’s
endogenous antioxidant defence system, protecting cellular components such as cell
membranes, lipids, lipoproteins and DNA from oxidative damage by free radicals,
reactive oxygen and reactive nitrogen species (Ponnampalam et al., 2009). As
oxidative damage is linked to the development of cardiovascular and
neurodegenerative diseases as well as cancers, several experimental in vivo studies,
on the effects of administration of Se compounds, have been undertaken (Valko et al.,
2007; Lobo et al., 2010; de Souza et al., 2014). For example, SeMet may have some
potential in degenerative disease by decreasing oxidative stress of small molecule
antioxidants used as a buffer for free radicals in brain tissue (Song et al., 2014; Reddy
et al., 2017), SeCys2 has been shown to reduce tobacco-derived nitrosamine-induced
lung tumour growth and enhance hepatic chemoprotective enzyme activities in mice
(Fan et al., 2013), whereas MSC has been shown to offer selective protection against
organ specific toxicity induced by clinically active antitumor agents, cisplatin,
oxaliplatin, and irinotecan in rat models (Cao et al., 2014). A number of benefits
regarding oncology treatments due the modulation of the therapeutic efficacy and
selectivity of anticancer drugs has been reported for these SeAAs also (Evans,
Khairuddin and Jameson, 2017).
Although essential, Se possesses a low therapeutic index, meaning that there is a fine
line between beneficial and toxic doses. Generally, organic Se shows a greater degree
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of bioavailability than the inorganic forms, as well as a higher threshold for toxicity
(Amoako, Uden and Tyson, 2009). For humans and animals, increased aging,
increased risk of cardiovascular disease and an increased risk of other degenerative
diseases are among the consequences of Se intake below the daily recommended
amount of 42 µg per day (Levander, 1991). On the other hand, hair loss, nail
brittleness, gastrointestinal disturbances, garlic breath, skin rash, irritability, fatigue
and nervous system abnormalities are all side effects of a Se intake above the tolerable
upper intake level of 400 µg per day (www.nap.edu). Despite the associated health
benefits, Se intake in Ireland is remarkably low, whereby, nearly 50% of females and
20% of males aged between 18 – 64 years fail to meet the average recommended
requirement (ARR) of 40 µg per day (Murphy and Cashman, 2002). This low Se
intake in the Irish population has been attributed to the drop in imports of high-protein
wheat for bread-making flour from North America and Canada (Barclay and
Macpherson, 1992), which are Se-rich in comparison to Irish flour varieties (Murphy
and Cashman, 2001). Suffice to say, the narrow safety margin and form of Se must be
carefully considered when designing an optimal Se supplement to ensure high
bioactivity and low toxicity impact (Whanger, 2002)
SeAAs possess lower bond energies for C-Se and Se-Se than those of C-S and S-S
(C-S 272 kJ mol-1 , S-S 240 kJ mol-1 , C-Se 244 kJ mol-1 , Se-Se 172 kJ mol-1 )
respectively (Kildahl, 1995). As such, delivery of these compounds can be
challenging, due to their distinctive electronegativity and atomic radius (i.e. larger
radius and less E- than S), which makes oxidation easier vs their S analogue
counterparts (Xu, Cao and Zhang, 2013). By using NPs as a drug delivery vehicle, it
is possible to provide or enhance a wide range of optimal characteristics for a given
BA compound, including: increased stability (Nair et al., 2010), reduction in
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dose/toxicity of free drug to non-target organs in the body whilst maintaining
therapeutic effects (De Jong and Borm, 2008), incorporation of both hydrophobic and
hydrophilic substances (Ron et al., 2010) and suitability for the various routes of
administration such as oral, pulmonary and topical applications (Helson, 2013).
With this in mind, an opportunity arises to improve human and animal health by the
provision of SeAAs through use of nanoparticulate delivery systems, as this strategy
can potentially improve the bioavailability, decrease toxicity and confer protection
from oxidative environments such found in the GIT.

1.4 Chitosan

Cs is a well-known, positively charged polyelectrolyte that has been extensively
investigated for NP delivery systems (Kwon, 2008; Kleine-Brueggeney et al., 2015).
This interest has been attributed to its high bio-compatibility, bio-degradability and
muco-adhesive properties (Pillai, Paul and Sharma, 2009). Furthermore, it has been
reported that Cs has the ability to transiently open the tight junctions found between
epithelial cells (Dodane, Khan and Merwin, 1999; Smith, Wood and Dornish, 2004)
which can in turn increase absorption of a given bioactive.
Invertebrates (Crustacean shells and insect cuticles) and fungi are considered the
predominant sources of Cs, the latter origin garnering much interest over the last
decade (Muzzarelli et al., 2012). This is due to the fact that mushroom bodies are
produced within a highly controlled production environment, which typically results
in Cs with highly reproducible physicochemical properties being manufactured on a
batch to batch basis (Plapied et al., 2010). Additionally, 50,000 tonnes of mushroom
waste are produced annually (Wu et al., 2004) by the commercial industry and it is
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considered a potential way of utilising by-products produced from the cultivation
process. In contrast, animal derived Cs suffers from seasonal shortages, heavy metal
contamination and inconsistent physicochemical characteristics (also attributed to
seasonal circumstances) on a batch to batch basis (Brine and Austin, 1981; Plapied et
al., 2010). In Ireland, the mushroom industry is the largest horticultural sector,
employing over 3,500 people, with a farm gate value of €136 million, of which
approximately 80% is exported to the UK (www.teagasc.ie). A. bisporus is the most
commonly consumed cultivated mushroom in Ireland, consisting of the three main
stages of maturity (Figure 1.1) (www.bordbia.ie). The Irish Food Board, Bord Bia,
have indicated that the UK market for mushrooms is growing steadily in recent years
at about 2% per year, with Button/Closed cup mushrooms holding the largest share of
the market, followed by Flat/Breakfast mushrooms. However, during white
mushroom (A. bisporus) cultivation, high quantities of by-products are generated, as
between 5 and 20% of fruiting bodies are discarded due to misshaped cups and stalks
that do not meet the specifications set by retailers (Wu et al., 2004). For example, in
the USA alone, mushroom production results in nearly 50,000 metric tons of
mushroom waste material per year, with no suitable commercial application
(Philibert, Lee and Fabien, 2017).

Figure 1.1 The different types of A. bisporus (pictures acquired from
www.monaghan-mushrooms.com).
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Production of Cs, predominately by acid and alkaline hydrolysis, is relatively straightforward, and is typically sourced from shellfish or mushroom waste. Depending on
the source and treatment method employed for Cs manufacture, the physicochemical
properties, such as the degree of deacetylation (DDA%) (which is defined in terms of
the percentage of primary amino groups present in the polymer backbone) and
molecular weight (MW) can range from 60-100% and 10-1000 kDa, respectively, and
are important characteristics to consider when deciding on the application (Ravi
Kumar, 2000). For example, DDA% and MW of the Cs have been shown to directly
influence the size, zeta potential and colloidal stability of NPs in biological media
(Kleine-Brueggeney et al., 2015). Generally, if the Cs is intended for use as a drug
delivery vehicle, a medium molecular weight (110-225kDa) with high DDA% (≥80%)
is considered ideal (Bowman and Leong, 2006).
PROTASAN™ CL113, a commercial Cs, derived from crustacean shells and
provided as a hydrochloride salt, has been previously promoted for its ability to
encapsulate and deliver food derived BAs such as Retinyl Palmitate (a vitamin A
isomer) and possesses the following physicochemical properties: MW of 110-150
kDa, DDA% ≥80 % and minimal metal contamination (Fernández-Gutiérrez et al.,
2015). It has also been used to slow and control the drug release profile of Triclosan
(an efficient anti-malarial drug) (Maestrelli, Mura and Alonso, 2004) and salmon
calcitonin (a potential osteoarthritic drug) (Ryan et al., 2013) owing to both its known
mucoadhesive and enhancer properties and its demonstrated effectiveness in
optimally controlling drug release rate. To date, much of the research involving the
employment of Cs as a nanocarrier, has been of animal origin (crustaceans) (Hamed,
Özogul and Regenstein, 2016). However, high batch to batch variability of Cs from
these sources have been reported, resulting in formulations with variable
12

physicochemical properties and with potential for inducing allergic responses (Smets
and Rüdelsheim, 2018). Hence, an alternative source of Cs, for example edible A.
bisporus mushrooms, could be well placed for pharmaceutical applications,
particularly if available with batch to batch reproducibility and high control over its
molecular characteristics, such as molecular weight and DDA%.

1.5 Ionotropic Gelation

A promising tool in the development of bio-compatible NP drug delivery systems is
ionotropic gelation (IG). IG is a process whereby polyelectrolytes (of opposite
charges) form inter- and intra- molecular cross-linkages mediated by the anionic
molecules, in the presence of BAs, to form a hydrogel mesh structure with the
bioactive encapsulated within (Calvo et al., 1997; Janes, Calvo and Alonso, 2001). It
has also gained popularity due to the eco-friendly nature of the process, whereby only
mildly acidic and basic solutions are required, in contrast to the expensive and toxic
organic solvents which have been previously employed in delivery systems (Sailaja,
Amareshwar and Chakravarty, 2011). The primary amino groups (-NH2) of Cs are
predominantly protonated at acidic pH (-NH3+), and it is this characteristic of Cs that
provides it with the ability to form stable complexes when crosslinked with anionic
polyelectrolytes, such as tripolyphosphate (TPP) (Janes, Calvo and Alonso, 2001). IG
is considered a suitable technique for the development of NP vehicles for the delivery
of sensitive drugs, as, once encapsulated within the hydrogel mesh work, their
structural integrity has been shown to persist during release (Hennink and Van
Nostrum, 2012). With regards to the optimum size of NPs, 100-300 nm in diameter
has been found to be enough for a high payload, while smaller than 100 nm may pass
through the GIT (Mohanraj and Chen, 2007).
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1.6 Trimethyl chitosan as a permeation enhancer

Trimethyl chitosan (TMC), a derivative of Cs in which the primary amine has been
quarternised with methyl groups, has shown promising results as a permeation
enhancer (PE), due to its intrinsic properties, including mucoadhesion and the ability
to transiently open the tight junctions of the intestinal barrier, which can help facilitate
both transcellular and paracellular transport of macromolecules (Chen et al., 2013).
The transcellular route is both active and passive and is based on the activity of
transmembrane pumps, channels, and carriers expressed in a polarised fashion. On the
other hand, paracellular transport is only passive and driven by the gradients
secondary to transcellular transport mechanisms (Figure 1.2) (Gleeson, Ryan and
Brayden, 2016). The major barrier in the paracellular route is the tight junction, which
is regulated and varies among epithelia in tightness and ion selectivity (Ghishan and
Kiela, 2014).

Figure 1.2 A schematic representation of Paracellular and Transcellular transport
adapted from (Gleeson, Ryan and Brayden, 2016).

This mucoadhesive feature of TMC may aid in its utility as a potential permeation
enhancer for assisting the delivery of drugs to mucosal tissues, such as the GIT, by
prolonging residence time through its ability to hold a positive charge at neutral pH.
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1.7 Design of Experiments

In the food industry, Design of Experiments (DoE) has become standard practice for
research and development (R&D) of improved manufacturing processes (Carneiro
and Azevedo, 2017). Employing such methodologies, it is possible to assess and select
the most appropriate materials and equipment from available alternatives and
subsequently identify variables for further study that can ensure a desired response
outcome. Additionally, if more than two variables are under study, their interaction
effects (if applicable) can also be evaluated.
Typically, in the early stages of industrial R&D, the main focus is on screening
designs, whereby extreme upper and lower bound level setting combinations of
process variables are employed, to identify their potential effect on a given response
(Politis et al., 2017). In the later stages of this work, the goal shifts from screening of
variables, to product and process optimisation, through use of statistical experiment
designs commonly termed "response surface methodologies (RSM)."
In addition to trialling experiments with one or more variables at extreme levels, the
benefits of RSM, are that midpoints of the study range are also included, allowing for
information to be harnessed on direct, interactive and curvilinear variable effects.
There are many variations of RSM. In this work, the main focus will be on two
commonly employed designs the central composite design (CCD) and Box Behnken
design (BBD) (discussed at length in Chapter 3, Section 3.1)) that were used to
optimise unloaded and Se loaded Cs:TPP NPs.
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1.8 Project Aims and Objectives

The aim of this research is to produce oral formulations of nutraceutical SeAAs using
ingredients from the food industry.
To achieve this aim, the following objectives have been set:
1. To assess the method of ionic gelation between the Cs and TPP, for production of
NPs with physicochemical properties suitable for oral delivery using CCD
optimisation.
2. To employ the SeAA, SeMet as a prototype encapsulant and identify the main
variables which affect EE%, particle size, PDI and ZP by use of BBD optimisation
and coating with the prolamine rich protein zein
3. To test the strength of the developed DoE models by encapsulating SeAAs with
comparable ionisable groups (SeCys2 and MSC) with evaluation of oral
compatibility in terms of stability, cytotoxicity and release profiles in vitro
4. To extract chitin from the edible basidiomycete mushroom A. bisporus and derive
to fCs with equivalent properties (DDA%, MW and purity) to that of an ultrapure
Cs (CL113) product, for potential use in future NP formulations
5. To chemically derive fCs to TMC and assess if it may offer potential use as a
permeation enhancer
6. To validate the strength of the developed DoE models by encapsulating synthetic
SeCys2 with the fCs produced in this work
7. To extract and characterise SeAAs in Irish mushrooms with the objective to
demonstrate the possible availability of the species for supplement production in
the Irish context.
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1.9 Thesis outline

Chapter 1 has introduced Se and its associated health benefits, alongside limitations
that can occur when designing a Se supplement. The prospects of employing Cs based
NPs for use in oral delivery of Se was introduced and the importance of NP
physicochemical properties (size, PDI and ZP) for oral delivery purposes was
highlighted. The fundamentals of ionotropic gelation were elucidated and its
employment for the development of a SeAA loaded Cs NP delivery systems was
recommended. TMC, a derivative of Cs that has shown promising results as a
permeation enhancer, was also discussed. Finally RSM, a mathematical and statistical
technique for empirical model building, was discussed.
Chapter 2 is a review chapter that was published in Nutrition - Nutrient delivery. In:
Nanotechnology in the Food Industry (Vozza et al., 2016) and gives the reader a
broader outlook on nutrient delivery through nanoparticulate systems. Briefly, it
discusses functional food and BAs in relation to nanotechnology in the food industry,
basic concepts of NPs for nutrient and food grade delivery systems, in addition to
common obstacles encountered. Attention is paid to nano systems based on
encapsulation technology using polymeric NPs, and studies detailing the delivery of
food derived nutraceuticals are presented. Key issues such as enhanced level of
nutrient absorption consequences and nanotoxicology are also considered. Lastly, the
need for labelling, regulation and recommendations for consumer acceptance of these
products is highlighted.
Chapter 3 introduces the key research methodologies employed in Chapters 4-8 and
comprises five segments. Section 3.1 details NP experimental design using RSM
techniques, specifically CCD and BBD. Section 3.2 describes the physicochemical
17

techniques employed to assess the produced NP properties (size, PDI and ZP),
morphologies and EE%, via DLS, SEM and high performance liquid chromatography
coupled with a diode array detector (HPLC-DAD). Section 3.3 details the in vitro
techniques used to evaluate the produced NPs likelihood of oral compatibility in terms
of stability, cytotoxicity and release profile. Section 3.4 describes the analytical
techniques used to assess the physicochemical properties of chitin and Cs, such as
DDA% and MW, with FTIR, NMR (1H and 13C) and Gel permeation chromatography
(GPC), in addition to transepithelial electrical resistance (TEER, Ω cm2) for
assessment of TMC as an intestinal permeation enhancer. Lastly, Section 3.5
describes the extraction methods for qualitative and quantitative Se speciation
analysis through use of HPLC-DAD.
Chapter 4 details the production of unloaded Cs:TPP NPs via ionotropic gelation. A
CCD statistical design was employed to generate a mathematical model that identified
the optimum mass ratio of Cs:TPP for NPs, with properties reported to be beneficial
for oral drug delivery. The results of the CCD identified a feasible region in which NP
target properties could be achieved as determined by DLS. Evidence for the formation
of NPs was acquired via FTIR analysis, through identification of key functional
groups on Cs and TPP and identifying their shifts in the crosslinked matrices. The
morphology of the NPs was then assessed by SEM analysis.
Chapter 5 presents a manuscript submitted to the International Journal of
Pharmaceutics (April 2018), detailing the study of SeMet, as a prototype encapsulant
for Cs:TPP NPs (Vozza et al., 2018a). A BBD statistical design was employed to
optimise the main variables that affected NP EE%, particle size, PDI and ZP. Two
further studies were then conducted to increase the EE% of SeMet within the NP
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matrix, 1) ionisation/protonation of NP formulation components and 2) The use of
zein, as a co-formulation component for coating the NPs. Physicochemical properties
of the NPs produced from the study were characterised via DLS, FTIR and SEM
analysis.

MTS

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium) studies were employed to test for potential cytotoxicity
in the human intestinal epithelium (Caco-2), and human liver hepatocellular (HepG2),
cell lines. Accelerated thermal stability of the loaded NPs was conducted to assess NP
stability under normal storage conditions. Lastly, a compartmental, simulated gastric
fluid and membrane analysis model enabled assessment the NP release profile in vitro.
Chapter 6 presents a manuscript submitted to the Journal of Food Hydrocolloids
(May 2018), detailing the encapsulation of the SeAAs, SeCys2 and MSC using the
responses estimated from the derived quadratic polynomials identified previously
with BBD (Vozza et al., 2018b). Further optimisation of the mass ratios of zein:Cs
for NP coating was investigated. In vitro evaluation of the produced NPs was then
conducted, using the previously developed methodologies, to assess the likelihood of
oral compatibility in terms of stability, cytotoxicity and release profiles. Differences
between the encapsulated SeAAs were then identified in terms of cytotoxicity profiles
and release rates by the in vitro techniques.
Chapter 7 details a manuscript submitted to the Journal of Carbohydrate Polymers
(May 2018), for the extraction of chitin and derivatisation to Cs from the edible
basidiomycete mushroom A. bisporus, using alkaline treatments coupled with
microwave irradiation (Vozza et al., 2018c). The Cs produced was compared to that
of CL113, an ultrapure Cs product that has been assessed extensively for drug delivery
applications and assessed for equivalent properties (DDA%, MW and purity), using
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FTIR,

13

C/1H NMR and GPC. A commercially available, fungal sourced Cs, from

Sigma Aldrich was also compared to the Cs produced in this work, as an additional
reference check point. Following production of Cs with a satisfactory match to
CL113, a further chemical modification of the product to TMC was performed to
assess whether fungal derived TMC may offer potential use as a permeation enhancer
and as an alternative to crustacean derived.
Chapter 8 presents a manuscript to be submitted to the journal of Innovative Food
Science and Emerging Technologies and considers the employment of fCs to
formulate NPs loaded with synthetic SeCys2, by employing the optimised formulation
conditions previously identified by the DoE approach. In vitro evaluation of the
produced NPs was then conducted, using the previously developed methodologies, to
assess the likelihood of oral compatibility in terms of stability, cytotoxicity and release
profiles. Differences between the CL113 and fCs NPs were then identified in terms of
physicochemical properties and release rates by the in vitro techniques. Finally, a
preliminary study to assess the feasibility of Irish mushrooms providing Se species
for supplementation purposes was conducted. In that study, a Reverse phase, high
performance liquid chromatography, Photodiode Array Detector (RP-HPLC-PDA)
method was validated to analyse Se supplemented A. bisporus
Chapter 9 summarises the conclusions of the research findings and includes a
detailed discussion on potential considerations and future perspectives.
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2.1 Introduction

A new area in research and development has been instigated in the functional food
industry by the emergence of nanotechnology. In particular, the enhanced delivery of
nutrients to both humans and animals has garnered much attention from both
academic and industrial bodies over the past decade (Neves et al., 1999; Scrinis and
Lyons, 2007; Srinivas et al., 2010; Yao, McClements and Xiao, 2015) . With
consumers now acknowledging the ability of certain foods to reduce disease risk or
improve health (Hasler, 2000), in addition to the food industry’s recognition that they
may stand to gain a competitive edge over their competitors by satiating user specific
dietary requirements and consumers’ diverse demands for foods, it is not surprising
that the nutraceutical industry has expanded within the past two decades (DeFelice
1995; Verbeke 2005; Lagos et al. 2015). It is estimated that the industry is currently
worth $151 billion in annual worldwide sales, and is anticipated to grow to $207
billion by 2016 (BCC research, 2015).
The chief purpose of the diet is to deliver appropriate nutrients to an individual in
order to meet their nutritional requirements. Foods and food constituents that provide
health benefits beyond rudimentary nutrition are classified as nutraceuticals (Kalra
2003). Nutraceuticals have elements of both foods and medicinal products. If the
substance contributes only to the maintenance of healthy tissues and organs, then it
may be considered to be a food ingredient. On the other hand, if it can be shown to
have a modifying effect on the body's natural physiological functions and is supported
by favorable scientific opinion, it is considered a nutraceutical (Ec.europa.eu, 2015).
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In the EU, a substance is characterised based on its exhibited effects on the body (JRC
Science Hub, 2015). The European Commission (EC) defines nutraceuticals as
“substances which are not traditionally recognised nutrients but which have positive
physiological effects on the human body” (Coppens, Da Silva and Pettman, 2006). A
plethora of scientific evidence has been accumulating, particularly over the last
decade, proposing the ability of nutraceuticals to reduce the risk of numerous chronic
diseases which has led to a boom in the food supplementation market (Brown and
Arthur, 2001; Dickinson and MacKay, 2014; Luo, 2014). In response to this, the EC
have published regulation (EC) No 1170/2009, which includes a list of vitamin and
mineral ingredients approved in foods and food supplements (European Commission,
2009), in order to “harmonise the legislation and to ensure that these products are safe
and appropriately labeled so that consumers can make informed choices” (European
Parliament, 2006)

2.2 Functional foods and bioactives

Functional foods have been defined as foods that provide a health benefit beyond the
basic nutritional requirements, by virtue of their physiologically active components
(Hasler, 2000). For example, soy protein, associated with a reduction in
cardiovascular disease, is referred to as a functional food because soy protein is not
considered to be an essential nutrient (Song et al., 2007; Kuan et al., 2012).
Most commonly, there are two ways in which a functional food may be presented.
One is where the nutraceutical is trapped within the food matrix, for example
polyphenol antioxidants found in blackberry fruiting bodies (de Souza et al., 2014),
the other being processed foods in which the nutraceutical has been isolated prior to
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manufacture and has subsequently been incorporated into the product during
processing, for instance, nano-selenium-enriched Nanotea from Shenzhen Become
Industry & Trade Co., Ltd (Blasco and Picó, 2011).
Nutraceuticals with prospective health benefits have been identified in several
traditional foods such as fruits, vegetables, dairy, soya and whole grains (Brouns,
2002; Liu, 2007; Jelen, 2010; Thilakarathna and Rupasinghe, 2012; Mann, 2015). In
addition to traditional foods, new foods have been developed in which isolated
bioactives have been amalgamated with a specific food matrix in order to harness their
potential health or physiological effects (Wang et al., 2014; McClements, 2015).
The emergence of dietary compounds with health benefits offers an excellent
opportunity to improve public health. Presently, a number of functional food
components are being explored for their potential roles in disease prevention and/or
beneficial health effects (Li-Chan, 2015). These include, but are not limited to
vitamins, probiotics, bioactive peptides, anti-oxidants etc. (Ha and Zemel, 2003;
Molina et al., 2012; Roberts et al., 2013; Blondeau, 2015).
Nutraceuticals have also emerged in areas such as food supplementation, with more
than 50,000 dietary supplements available to date, as well as in the area of oncology
research (Nair et al. 2010; Braithwaite et al. 2014). Table 2.1 details examples of
current research regarding common nutraceuticals.
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Table 2.1 Examples of some common nutraceuticals.
Origin

Physiological
Function/Claim

Reference

Chitosan

Fungal
mycelium

Reduction of low-density
lipoprotein (LDL)
cholesterol, triglycerides
and increase high-density
lipoprotein cholesterol

(Rizzo et al., 2013)

Guggulsterone

Medicinal herbs

Hypoglycemic and
hypolipidemic effect for
treatment of type 2 diabetes

(Sharma et al.,
2009)

Pomegranate
juice

Pomegranate

Dyslipidemia treatment

(Jadeja et al., 2010)

Oleocantha

Olive oil

Anti-inflammatory effects

(Guasch-Ferré et al.,
2014)

Luteolin

Rosemary,
celery, and
parsley

Protective role of DNA
against hydrogen peroxideinduced toxicity and antiinflammatory actions

(Seelinger et al.,
2008; MoncadaPazos et al., 2011;
Nordeen et al.,
2013)

Fucoxanthin

Marine algae

Antioxidant, anticancer and
anti-obesity activities

(Fung, Hamid and
Lu, 2013)

Omega-3 fatty
acids

Nuts seeds,
plant and marine
oils

Decreased thrombus
formation, lower LDL
cholesterol; moodstabilising properties,
cardiovascular disease

(Simopoulos, 2002;
Blondeau, 2015)

Methyl
selenocysteine

Garlic

Prostate cancer,
Cholesterol-lowering
effects

(Arnault and Auger,
2006)

Nutraceutical
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2.3 Nutraceutical formulation challenges

The effectiveness of nutraceutical products in preventing diseases depends on the
preservation and effective provision of the targeted BA of the active ingredients (Ting
et al., 2014). Innovative therapies are currently the focus of scientific research and
there is a growing interest in optimizing dosage forms and formulation methods to
increase the BA of promising natural candidates (Ubbink and Krüger, 2006; Acosta,
2009; Harde, Das and Jain, 2011; Wang et al., 2014).
There are, however, a number of challenges that can be encountered when
supplementing a food with a nutraceutical (Augustin and Sanguansri, 2015). For
instance, the solubility of the active component in the food product it is being
introduced to must be considered. The physicochemical and physiological
characteristics of the bioactive are also important:
•

Does it have low water solubility that would hinder its uptake in target cells?

•

Does it have a high melting point that would be able to withstand high temperature
processing methods?

•

What is its’ chemical stability, does it need to be shielded from harsh pH
environments?

•

Does it exhibit high or low BA in the body? If not, how can the component/s
efficacy as a disease preventing agent be increased?

These considerations must be borne in mind when designing a new product, as harsh
conditions may lead to deleterious effects on the overall food properties, hindering
food sensory properties and limiting the bio-accessibility and BA of the bioactive
compounds (Handford et al., 2014).
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Supplements (Bonifácio et al., 2014), food processing (Abbas et al., 2009), agriculture
(Chen and Yada, 2011) and food packaging (Duncan, 2011) have been identified as
the four major applications of nanotechnology by food technology experts (Institute
of Medicine (US) Food Forum, 2009). However, this type of segregation is quite
arbitrary, due to the fact that the most interesting applications can be seen when one
or more of these areas intersect. For example, interdisciplinary efforts are gaining
increasing popularity as food engineers and drug delivery scientists collaborate in
order to develop new nutrient delivery systems (Chen, Remondetto and Subirade,
2006; McClements and Li, 2010; Fathi, Mozafari and Mohebbi, 2012; Fathi, Martín
and McClements, 2014). By adapting a pharmacological approach, various methods
have previously been considered in the development of food-grade delivery systems,
which offer the possibility to fabricate products that would protect, control and target
the release of the bioactive ingredient to its desired location (Benshitrit et al., 2012).
Most approaches share one key methodology: entrapment, encapsulation and coating
(Augustin and Hemar, 2009). This not only helps shield the nutraceuticals from their
exposure environment but can also enable the release of the active component in a
more controlled way (Shoji and Nakashima, 2004; Velikov and Pelan, 2008;
McClements and Li, 2010).
Resultant nutraceutical particles occur in an extensive range of shapes and sizes
(Figure 2.1). They can also be delivered in a wide array of formations, such as tablets,
granules and micro/nanoparticles, the latter arising from the most recent development
in drug delivery research areas (Lee, Yun and Park, 2015).
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Figure 2.1 Scalar representation of various nutraceutical particles, ranging from
nanoparticles to tablets.

Microparticles (MP) have been applied to deliver bioactives and/or drugs over long
periods of time (months/weeks) in a variety of formulations, such as, depot
administration via subcutaneous or intramuscular injection, pulmonary routes and oral
delivery (Chen et al., 2010; Nair et al., 2010; Zhou et al., 2015). MPs delivered
intravenously have been shown to accumulate in the minute blood vessels of the lungs
and have recently become an attractive approach in treating chronic obstructive
pulmonary disease (Nair et al., 2010). Complications can, however, arise when using
MPs for drug delivery, as they have been shown to induce higher immune responses
than submicron particles (Gutierro et al., 2002).
Table 2.2 details a number of approaches that have been used to formulate
nutraceuticals in order optimize their health benefits and/or to avoid harsh conditions
during consumption and processing.
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Table 2.2 Formulation aspects of current marketed nutraceutical products .

Brand Name

Formulation

Bioactive
Compound

Indication

Company

Zacol NMX®

Tablets
(controlled
release matrix
technology)

Calcium Salt of
Butyric Acid and
Inulin

Intestinal
Disorders

Da Cosmo
Pharmaceuticals

Berocin CZ Softgel Capsule

Folic acid

Mecobalamin

Treatment and
prevention of
folate
Eros Pharma Ltd
deficiencies and
megaloblastic
anemia.
Peripheral
neuropathies

Meconerv®

Injection

Micro Labs Ltd

Pediasure®

Liquid
supplement

Betafactor®

Capsules

Beta–glucan

Immune
supplement

Ameriden®
International
Inc.,USA

Chaser®

Tablet

Activated calcium
carbonate and
vegetable carbon

Hangover
supplement

Living Essentials,
Walled Lake, MI,
USA

Protein, vitamin
and other natural Pediatric growth Abbott nutrition
supplementation
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2.4 Oral delivery

The fundamental applications of nutraceuticals entail the delivery of nutrients,
bioseparation of proteins, rapid sampling of biological/chemical contaminants, and
entrapment of nutraceuticals (Sozer and Kokini, 2009). Oral delivery is regarded as
the gold standard for nutraceutical delivery due to high levels of patient acceptance,
long term compliance and ease of administration (Sastry, Nyshadham and Fix, 2000).
Moreover, it is preferable to maintain the natural process of food and nutrient
consumption. However, in order for the nutraceutical (such as bioactive peptides,
minerals and vitamins) to elicit the desired physiological effects via the oral route, a
number of challenges for oral administration must be overcome (Chen, Remondetto
and Subirade, 2006). These include insufficient gastric residence time, low
permeability and/or solubility within the gut, instability under food processing
conditions (temperature, oxygen, light) or in the gastrointestinal tract (GIT) (pH,
enzymes, presence of other nutrients), all of which may limit the activity and potential
health benefits of nutraceutical molecules (Agrawal et al., 2014).
In order to overcome these challenges, it is necessary to construct an appropriate
formulation that will protect and maintain the active ingredient in the relevant location
for it to deliver its physiological/therapeutic effect within the required timeframe
(McClements 2012). Table 2.3 lists common oral delivery systems for nutraceuticals.
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Table 2.3 Common oral delivery systems for nutraceuticals .
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Phospholipid based delivery systems
Amphipathic lipids that can orientate themselves into lipid bilayers, examples include Liposomes
and Phytosomes. They have been shown to enhance potency and dose efficiency of both hydrophilic
and lipophilic compounds.
Emulsion based delivery systems
Mixture of two or more immiscible liquids stabilised by amphipathic compounds, examples include
micro/nano-emulsions and solid lipid NPs. They have been shown to enhance potency and dose
efficiency of lipophilic compounds
Chemical modification
Involves the association of non-bioactive pro-moieties (such as functional groups and polymers) with
bioactive compounds that can subsequently be dissociated within the body by the action of enzymes
or other chemicals. They have been shown to enhance potency and dose efficiency of the parent
compound from the molecular level.
Chitosan-based delivery systems
Chitosan is a positively charged polyelectrolyte that is biocompatible, pH responsive and
biodegradable. It has been formulated in both micro and nano-sized particles to deliver bioactives.
They have been shown to possess muco-adhesive properties that facilitates tight junction widening
thus increasing BA of target nutraceutical
Nanodispersions
Bioactives > 100 nm homogeneously distributed within a carrier free solution. Allow for higher
dosing of bioactive with minimal processing. They have been shown to enhance potency and dose
efficiency of bioactive compounds.
Mesoporous silica particles
Bioactives > 10 nm distributed within the nanopores of a micro scale silica particle. Allow for the
further use of pH or Redox potential sensitive gates to maximise dosing of bioactive in a specific
area of the GIT.

References
(Coimbra et al. 2011; Chen et al.
2010; Mishra et al. 2012)
References
(Davidov-Pardo & McClements
2014; Wang et al. 2014; Josef et al.
2010;)
References
(Mulholland et al., 2001; Liang et
al., 2013; Zhou et al., 2014)
References
(Jang and Lee, 2008; Kwon, 2008;
Akhtar, Rizvi and Kar, 2012;
Mukhopadhyay et al., 2013)
References
(Chu et al., 2007; Anarjan et al.,
2010; Adjonu et al., 2014)
References
(Pérez‐Esteve et al., 2015)

NPs have shown promise for oral drug delivery systems, as they posses the potential
to provide a remedy to these obstacles whilst maintaining the aforementioned health
benefits (Ensign, Cone and Hanes, 2012). For example, a protein or peptide drug can
be encapsulated in a nanoparticle environment which can protect against enzymatic
degradation, consequently improving the pharmacokinetics and stability of the
molecule (Almeida and Souto, 2007; Patel, Cholkar and Mitra, 2014). By using NPs
as a drug delivery vehicle, it is possible to provide or enhance a wide range of optimal
characteristics for a given nutraceutical drug, including increased stability (Nair et al.,
2010), incorporation of both hydrophobic and hydrophilic substances (Ron et al.,
2010), high carrier capacity (Yao, McClements and Xiao, 2015) and suitability for the
various routes of administration such as oral, pulmonary and topical applications
(Helson, 2013).
NPs can also help deliver drugs with low solubility, also providing controlled release
in order to sustain the drug. These characteristics enable optimum drug BA and
reduction of frequency of drug administration (Huang, Yu and Ru, 2010). NPs made
from biocompatible and biodegradable materials found in food, which are generally
regarded as safe (GRAS), have the potential to be approved by regulatory bodies faster
than alternative compounds (Hans and Lowman, 2002). From here on in, the
discussion will focus on an area that has garnered much interest in nutrient delivery
the past decade -the use of nanoparticles (NPs) for nutraceutical delivery.

2.5 Bioavailability enhancement with nanoparticles

The drivers for utilizing nanotechnology in foods include taste or flavour
enhancement, improved delivery and solubility, protection against oxidation and
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enzymatic degradation, prolonged residence time and efficient permeation through
the GIT and improved BA at the target site (Chen, Remondetto and Subirade, 2006).
Recently, a number of nutraceuticals, such as omega 3 and omega 6 fatty acids,
probiotics, prebiotics, vitamins and minerals, have been investigated as bioactive
compounds in nanoparticle formulations (Anal and Singh, 2007; Gökmen et al., 2011;
Rashidi and Khosravi-Darani, 2011; Luo, Teng and Wang, 2012).
Nanoparticles can be generated both intentionally (for therapeutics or other
applications) or unintentionally (e.g. by combustion). In the field of food and
medicine, several nanoparticle applications have already been approved for clinical
use, and many others are at different stages of development (Wacker, 2014). Table
2.4 shows some examples of marketed nanoformulations of drugs, beverages, foods
and health supplements developed from the Pharmaceutical and Food industry
targeting the oral delivery route of administration. There are also a number of
nanoformulations that are currently in pre-clinical development in order to assist
targeting of oncology drugs, such as Folic acid-PAMAM dendrimers for Epithelial
cancer (Thomas et al., 2013), Albumin-bound nanoparticles and Glycol chitosan
nanoparticles for cancer treatment (Miele et al., 2009; Yoon et al., 2014), Starchcoated iron oxide nanoparticles of magnetically guided Mitoxantrone for tumour
angiogenesis (Wahajuddin and Arora, 2012) and Silica-based nanoparticles for
photodynamic therapy (Couleaud et al., 2010).
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Table 2.4 Current nanomaterial’s in the Food and Pharmaceutical industry (websites accessed 16/6/2015) .

Current Marketed Drugs
(Pharmaceutical)
Liposomal amphotericin B
PEG–L-asparaginase

Function
Fungal
infections
Acute
lymphoblastic
leukemia

Trade name

Company

References

Abelcet®

Sigm-Tau

www.sigmatau.com

Oncaspar®

Enzon

www.oncaspar.com
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Current Marketed Nanomaterials
in Foods/Beverages

Function

Trade name

Company

References

Nano-sized self-assembled structured
liquids (micelles)

Food

Canola Active
Oil

Shemen

www.shemen.co.il
(website only in Hebrew).

Nano Zinc Oxide (food grade)

Food additive

AdNano®

Evonik
(Degussa)

www.advancednanomaterials.com

Current Marketed Nanomaterials
in health supplements

Function

Trade name

Company

References

Nano silver

Health
supplement

Skybright
Natural Health

hwww.skybright.co.nz

Nano humic and fulvic acid

Health
supplement

Colloidal
Silver Liquid
Nano Humic
and Fulvic
Acid

Nano Health
Solutions

www.fulvic.org

Studies have shown that the enhanced surface area per mass compared with larger-sized
particles of the same chemistry renders nanosized particles more biologically active
(Oberdörster et al., 2005; Heitbrink, Lo and Dunn, 2015). The biological interactions of
a nanoparticle system are highly dependent on the nanoparticles size and size distribution
(Hagens et al., 2007). Etheridge et al. (2013), state that the enhancement of a drugs BA
at the systemic level results from the increased surface area provided by the submicron
size of the nanoparticle formulation. For example, a given drug formulated within a
smaller sized nanoparticle (approx. 100 nm) has an increased likelihood to be associated
on or close to the surface of the particle allowing the drug to be released at a higher rate
(Hans and Lowman, 2002). On the other hand, larger particles (>100nm) have a smaller
initial burst release and longer sustained release than smaller particles as the load tends
to be encapsulated in the core centre of the particle (Hans and Lowman, 2002). Generally,
passive diffusion allows for the slow release of the drug into the systemic system, as a
result of the drug releasing from the larger NP core (Mohanraj and Chen, 2007).
The higher mobility and cellular uptake of NPs compared to microparticles is another
advantage provided by nano-scale formulations. For example, when comparing the
uptake of 1 and 10 µm particles against 100 nm particles in in vitro models, an increase
of 2.5-6 fold higher uptakes were observed respectively (Mohanraj and Chen, 2007).
Etheridge et al. (2013) also commented that the effect of particle size on cellular intake
can be influenced by the constituent material and the particle geometry. With this in mind,
it is important to consider the particle size and morphology on a case by case basis that
will allow for specific evaluation for formulation processes that use different
encapsulating materials for delivery of nutraceuticals (De Jong and Borm, 2008)
Encapsulating nutraceuticals within engineered nanoparticle based delivery systems

45

presents the potential to improve BA and the ability to tailor a given particle in order to
withstand detrimental pH, processing and enzymatic environments (Yao, McClements
and Xiao, 2015). Further advantages of using nanoparticles as drug carriers can be seen
in Table 2.5.
Table 2.5 Advantages associated with Nano-carriers for drug delivery (Abbas, K. A. et
al. (2009).

Advantages of nanoparticles as drug carriers
Controlled and sustained release profile of the drug to a given target site
Several routes of administration can be applied
High drug loading under mild conditions and in the absence of harsh chemicals
Ability to manipulate particle physicochemical properties such as size and
morphology to achieve optimum passive/active drug targeting
Increased retention time of NPs at mucosal surfaces by exploiting mucoadhesive
formulation components
Increase the chemical stability of a drug by shielding it from harsh pH environments
such that are found in the GIT
Prevent aggregation of proteins/peptides when the pH of the surrounding
environment approaches their isoelectric point

It is also important to keep in mind that the main advantage for formulation of NPs is
targeted drug delivery, which can be achieved using two different routes, passive
targeting and active targeting (Singh and Lillard, 2009). Passive targeting occurs when
NPs exhibit localization to specific organs or to sites of disease via biological
mechanisms, such as the reticuloendothelial system (RES) or the enhanced permeability
and retention (EPR) effect (Maeda et al., 2000). One example is PEGylatyed liposomedoxorubicin, Doxil®, which encapsulates an anti-tumor drug, doxorubicin (Kroon et al.,
2014). On the other hand, active targeting is the conjugation of antibodies, peptides, or
other ligands onto the nanocarrier surface which will recognise and bind to target cells
through ligand–receptor interactions by the expression of receptors or epitopes on the cell
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surface (Nobs et al., 2004). For example, monoclonal antibody-conjugated PLGA NPs
formulated to actively target cancer cells, resulting in better cancer cell recognition of
surface-modified NPs than non-coated NPs (Kocbek et al., 2007).
The European commission recommends that a nanomaterial be defined as (Ec.europa.eu,
2011):
A natural, incidental or manufactured material containing particles, in an
unbound state or as an aggregate or as an agglomerate and where, for 50 %
or more of the particles in the number size distribution, one or more external
dimensions is in the size range 1 nm - 100 nm.
In specific cases and where warranted by concerns for the environment,
health, safety or competitiveness the number size distribution threshold of 50
% may be replaced by a threshold between 1 and 50 %.
By derogation from the above, fullerenes, graphene flakes and single wall
carbon nanotubes with one or more external dimensions below 1 nm should
be considered as nanomaterial’s.
With this in mind, it is worth noting that NPs in themselves are not easily categorised in
terms of properties, as the physical size of a drug can greatly affect the drug’s effect when
compared to a smaller or larger particle of the same makeup (Oberdörster, Oberdörster
and Oberdörster, 2005). As nanoparticles can be any number of particles within the scale
of 1-100 nm, the term nanoparticle is in itself broad, thus leading to a difficulty of clear
and defining chemical and physical properties (Ju-Nam and Lead, 2008).
In other words, variations in size and shape can have unpredictable effects on the physical
and chemical properties of nanomaterials: a substance that is non-toxic at 50 nm may be
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toxic at 1 nm or vice versa (Resnik and Tinkle, 2007). Because their properties are
dependent on their microenvironment, nanomaterials may change in size or shape inside
an organism. A 100 nm particle could disintegrate into 1 nm particles, or 1 nm particles
could aggregate into a 100 nm particle (Resnik and Tinkle, 2007).
By limiting size in the definition of nanotechnology to the 1–100 nm range, numerous
materials and devices are excluded, in particular with regards to the pharmaceutical and
agricultural fields, in which nanomaterials of 100 nm to 300 nm are considered of most
interest with regards to oral delivery due to the toxicity issues that arise from smaller sizes
(Umerska et al., 2012; Andreani et al., 2014; Koppolu et al., 2014; Sakai-Kato et al.,
2014). The driving force for the size restriction of the definition of nanoparticles is one
of regulation, and therefore, in the following sections, a broader definition of nanoscale
shall be considered.

2.6 Food Grade delivery systems

Nanoparticles in a size range of 100-300 nm have attracted a lot of attention as drug
delivery nanocarriers and have shown remarkable therapeutic potential when formulated
into different delivery systems, depending on the nature of the bioactive, release rate and
compatibility with the carrier (Almeida and Souto, 2007; Sarvaiya and Agrawal, 2015).
Most commonly used nanoparticle carrier systems are magnetic, dendritic, polymeric,
solid-lipid liposomal, all of which exhibit different properties that are used in drug
delivery. There are two ways in which nanoparticles can be made: by "bottom-up" and
“top-down” approaches (Thiruvengadathan et al., 2013; Diaz Fernandez et al., 2014;
McClements, 2015) represented in Figure 2.2.
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Figure 2.2 Schematic representation of top-down and bottom-up techniques used to
produce nano-delivery systems.

In a “bottom-up” approach, materials and devices are built from molecular components
which come together chemically by principles of molecular recognition (Chan and Kwok,
2011). On the other hand, the "top-down" approach entails the construction of nanoproducts from larger entities without atomic-level control (Acosta, 2009). Food grades,
for example, are used to classify products according to certain quality characteristics. To
establish an oral delivery system, all substances used which pass through the oral route
should be classified as safe.
By instigating a pharmacological approach in order to develop food grade delivery
systems, products can be potentially produced which possess the ability to protect a given
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bioactive during processing and storage stages, whilst allowing for controlled delivery of
the therapeutic at its target site (Lawton, 2002; Zhang et al., 2015). It is generally accepted
that food grade delivery systems can be classified in a wide variety of ways. However,
most commonly, size and the main nutritional component are used when classifying
systems (Benshitrit et al., 2012).
With regards to size classification, this is considered an important means of assessment
due to the behaviours of compounds on a scalar level. A given system’s functionality can
generally be linked to the availability of the bioactive to the body according to size
(Kumari, Yadav and Yadav, 2010). By changing size of the encapsulating vehicle of a
molecule, the rate of its release, its solubility and it retention at a given target site can be
tuned (Mohanraj and Chen, 2007), enabling the optimisation of a formulation in order to
achieve specified results. An alternative, common way of classifying these delivery
systems is via their main nutritional component (Benshitrit et al., 2012). Such food grade
delivery systems can be divided into three groups: Protein-based delivery, Lipid-based
delivery and Carbohydrate-based delivery (Benshitrit et al., 2012). These systems
provide a wide array of potential in addition to some limitations and shall be discussed in
the following sections.

2.7 Protein-based nano-delivery systems

Food biopolymers, specifically food proteins, are commonly used to formulate bioactives
because of their high nutritional value, biodegradability, non-antigenicity, excellent water
binding capacity, cost efficient and GRAS nature (Benshitrit et al., 2012; Elzoghby, Samy
and Elgindy, 2012). It is also possible to exploit the delivery of bioactives over a wide
range of platforms due to their physical and physicochemical diversity attributable to the
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multiple functional groups present in the primary sequence of polypeptides (Chen,
Remondetto and Subirade, 2006). With this in mind, it is possible to modulate protein
carrier interactions with therapeutic agents and produce three dimensional networks
allowing for a host of possibilities, for example, the reversible binding of active molecules
to a given target site (Chen, Remondetto and Subirade, 2006). Additionally, studies have
shown that the generation of bioactive peptides via enzymatic degradation in vivo can
subsequently elicit a number of physiological effects, leading to an advantage regarding
acceptability of protein carrier employment for drug delivery (Li-Chan, 2015).
Proteins can be sourced from bacterial, fungal, plant and animal origin, with the latter
two utilised as a food grade delivery system not only because of their cost effectiveness
but also because they enable excellent delivery of both hydrophilic and hydrophobic
bioactives (Elzoghby, Samy and Elgindy, 2012). The preparation methods that can be
employed in order to produce protein based carriers has also been cited as a major
advantage of this particular delivery vehicle (Chen, Remondetto and Subirade, 2006).
Techniques such as gelation, emulsification, extrusion, spray drying and coacervation are
commonly used to produce delivery systems such as hydrogels, hydrocolloids, micelles,
nano-assemblies, films and micro and nanoparticles (Ibrahim 2015; Zhang et al. 2014;
Park et al. 2013,Yang et al., 2014). Common protein carriers investigated from animal
sources are gelatine, collagen, casein, elastin, albumin and whey proteins, and from plant
sources are soy glycinin, wheat gliadin and zein (Kimura et al. 2014; Song et al. 2009;
Xiao et al. 2011; Nӓgele et al. 1991).
Nanoparticulate protein carriers from vegetal origin have garnered interest in the field
due to their potential advantages over their animal derived counterparts (Ezpeleta et al.,
1996; Lai and Guo, 2011; Elzoghby, Samy and Elgindy, 2012) It is hypothesised that, by
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exploiting the low solubility and high hydrophobicity characteristics of these particular
proteins, it is possible to negate the need for further chemical and/or physical treatments
of the nanoparticles in order to harden them (Ezpeleta et al., 1996). As an alternative to
hydrophilic animal protein carriers such as albumin and casein, hydrophobic plant
proteins such as gliadin and zein have been investigated for their ability to increase the
amount of bioactive entrapped within a given carrier system in addition to their ability to
improve the controlled release of target bioactives (Ezpeleta et al., 1996; Xijun et al.,
2014; Zhang et al., 2015). Moreover, they are less expensive to produce, and satisfactory
supplies can be assured due to the nature of their growth and harvest processes. Plant
proteins can also be regarded as a safer therapeutic delivery system due to the reduced
risk of spread of disease associated with animal origin compounds, for example, bovine
spongiform encephalitis (Elzoghby, Samy and Elgindy, 2012). An example of a plant
derived protein carrier that has begun garnering much interest for nutrient delivery is Zein
(Lawton, 2002; Paliwal and Palakurthi, 2014).
Zein is a class of alcohol soluble prolamine storage proteins found in corn (Esen, 1987).
It is extracted from the endosperm of corn kernels, where it is predominantly present
(Larkins et al., 1984; Dombrinkkurtzman and Bietz, 1993), during corn wet milling
processes. It exists as a mixture of proteins, of varying molecular weights and can be
categorized by sequence homology and solubility into four main classes known as: α-zein
(19 and 22 kDa), β-zein (14k Da), γ-zein (16 and 27 kDa) and δ-zein (10 kDa) (Esen,
1987). The most abundant of these, α-zein, accounts for 70-80% of the total mass fraction
of zein, whilst, γ-zein, the second most abundant, accounts for 10-20% (Wilson, 1991).
All groups of zein possess a fairly abundant amount of neutral and hydrophobic amino
acids (AA) (e.g. proline) with a more moderate amount of polar AA residues such as
serine (Zhang et al., 2015). In addition, what differentiates zein from most other proteins
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is that it contains negligible amounts of lysine and tryptophan, as well as low amounts of
arginine and histidine residues (Zhang et al., 2015). It is this inherent AA composition
that lends to zein proteins unique solubility properties, whereby it is insoluble in pure
water and alcohol but soluble in aqueous alcohol and alkaline solutions as well as acetic
acid and acetone (Lawton, 2002).
As zein has been GRAS approved by the United States Food and Drug Administration as
a pharmaceutical drug excipient since 1985 (Accessdata.fda.gov, 2014), it has been
proposed as a nanodrug delivery vehicle (Paliwal and Palakurthi, 2014). It has been
shown to possess the ability to improve the colloidal stability and encapsulation
efficiency of bioactive components in addition to tailoring of their release profile (Zhang
et al., 2015). In studies conducted by Luo et al. 2010, zein was used to coat chitosan
nanoparticles loaded with selenite and was shown to not only increase the encapsulation
efficiency of the mineral from 60% to 96% but also protected the drug from the harsh
conditions of the GI tract. This allowed for a slower sustained release of selenite at the
intestinal target site, reducing the release of selenite from 85% in the first 4 hrs to 30%
(Luo et al., 2010). Zein has also been used to successfully deliver fat soluble compounds
due to its high hydrophobicity (Zhong, Tian and Zivanovic, 2009).

2.8 Lipid-based nano-delivery systems

It is sometimes important to deliver lipophilic bioactives in a more edible form. For
example, fatty acids such as conjugated linoleic acid and butyric acid have shown
potential health benefits for Coronary Heart Disease (Haug, Hostmark and Harstad,
2007). In order to do so, lipid-based delivery systems have been shown to be a promising
approach. These lipophilic components may be a diverse range of substances, including
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bioactive lipids, vaccines, flavors, antimicrobials, antioxidants, and drugs (H du Plessis
et al., 2014).
It is advantageous for lipid bioactives to be encapsulated in a liquid form, which has
shown to increase their palatability, desirability, and bioactivity due to the differing
molecular, physicochemical and psychological properties (McClements, Decker and
Weiss, 2007). Consequently, all of these differing properties of each lipid bioactive need
to be addressed to produce the optimal formulation and effect. The most commonly used
lipophilic nutraceuticals investigated recently are fatty acids (ω-3 fatty acids, conjugated
linoleic acid, butyric acid), carotenoids (β-carotene, lycopene, lutein, zeaxanthin),
antioxidants (tocopherols, flavonoids, polyphenols) and phytosterols (stigmasterol, βsitosterol, campesterol) (Pol and Patravale, 2009; Puri et al., 2009; Bassaganya-Riera and
Hontecillas, 2010; Leong et al., 2011; Song et al., 2011).
The principle used to formulate a lipid based delivery system is emulsification, as oil in
water (O/W) microemulsions, liposomes, multilayer emulsions, filled hydrogel particles,
or solid lipid nanoparticles (Spernath and Aserin, 2006; Iglesias et al., 2013; Han et al.,
2014). Phospholipid-based microemulsions (ME) use food-grade ingredients, soybean oil
and soybean lecithin, to replace ethyl oleate and purified lecithin (Patel, Schmid and
Lawrence, 2006). However, the formation of multiphase colloidal dispersions into
nanoscale droplets enables the production of nanoemulsions (NE).
NE (also known as submicron emulsions) can be prepared by the physical shear induced
by rupturing of one liquid within another immiscible liquid (Mukherjee, Ray and Thakur,
2009). NE have interesting properties compared to their micro sized counterparts in that
they have the ability to remain stable in diluted water without a change to their relative
size distribution (Gutiérrez et al., 2008). Consequently, the droplet sizes in
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nanoemulsions allow for optically transparent formulations due to their scalar size being
smaller than visible wavelengths. Microparticles, on the other hand, usually show
multiple scattering of visible light resulting in formulations with opaque appearances
(McClements 2012). With this in mind, it is fair to conclude that NE may be more
advantageous for nutrient delivery in commercial food products, for example, beverages,
in that they will allow for no discernible change in photoreception sensory properties of
the product (Fathi, Mozafari and Mohebbi, 2012).
An example of a lipid based nutraceutical carrier system that has begun garnering interest
for nutrient delivery is Solid Lipid NPs (Almeida and Souto, 2007; Harde, Das and Jain,
2011; Fathi, Mozafari and Mohebbi, 2012). Solid Lipid NPs (SLNs) have the ability to
solubilize lipophilic molecules and generally exist as spherical particles ranging from 10–
1000 nm (Almeida and Souto, 2007). They contain a solid or semi-solid lipid core matrix
and are typically stabilized by surfactants (Kalepu, Manthina and Padavala, 2013). When
compared to other lipid based carries such as nanoemulsions and liposomes, SLNs have
been shown to possess some distinct advantages over their alternative counterparts (Fathi,
Mozafari and Mohebbi, 2012). For example, they have been shown to offer robust
protection against GI tract degradation due to the reduction in crystalline mobility of the
lipid structure, particularly beneficial for the delivery of bioactive peptides which are
susceptible to enzymatic and or acidic degradation in the GI environment (Almeida and
Souto, 2007; Ting et al., 2014).
In addition, SLNs have the ability to provide controlled release profiles of a given
bioactive due to the intrinsically slow degradation rate of the crystalline lipid core. These
advantages have been shown to improve the pharmacokinetic profiles of bioactives
delivered via SLNs, typically resulting in slow evolution of peak therapeutic responses
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and more stable plasma concentration trends in comparison to lipid-lipid emulsion
systems (Ting et al., 2014).
There are many ways in which SLNs can be produced (Chattopadhyay et al., 2007;
Mehnert and Mäder, 2012; Nabi-Meibodi et al., 2013). Typically, on the laboratory scale,
SLNs can be simply prepared by the emulsification-evaporation and subsequent
sonication methods (Fathi, Mozafari and Mohebbi, 2012). Usually, the oil phase is mixed
with organic solvents, emulsifiers and bioactive(s) in order to form a coarse emulsion
known as the pre-emulsion (PE). After combining, the PE is then subjected to sonication
for a specified amount of time, at a temperature above the melting point of the lipid
carrier. The SLNs are then finally produced upon addition of the hot PE to cold surfactant
containing water, under constant mixing, in order to allow for solvent evaporation (Fathi,
Mozafari and Mohebbi, 2012).
Previously, it has been shown that SLNs size may remain stable in aqueous dispersions
for 12-36 months (Mehnert, 2001). Nevertheless, SLNs may become unstable and
increase in size during storage and, as a result lyophilisation, has been proposed as a
technique to be employed in order to avoid the sample becoming physically and/or
chemically unstable (Fathi, Mozafari and Mohebbi, 2012). It is important to note that,
although freeze drying has been shown to increase physicochemical stability, there is a
possibility that the SLNs may acquire changes in their osmolarity and zeta potential
(known as the freezing out effect) resulting in instability of the sample (Abdelwahed et
al., 2006; Fathi, Mozafari and Mohebbi, 2012; Soares et al., 2013). With this in mind,
cryoprotective agents such as trehalose (Augustin and Hemar, 2009) and glucose (Soares
et al., 2013) have been recommended as formulation components due to their ability to
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reduce the osmotic activity of water and also to prompt the frozen sample to favour the
glassy state (Hauser and Strauss, 1988; Mehnert, 2001).
Spray drying is another technique that has been used in order to increase the stability of
SLNs as an alternative to lyophilisation. It does, however, have some disadvantages over
freeze drying due to the fact that the SLNs may aggregate upon exposure to the high
temperatures and shear forces imposed during the process (Freitas and Müller, 1998). To
overcome the obstacles encountered during spray drying, it is recommended to use lipids
with melting points greater than 70°C (Mehnert, 2001).
Studies by Wang et al. (2013) involving SLNs used in the delivery of nutrients, include
the encapsulation of Curcumin (CUR) (a hydrophobic polyphenol present in the rhizomes
of Curcuma longa) and the evaluation of its effects in vitro and in vivo, whereby CURloaded SLNs (SLN-curcumin) showed a significantly higher anti-cancer efficiency on
A549 lung cancer cell lines and xenografts in mouse models. SLN-CUR was shown to
reduce tumour volume by 65.3% compared with a 19.5% of reduction when using CUR
in its native form. In addition, in 2014, Pandita et al. incorporated resveratrol, a bioactive
polyphenolic phytoalexin found in common foods such as grapes, peanuts, and red wine
into SLNs (Pandita et al., 2014). This bioactive has been shown to provide a range of
health benefits such as cancer prevention (Savouret and Quesne, 2002), increased
immune cell function (Falchetti et al., 2001) and increased fertility (Özcan et al., 2015).
In the study by Pandita et al., the formulation of resveratrol into SLNs produced a
significant 8 fold improvement in the oral BA of the drug as compared to the native drug
suspension (Pandita et al., 2014).
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2.9 Carbohydrate-based nano- delivery systems

Carbohydrate-based delivery systems are widely used in the nutraceutical and
pharmaceutical industry for targeted and controlled release (Sunasee et al., 2014). These
are classified as mono, oligo and polysaccharides. Mono and oligosaccharides are often
used as constituents of the encapsulating matrix (Benshitrit et al., 2012), polysaccharides
most often being used as the carrier component due to their massive molecular structure
and thus ability for greater bioactive entrapment (Fathi, Martín and McClements, 2014).
Polysaccharides exist as natural polymers of monosaccharaides, varying in type,
distribution, number and bonding of the monomers in the chain (Fathi, Martín and
McClements, 2014). They can be derived from animal, algal, microbial and protein
sources and are typically subdivided into three groups: neutral, anionic and cationic
(Daniel-da-Silva and Trindade, 2011). Polysaccharide examples include starch &
cellulose (neutral), alginate & xanthan gum (anionic) and chitosan (cationic) for which
the magnitude of electrical charge depends on the pH relative to the pKa (Liu et al., 2008).
For example, anionic polysaccharides are neutral at pH values below their pKa value but
negative above, whereas cationic polysaccharides tend to be neutral at pH values above
their pKa value but positive below (Kumari, Yadav and Yadav, 2010).
Alginate is an example of an anionically charged polysaccharide that has been used for
NP production. It is composed of 1,4-linked-β-d-mannuronic acid and α-l-guluronic acid
residues, exhibits a propensity for gelation upon exposure to proper conditions and has
been shown to be both biocompatible and non-toxic (Josef, Zilberman and Bianco-Peled,
2010).When being formulated as a nano-carrier system, alginate is cross-linked with a
divalent ion such as calcium chloride and magnesium chloride, the former being the most
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employed counter ion for complexing alginate-based nanoparticles (Alg-NPs). Alg-NPs
have been applied to deliver drugs and nutraceuticals such as insulin (Sarmento et al.,
2006) and vitamin D3 (Sun et al., 2012).
Various modifications have been explored to date, in order to improve the functionality
of these carbohydrate-based delivery systems. For example, hydrophobically modified
starch was used to increase water solubility and in vitro anti-carcinogenic activity of
CURNPs (Ha et al., 2012). Mahjub et al. (2014) used N-aryl derivatives of chitosan for
insulin nanoparticles to produce a permanent positive charge causing the polymer to be
soluble in wide range of pH values.
The type of environmental and solution conditions present within a particular food is
often important for selecting the most appropriate polysaccharide building blocks, in
order to provide protection and targeted/controlled delivery (Cushen et al., 2012).
Carbohydrate-based delivery systems have proven useful not only in the oral delivery
route but in topical delivery too. For example, Calcium alginate was chosen to design the
delivery system of L. plantarum as a polymer widely used in burn wound treatment due
to its haemostatic, gel-forming and granulation-encouraging properties (Brachkova,
Duarte and Pinto, 2012). More specifically, polysaccharides appear to be the most
promising materials in the preparation of nanometric carriers. In fact, over the past few
years, these systems have emerged as potential carriers for delivering agents across a
variety of different routes, such as nasal (Amidi et al., 2006), oral (El-Shabouri, 2002)
and pulmonary (Al-Qadi, Grenha and Remuñán-López, 2011).
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2.10 Polysaccharide Nanoparticles for nutrient delivery

Due to their biocompatible and biodegradable nature, polysaccharide based delivery
systems have found many uses in industrial applications (Fathi, Martín and McClements,
2014). Part of the reason they have attracted the attention of both industrial and academic
institutions is the fact that it is possible to modify polysaccharides to exhibit requisite
properties. Unlike lipid carriers, carbohydrate based carriers possess the ability to interact
with a wide array of both hydrophobic and hydrophilic bioactives (Joye, Davidov-Pardo
and McClements, 2014). This is due to the presence of functional groups that allow for
complex formation with bioactives via electrostatic interactions, both hydrophobic and
ionic in nature (Rinaudo, 2006b).
Another important aspect of polymeric materials that is particularly engaging to the
industrial researcher is the robustness the compound can exhibit under high temperatures
(Fathi, Martín and McClements, 2014). This is particularly useful from a manufacturing
standpoint, as polysaccharides can then also be used as a protective coat during
processing steps (Jang and Lee, 2008). In contrast to their protein and lipid counterparts,
polysaccharide systems are unlikely to become denatured or melt due to their high
temperature stability. Moreover, naturally occurring polysaccharides are considered safe
and already have found wide usage as food ingredients (Blanshard and Mitchell, 2013).
In fact, their functional attributes are generally custom-made by their biological origins,
isolation methods or physical and/or chemical modifications (Fathi, Martín and
McClements, 2014), which lends to them being viewed as an ideal carrier for
nutraceuticals (Hans and Lowman, 2002). For example, non-ionic Pullulan can be
modified by hydrophobic molecules such as curcumin. This was evidenced by studies
conducted by Yuan et al. (2014) that showed self-assembled NPs could be synthesized
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from Glycyrrhetic Acid-Modified Pullulans with varying molecular weight and/or degree
of substitution and exhibited increased solubilization, stabilization, and controlled
delivery of CUR when compared to its native form (Yuan et al., 2014).
Similarly, Dextran, a neutral, water soluble and bio-friendly polysaccharide, has proven
a useful tool in the field of nano-medicine, being chosen by a lot of researchers as
biomaterial in the preparation of nanosystems. For example studies conducted by Susa et
al. (2009) showed that nanoparticles loaded with doxorubicin showed increased apoptosis
compared to free doxorubicin on both wild type and the MDR osteosarcoma cells in vitro
by drug accumulation in the nucleus.

2.11 Chitosan-based delivery systems

An emerging polymeric nutraceutical carrier that has received attention for nutrient
delivery is chitosan (Cs) NPs (Luo et al., 2010; Akhtar, Rizvi and Kar, 2012; Chen et al.,
2013; Fathi, Martín and McClements, 2014; Sarvaiya and Agrawal, 2015). Chitosan is a
linear polysaccharide, prepared by N-deacetylation of chitin (Figure 2.3). It is positively
charged, biocompatible, non-immunogenic, nontoxic, pH responsive and biodegradable,
making it a choice as a component of oral drug delivery systems and attractive for
biomedical and drug delivery applications (Agnihotri, Mallikarjuna and Aminabhavi,
2004; Bezerra et al., 2008; Saini et al., 2014). Given that chitosan has a GRAS status,
this potentially can be translated to applications of delivery of nutraceuticals (Kean and
Thanou, 2010). Chitosan has been extensively used in a number of areas in medicine, for
example in tissue engineering (Suh and Matthew, 2000), bioimaging (Agrawal, Strijkers
and Nicolay, 2010), wound-healing and drug delivery formulations (films, hydrogel
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system and particulate system) (Agnihotri, Mallikarjuna and Aminabhavi, 2004;
Jayakumar et al., 2010).

Figure 2.3 Chemical structure of chitosan.

Chitosan has an isoelectric point of 6.5 and at this pKa value it exhibits its lowest
solubility, as the net charge is 0. Chitosan salts are soluble in water, the solubility
depending on the degree of deacetylation and the pH of the solution.
The degree of chitosan deacetylation (DD) from chitin signifies the percentage of
deacetylated primary amine groups along the molecular chain, which can determine the
positive charge density when chitosan is dissolved in acidic conditions. The higher the
DD, the more soluble the chitosan will be at acidic conditions (Hejazi and Amiji, 2003)
and subsequently the more it will exhibit its muco-adhesive properties in the GI tract
(Ting et al., 2014).
Chitosan with a low degree of deacetylation (<40%) is soluble up to a pH of 9, whereas
highly deacetylated chitosan (>85%) is soluble only up to a pH of 6.5 (Rinaudo, 2006a).
A high degree of deacetylation more readily allows ionization of Cs as increasing the
degree of deacetylation increases the viscosity and results in an extended conformation
with a more flexible chain because of the charge repulsion in the molecule (Kumirska et
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al., 2010). Hence, chitosan with a high degree of deacetylation is commonly used for drug
delivery research. Table 2.6 summaries the main chemical and biological properties of
chitosan.
Table 2.6 Chemical and Biological Properties of Chitosan (Adapted from Hejazi and
Amiji 2003).

Chemical and Biological Properties of Chitosan
Chemical Properties

Biological Properties

Cationic polyamine

Biocompatible

High charge density

Natural Polymer

Forms gels with polyanions

Biodegradable

Amiable to chemical modification

Spermicidal

Reactive amino/hydroxyl groups

Anticancerogen, Anticholesteromic

Swelling properties

Mucoadhesive

High mol wgt linear polyelectrolyte

Safe and non-toxic

Chelates certain transitional metals

Hemostatic, bacteriostatic,

2.12 Regulations surrounding nanomaterial safety

Nano-engineered particles have been used to enhance the drug delivery of actives, but
due to the small sizes, increased surface area and reactive nature of the nano materials,
the effectiveness and safety is a key consideration in Nanomedicine and even though the
successful implementation of nanotechnology is pertinent for the growth of the global
economy, there is also a need to consider the possible environmental health and safety
impact for nanoparticles that could lead to hazardous biological outcomes (Martirosyan
and Schneider, 2014).
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The FDA (Food and Drug Administration) is one of the main regulatory nanotechnology
bodies in the US and collaborates with the National Nanotechnology Initiative (NNI). In
Europe, the Institute for Health and Consumer Protection (IHCP) is the main regulatory
body actively involved in research into nanomaterials safety, identification and detection.
For both agencies, their key goal is to deal with questions about the potential effects on
health and the environment with particular emphasis on the risks and benefits to the
public. With regards to foods, the European Food Safety Authority (EFSA) works closely
with the IHCP to examine the behaviour of engineered nanomaterials in foods and to
validate methods of characterisation.
Following a report by the European Nanoforum, a food product is considered a
“Nanofood when nanoparticles and nanotechnology techniques or tools are applied
during cultivation, production, processing or packaging of the food, not intending to
produce atomically modified food or food produced by nanomachines” (Joseph and
Morrison, 2006). Due to the increasing use of nanomaterials in foods, recent EU
legislation (No 1169/2011) on novel foods has introduced obligatory labelling of
nanomaterials on packaging (European Parliament, 2011).

2.13 Uptake of nanoparticles and potential toxicity

Micro- and nano-particles have been shown to permeate through GI barriers, with the
latter estimated to have a 15-250 times higher absorption (Fröhlich and Roblegg, 2012).
Ingestion, inhalation and dermal absorption are the main physiological routes in which
NPs can enter the body, consequently resulting in the potential ability to distribute
themselves to a given organ over several exposure points (Smolkova et al., 2015).
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Absorption, Distribution, Metabolism and Elimination (ADME) are the characteristics
that effect the extent of NP exposure to a given system (Hagens et al., 2007).
Previous investigations have shown that the uptake of NPs is low in healthy orogastrointestinal mucous. However, the level of absorption varies dependent upon type of
GI cell, for example absorption is higher in the lumen in comparison to the oral cavity
(Roblegg et al., 2012). Epithelial barriers allow for the separation of NPs from the blood
and as a result translocation of NPs into secondary organs can occur due to their ability
to reach the connective tissue that is present beneath the epithelial layer surrounding the
intestines (Smolkova et al., 2015). For example, previous studies have found that titanium
oxide (TiO2) NPs when acutely exposed to both ex vivo and in vivo systems, possessed
the ability to pass through both the follicle-associated epithelium (composed of
enterocytes and microfold cells) and regular intestinal epithelium (mucous secreting
cells) becoming localized in the tissues situated below both epithelial layers (Brun et al.,
2014). Other studies have indicated that accumulation of TiO2 inside epithelial lining can
give rise to detrimental outcomes such as inflammation and may be involved in
inflammatory bowel disease pathogenesis (Lomer, Thompson and Powell, 2002;
Nogueira et al., 2012).
The surface properties and size of ingested NPs are affected by several environmental
factors such as pH, ionic strength, protein, sugar and lipid content that are naturally
present in foods such as the mucus of the saliva (Roblegg et al., 2012). In addition, upon
NP entrance to the system, interactions can occur between plasma proteins, platelets,
peripheral blood cells as well as with the organelles and DNA of the cells (Smolkova et
al., 2015). Due to some NPs low excretion rate, it is plausible to suggest that more often
than not, long term dose exposures occur. In spite of the fact that NP penetration into the
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body is low, toxicity screening is based predominantly on high dose, short exposures
(Oberdörster, 2010). This lends to acute toxicity issues being reported whilst minor
changes resulting from long term accumulation in a given system go unidentified.
NPs derived from occurring nontoxic substances in the body (i.e. protein and
carbohydrates) should pose less of a risk to the body than inorganic nano-delivery
systems. However, the effects from the increased bioavailability of these compounds may
have significant consequences on the body and must be considered also. In addition,
alterations in protein and carbohydrate structure have been shown to potentially increase
the allergenicity of said molecules (Říhová, 2007; Dobrovolskaia et al., 2008).
Regarding the increased bioavailability of compounds when delivered in a nano-enabled
format, currently safe upper levels and recommended daily allowances (RDAs) only
consider the delivery of essential nutrients in their macromolecule form (Chaudhry and
Castle, 2011). The use of nanotechnology to deliver these compounds may have
implications when estimating a given value (Food Safety Authority of Ireland, 2006;
Bouwmeester et al., 2009). Conversely, inherently toxic materials (for instance some
inorganic particulate metals) produced in a nano format and introduced to an environment
in which it can solubilise may give rise to greater exhibited toxicity than organic forms;
in fact several studies have exhibited that this may be the case in which many NPs have
shown greater reactivity in in silico and/or in vitro models (Papageorgiou et al., 2007;
Singh et al., 2007; Puzyn et al., 2011).
Due to the complexity of accessing the penetration and biological effects of ingested NPs
on the body it can be difficult to ascertain which chemical or physical properties can be
exploited for commercial use whilst avoiding potential toxicity effects on cells and tissues
(Singh et al., 2007). For example, properties such as physical dimensions and surface
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charge determine a particles ability to penetrate an organ or cell, in addition to the
likelihood that it will be uptaken and phagocytosed by leucocytes (Owens and Peppas,
2006). Retention time of particles, together with their solubility is another facet that needs
consideration, as it is well documented that increased residence time of particles at cell
membrane surfaces give rise to greater toxic reactions and damage (Dowling et al., 2004;
Nel et al., 2009).
Particle interactions represent another specific caveat that deems consideration. For
example, particle contact with endogenous compounds present in the body or food matrix
give rise to biomolecule coronas that may assist the absorption of novel entities into the
small bowel lumen (Lomer, Thompson and Powell, 2002; Nel et al., 2009). These
considerations must be kept in mind when assessing the effects of using NPs for food or
supplementation purposes with the intent to increase bioavailability. However, to date,
there is limited information available on ADME and toxic properties of NPs, leading to
recommendations to consider each NP formulation on a “case by case” basis (SCENIHR,
2007). For example, Cs NPs are insoluble yet ultimately biodegradable; they will
breakdown to their substituent counterparts at a rate dependent on their physicochemical
properties (Xu and Du, 2003). In contrast TiO2 NPs lack the ability to be broken down in
the body and thus have been shown to accumulate in the RES of the liver and spleen
(Elgrabli et al., 2015).
It is important to note that humans have been exposed to NPs throughout evolution, and
there is even evidence that we have adapted strategies to benefit from dietary and
physiological use of NPs in the gut (Powell et al., 2010). In addition, many foods are
already comprised of compounds such as proteins, carbohydrates and fats which exist in
a range of sizes, at present outspreading from macromolecules to the nano scale (Food

67

Safety Authority of Ireland, 2006). Generally, food ingested in macro scale format is
subsequently digested to the nano scale in order to exploit the energy contained in the
molecule for body gains. For example, it has been shown that nanoparticulate ferritin may
be utilised by gut epithelial cells as a source of dietary iron post endocytosis (Pan et al.,
2009). With this in mind, it is fair to state that nanoparticulates cannot be considered
inherently safe or toxic. They do, however, need to be assessed such that their molecular
structure, biological environment, degree of exposure and host acceptability are
understood and consequently assigned a potential hazard risk value accordingly (Food
Safety Authority of Ireland, 2006).

2.14 Conclusion and future directions

There is growing emphasis on health and welfare derived from food, which is being
driven by demographic and social factors, such as larger emphasis on healthy living in
industrial societies, the ageing of the population within the developed world in addition
to the increasing prevalence of sickness and diseases related to high-fat and high
cholesterol foods in rising and industrial economies (Verbeke, 2005; Annunziata and
Vecchio, 2013). Innovation in food merchandise has capitalised on these trends to
develop the growing marketplace for practical and/or health enhancing foods. Matching
specific foods or food decisions with an individual’s exact health desires appears to be
the way forward for the nutrition and food business future.
Whilst it is recognised that the application of nanotechnology to nutrient delivery can
give rise to several challenges within safety, ethical and regulatory perspectives
(Bouwmeester et al., 2009), it is important to keep in mind the major scope of potential
benefits it can offer to both consumers and manufacturers alike. At this moment in time,
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the long-term effects of nanomaterial exposure to human health remains largely
unknown. However, by ensuring enhanced knowledge is acquired during the realisation
of NP incorporation into food products it is possible to ensure consumer acceptance
remains in favour of this highly promising technology (Ravichandran, 2010).
With regards to global economic effects anticipated as a result of nano-enabled
nutraceuticals being applied in food product markets, undoubtedly nations who are able
to develop products that deliver smarter and healthier foods whilst maintaining increased
food production at cost effective margins can expect to profit in the economic long term.
If regulated correctly, the sustainability of nanomaterials in foods, alongside the potential
health and environmental benefits of the more efficient delivery of nutraceuticals, can be
expected to hugely impact the future direction of the food industry (Ravichandran, 2010).
With this in mind, it is of importance to ensure that human and environmental concerns
are addressed and subsequently not compromised as new products hit the market. In order
to assure this approach is embodied, the rate at which nanotechnology is introduced into
food products should be sufficiently reduced in order to allow for potential risks to be
identified and rectified prior to successful implementation on the food market.
Special attention should also be given to public opinion regarding the use of
nanotechnology in foods in order to mitigate negative consumer responses such that was
seen upon the introduction of genetically modified foods (Costa-Font, Gil and Traill,
2008; Hudson, Caplanova and Novak, 2015). As with any new technology, it is pertinent
that the potential benefits and risks are thoroughly discussed in addition to appropriate
labelling and regulation guidelines, in order to safeguard increased consumer
acceptability.
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3.1 Design of experiments: Response Surface Methodology

Response surface methodology (RSM) is an empirical modelling approach for defining
the relationship between various process parameters and responses with various desired
criteria and searching the significance of these process parameters on the coupled
responses. Originally developed by Box & Wilson (1952), RSM is based on the fit of
mathematical models (linear, square polynomial functions and others) to experimental
results produced from a designed experiment and the verification of the model obtained
by means of statistical techniques. In situations where several variables may influence
system properties, RSM is a useful technique to employ as it allows for the relationships
between a given response and independent variables (or factors) to be identified and
optimised (Anderson and Whitcomb, 2005). RSM is a more efficient approach to
experimentation than one factor at a time (OFAT) experiments due to the fact that it:
1.

Reduces the number of experimental runs typically required to gather the same
information as OFAT, thus reducing resource requirements.

2.

Is useful in detecting interaction amongst variables that would not be typically
identified during OFAT experiments.

3.

Improves the prediction of a response through use of gathered information from a
larger space.

Two of the most commonly applied RSM designs for process optimisation are the CCD
and BBD (Dayal et al., 2005; Singh, Chakkal and Ahuja, 2006; Varshosaz, Tabbakhian
and Mohammadi, 2010; Anarjan et al., 2011; Nabi-Meibodi et al., 2013; Maleki Dizaj et
al., 2015). Both methods require the user to supply minimum and maximum values for
each factor that defines the experimental domain to be investigated during the
optimisation procedure (Ferreira et al., 2007). The combinations of the different factor
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levels used to perform the actual experiments are subjected to multivariate optimisation
by employing the following steps (Ferreira et al., 2007).
1.

Run experiments in random order to mitigate bias

2.

Fit a full polynomial regression model on the obtained data.

3.

Identify the significant terms via analysis of variance (ANOVA).

4.

Assess the R2 or R2 adjusted to determine how well the constructed model explains
variation (ideally as close to 1 as possible).

5.

Ensure that there is no evidence of lack of fit for the produced model of the
representative data.

6.

Construct an objective function either with the individual response or the linear
combination of all the responses (Desirability function)

7.

Examine contour and surface plots and perform canonical analysis in order to identify
optimum variable conditions.

CCD considers 5 levels of factors with three different design points: edge points as in
two-level designs (±1), star points at (±α), that take care of quadratic effects and centre
points (α) that allow for the estimation of error (Bezerra et al., 2008). CCD designs
provide predictions over the entire design space, although, when factor levels are at
extreme points in the design, loss of information may occur (Singh, Chakkal and Ahuja,
2006).
BBD is an independent quadratic design approach in which factor combinations are
considered at 3 levels: the midpoints of edges of the process space and the centre. The
primary advantage is in addressing the issue of where the experimental boundaries should
be, and in particular to avoiding treatment combinations that are extreme (Sivamani and
Baskar, 2015). As the design avoids extreme experiment points, a reduced number of
experimental runs is required for BBDs than that of CCDs. However, it should be
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emphasised that the vertices of the cube are not covered by the design, and therefore,
prediction at these points is an extrapolation and should be avoided (Zolgharnein,
Shahmoradi and Ghasemi, 2013)

3.1.1 Nanoparticle characterisation

As discussed in chapter 1 (section 1.2), to ensure activity of a bioactive within a NP oral
delivery system, it is recommended to achieve specific physicochemical properties such
as a NP size of 100-500 nm, PDI ≤ 0.5 and ZP ≥ 30 mV (des Rieux et al., 2006). In this
work, these properties were measured using the following methodologies.

3.1.2 Particle Size and Zeta Potential Characterisation using DLS

A powerful technique employed for the sizing of NPs and their and characterisation in
the liquid phase is DLS, in which a laser beam is passed through the NPs (in suspension)
and is scattered by the particles. DLS measures random Brownian motion, whereby the
smaller the particle, the more rapidly it moves, the viscosity of the solution also playing
a role in the analysis. Fundamentally, the Stokes-Einstein equation allows us to link
Brownian motion with the NP size, by measuring the time dependant fluctuations in the
scattering intensity, allowing for determination of the translational diffusion coefficient
(D), and subsequently the hydrodynamic radius (Uskoković, 2012). The ZP of NPs can
be indirectly detected with DLS based on electrophoretic mobility of particles and
calculated by the application of the Henry equation. This provides information of the
colloidal stability of the nanoparticles (Malvern Instruments Ltd., 2007).
In Chapters 4, 5, 6 & 8, freshly prepared NP solutions were analysed. The mean particle
size and PDI of the NP formulations were determined by DLS. The ZP values were
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measured with the use of laser Doppler velocimetry (LDV). Both DLS and LDV analysis
were performed in triplicate at 25 °C with a Zetasizer Nano series Nano-ZS ZEN3600,
fitted with a 633 nm laser (Malvern Instruments Ltd., UK), using a folded capillary
cuvette (Folded capillary cell-DTS1060, Malvern, UK). The values presented herein were
acquired from three separate experiments, each of which included three replicates, N=3.

3.1.3 Scanning electron microscopy (SEM)

SEM produces images of a sample by scanning it with a focused beam of electrons.
Different types of electron signals, emitted at or near the specimen surface, arise as a
consequence of interactions between the sample and the electron beam that scans across
the sample surface. These electronic signals are then collected, processed, and eventually
translated as pixels on a monitor to form an image of the specimen’s surface topography
that appears three dimensional (Carter et al., 2015). SEM can achieve a resolution of up
to 1 nm. Specimens can be observed in high vacuum, in low vacuum, in wet conditions
(in environmental SEM), and at a wide range of cryogenic or elevated temperatures
(Stokes, 2003).
In this work (Chapters 4, 5, 6 & 8), NP morphology was evaluated by SEM (Hitachi,
SU6600 FESEM, USA), at an accelerating voltage of 20 kV, using the secondary electron
detector. The fresh NP solutions were spin coated onto Si wafers, dried at room
temperature and then sputter coated with 4 nm Au/Pd prior to imaging (Mukhopadhyay
et al., 2013).
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3.1.4 Encapsulation efficiency

Encapsulation efficiency (EE%), refers to the percentage amount of a given bioactive
entrapped within a colloidal system, after the formulation process (Koppolu et al., 2014).
Personal communication with various industrial stakeholders in this project set the target
of EE% to be ≥ 80%.
In this work (Chapters 5, 6 & 8), the EE% of organic Se entrapped within the produced
NPs was determined by the separation and quantification of Se left in the supernatant.
This was performed by ultracentrifugation of the loaded NPs at 3000 rpm, 4 °C for 30
min. Unentrapped Se in the supernatant was then quantified by reverse phase high
performance liquid chromatography (RP-HPLC), as previously described (Ward,
Connolly and Murphy, 2012) with the following modifications. Samples were analysed
with a Waters 2998 HPLC and Photodiode Array Detector, (Waters, USA), using a
Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7 μm, (Agilent Technologies, UK).
Isocratic elution was carried out at a flow rate of 0.4 mL/min, column temperature 45.0
± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid (97.9:2.0:0.1).
Samples were monitored according to their UV absorbance at 218 nm. The encapsulation
efficiency was calculated according to Equation 3.1 (Xu and Du, 2003):

𝑬𝑬% =

𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕−𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕

X 100
(Equation 3.1)
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3.2 Nanoparticle in vitro assessment

3.2.1 Cytotoxicity

The cytotoxicity of a specific material or carrier for a specific in vivo application is
initially accessed via in vitro testing. In this work, a commonly employed cytotoxicity
assay which employs a tetrazolium salt, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), was used.
This assay is based on the reduction of MTS tetrazolium compound by viable cells to
generate a coloured soluble formazan product. This conversion is due to NAD(P)Hdependent dehydrogenase enzymes in metabolically active cells. The formazan dye
produced by viable cells can be quantified by measuring the absorbance at 490-500 nm.
MTS is a derivative of the more commonly employed MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) test, which produces a dye within cells with
functioning mitochondrial activity. The MTS assay has the advantage that the reagent is
added directly into the cell culture media without the intermittent steps which are required
in the routine MTT assay (Malich, Markovic and Winder, 1997).
Generally, it is accepted that an early indication of cellular damage is related to the
reduction of cellular metabolic activity (Rodrigues et al. 2012). Regardless of whether
one uses MTS or MTT, both indicate mitochondrial activity dysfunction, which can be
used to detect disrupted cell function (Rodrigues et al. 2012). The higher the assay
response, the higher the amount of metabolically active cells, which indicates higher cell
viability.
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Cytotoxicity was assessed using human cell lines: Caco-2 (derived from continuous cells
of heterogeneous human epithelial colorectal adenocarcinoma) and HepG2 (derived
from, human hepatocellular carcinoma), to assess whether the NPs formed would be
suitable for oral delivery.
In Chapters 5, 6 & 8, Caco-2 and HepG2, were seeded at a cell density of 2 x 104 cells/well
and cultured on 96 well plates in Dulbecco's Modified Eagle Medium (DMEM) and
Eagle's Minimum Essential Medium (EMEM), respectively, supplemented with 10%
foetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin and 1% non-essential
amino acids at 37°C in a humidified incubator with 5% CO2 and 95% O2. The assay was
carried out using 4 h exposure times for the test compounds on Caco-2 cells (Neves et
al., 2016) and 72 h on HepG2 cells (Gleeson et al., 2015), using Triton X-100™ (0.05%)
as a positive control. The time points were selected to mimic in vivo conditions for each
cell type. The concentrations of the test compounds applied were 25, 50 and 100 uM.
After exposure, treatments were removed and replaced with MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium).
Optical density (OD) was measured at 490 nm using a microplate reader (TECAN
GENios, Grodig, Austria). Each value measured was normalised against untreated control
and calculated from three separate experiments, each of which included six replicates.

3.2.2 Accelerated stability studies

The principle aim of accelerated stability testing is to provide reasonable assurance that
the product will remain at an acceptable level of fitness/quality throughout its timespan
in the market place (Bajaj et al., 2012). Broadly speaking, real-time, retained sample,
cyclic temperature and acceleration, are the four categories into which stability testing
procedures fall (Bhagyashree et al., 2015). In the latter, the product is subjected to
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elevated temperatures and/or humidity well above ambient values, to determine the
temperature at which product failure (i.e. degradation) will occur.
The Arrhenius equation, upon which the interpretation of accelerated stability testing is
based, allows for the determination of the activation energy and consequently, the ability
to extrapolate the degradation rate of a product at lower temperatures (i.e. ambient,
refrigerated etc.). In this instance, the data acquired can then be used to project the shelf
life of the product in a much shorter time than that of real time assessments (Ema, 2003).
This is a beneficial approach to stability testing, as it results in a greatly reduced product
development schedule and provides a good indication of the temperature sensitivity of
the product.
In this work (Chapters 5, 6 & 8), NPs were stored at accelerated conditions: 60°C for
720min, 70°C for 300min and 80°C for 120min (Danish et al., 2017). The particle size,
PDI and ZP were measured over different time intervals, to determine the degree of
degradation. The temperature dependence of the kinetic parameters of organic Se-loaded
NPs stability was measured by calculating the observed rate constants.
This was plotted in an Arrhenius representation and apparent activation energy, Ea and
reaction rate, kref were calculated according to Equation 3.2:

𝑪(𝒕) = 𝑪𝒐 + 𝒆

𝒍𝒏(𝒌)−

𝑬𝒂 𝟏 𝟏
( −
)
𝑹 𝑻 𝑻𝒓𝒆𝒇

𝒕
(Equation 3.2)

where C(t) is the property (particle size, PDI or ZP) at time t, Co is the initial property
conditions, k is the apparent zero order reaction constant, Ea is the energy of activation,
R is the universal gas constant, T is the temperature of the experiment (K) and Tref is the
reference temperature (343 K).
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3.2.3 In vitro controlled release studies

In vitro techniques are advantageous for modelling potential interactions between NPs
and the in vivo environment of the GI tract. Simulated gastric fluid and membrane
analysis models enable assessment of in vivo environments without the use of human cell
lines. The site of target for Se is in the jejunum, in the small intestine. Therefore, it is
important to bypass the acidic stomach environment. Three basic mechanisms that are
typically applied to describe the release of drugs from polymeric particles, are
swelling/erosion, diffusion, and degradation (Liechty et al., 2010).
In this work (Chapters 5, 6 & 8), the total cumulative release of organic Se (SeMet,
SeCys2 or MSC) from the zein coated NPs was carried out using a dialysis bag diffusion
technique (Hosseinzadeh et al., 2012) over 6 hr (Calderon et al., 2013; Yoon et al., 2014).
Freeze dried Se loaded NPs were suspended in 5 mL H2O and probe sonicated (Branson
Ultrasonics; Ultrasonic processor VCX-750W, Wilmington, North Carolina, USA) at 35
% amplitude for 30 s with 5 s intervals and placed into a Float-A-Lyzer®G2 dialysis
membrane with a pore size of 25 kDa (Spectrum Laboratories, USA). The sample was
placed into 40 mL of simulated gastric fluid (SGF) or simulated intestinal fluid (SIF),
specified according to the British Pharmacopoeia (Pharmacopoeia, 2016). SGF was
composed of 0.1 M HCL and SIF was composed of 1 volume of 0.2 M trisodium
phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without
enzymes (British Pharmacopoeia Commission, 2016). Samples were placed in a
thermostatic shaker at 37 ºC and agitated at 100 rpm. At predetermined time points, 1mL
of release fluid was analysed and replaced with simulated fluid to maintain sink
conditions.
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Se release was measured by RP-HPLC (section 3.2.3), whereby Equation 3.3 was used to
determine the % drug release;

𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =

𝑫(𝒕)
∗ 𝟏𝟎𝟎
𝑫(𝒍)
(Equation 3.3)

where 𝑫𝒓𝒖𝒈𝒓𝒆𝒍 is the percentage of SeMet released, D(l) represents the concentration of
drug loaded and D(t) represents the amount of drug released at time t, respectively.

3.3 Chitin/Chitosan characterisation

In Chapter 7, several techniques were employed in the characterisation of chitin (CT),
chitosan (Cs) and trimethyl chitosan (TMC) produced during this project, as detailed in
the following subsections.

3.3.1 Fourier Transform Infrared spectroscopy– Quantitative analysis

In the infrared (IR) region of the electromagnetic spectrum, all covalent compounds have
the capability to absorb frequencies of electromagnetic radiation. Fourier Transform
Infrared spectroscopy (FTIR) is a useful technique for identifying functional groups
within a molecule as it identifies these groups based on the stretching and/or bending of
their bonds rather than on any given property of the atoms themselves. The wavenumber
unit (cm-1) in the IR energy spectrum represents the inverse of wavelength and is
proportional to frequency, typically extending from 4000-400 cm-1 (Pretsch et al., 2000).
This scale is directly proportional to energy, whereby a higher bond energy corresponds
to a higher wavenumber. Compounds with unsymmetrical bond stretching (such as NH2,
OH and C=O) are particularly suited for this type of analysis, attributable to the increased
energy required to vibrate the bond and increased intensity resultant from the change of
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dipole moment when the bond is stretched (Duarte et al., 2002) and as such this was
employed for the quantitative analysis of CT and Cs extracted in this work (Chapter 7).

Figure 3.1 Functional groups present in chitin and chitosan structures, particularly
sensitive to IR analysis.

3.3.2 Gel permeation chromatography - MW determination

MW is an important physical property of Cs and is typically determined via viscosity
measurements or gel permeation chromatography (Baxter et al. 2005; Zielinska et al.
2014). GPC is a useful technique for determination of the molecular weight of polymers
where analytes are separated based on the size or hydrodynamic volume (radius of
gyration) of the analytes. Smaller analytes tend to be retained in the column longer than
larger molecules, owing to their ability to enter the pores present within the column
packing. This contrasts with other chromatographic techniques (e.g. HPLC), which
depend upon chemical interactions between the columns surface chemistry (stationary
phase) and the analyte of interest during separation. Polymers can be defined according
to a number of conventions for molecular weight, including the number average
molecular weight (Mn), the weight average molecular weight (Mw), the size average
molecular weight (Mz), or the viscosity molecular weight (Mv). GPC allows for the
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determination of PDI as well as Mv and, based the concentration of molecules on a
weight/volume basis, the Mn, Mw, and Mz can be determined (Agilent Technologies Inc.,
2015). Essentially, what GPC truly measures is the molecular volume and shape function
as defined by the intrinsic viscosity. If comparable standards are used, this relative data
can be used to determine molecular weights within ± 5% accuracy.

3.3.3 Nuclear magnetic resonance -NMR
Nuclear magnetic resonance (NMR) techniques, such as proton NMR (1H NMR) and
carbon NMR (13C NMR) have been developed and employed to determine: the degree of
acetylation (DA%) of CT (Heux et al., 2000); degree of deacetylation (DDA%) of Cs
(Lavertu et al., 2003) and the degree of quaternisation (DQ %) of TMC (Verheul et al.,
2008). CT is effectively insoluble in most solvents and, as such, solid-state NMR
spectroscopy is suitable tool to analyse its structure, as it mitigates the requirement for
solubilisation. Figure 3.2 displays a typical 13C-NMR spectra of CT which exhibits eight
main peaks, whereby the peaks at 175 and 25 ppm are assigned to the carbonyl and methyl
carbons, respectively, and the peaks at 103, 82, 74, 72, 59 and 55 ppm were ascribable to
the resonances of C1, C4, C5, C3, C6, and C2 on the N-acetyl-D-glucosamine unit of CT,
respectively (Heux et al., 2000).
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Figure 3.2 Chemical structure of chitin and 13 C-NMR chemical shifts associated to each
carbon (adapted from Duan et al., 2013).

The DA% of the CT can then be calculated using the relative integrals of methyl or
carbonyl groups related to the carbon integrals of the polysaccharidic backbone (Equation
3.4,) (Heux et al., 2000).

𝑫𝑨 =

𝑨𝑼𝑪𝟐𝟓 𝒑𝒑𝒎
× 𝟏𝟎𝟎
𝑨𝑼𝑪𝟏𝟕𝟓𝒑𝒑𝒎
(Equation 3.4)

Several methods have been established in order to determine the DDA% of Cs, namely
FTIR (Beil et al. 2012), potentiometric titration (Jiang et al. 2003), UV-Visible
spectrophotometry (Wu & Zivanovic 2008) and 1H-NMR spectroscopy (Lavertu et al.
2003; Hirai et al. 1991), the latter being considered the “gold standard” analytical
methodology for DDA% analysis due to the lack of requirement for a calibration curve
or reference sample of known DDA% (Kasaai 2010, Bellich et al., 2016).
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A typical 1H-NMR spectra of Cs, outlining its structure and characteristic functional
groups, is represented in Figure 3.3 (Kumirska et al., 2011). C-H linkages are produced,
via the six hydrogen and seven carbon atoms present on each unit residue. Likewise, due
to the presence of four hydroxyl groups in each unit residue, O-H linkages are established
(Rinaudo, 2006; Kumirska et al., 2011) also. The characteristics of these unique bond
environments result in each proton possessing its own unique chemical shift. Essentially,
the 1H-NMR spectrum of Cs reflects a superposition of the individual unit residues which
become marginally modified due to their linkages to one another (Kasaai, 2010).

Figure 3.3 Chemical structure of chitosan and 1 H-NMR chemical shifts associated to
each hydrogen (adapted from Weinhold et al. 2009).

The DDA% can then be calculated using Equation 3.5 (Lavertu et al. 2003):

𝑫𝑫𝑨 (%) =

𝟏
(𝟏 − (𝟑 𝑯𝑨𝒄)
𝟏
(𝟔 𝑯𝟐𝟔)

× 𝟏𝟎𝟎
(Equation 3.5)

where HAc corresponds to the methyl protons of the acetyl group and H26 represents the
signal from protons H2, H3, H4, H5, H6, H6 of both monomers, through use of the
integral peak intensity values (Lavertu et al. 2003).
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Synthesis of TMC entails the methylation of the amino groups in the C-2 position of Cs
to form quaternary amino groups (with fixed positive charges) on the repeating units of
the TMC polymer chain (Figure 3.4 A) (Sieval, et al, 1998). There is also some degree
of methylation on the 3 and 6 hydroxyl groups of the Cs polymer and partial
quaternisation on the amine unit that can reduce the aqueous solubility of the product
(Figure 3.4 B) (Verheul et al., 2008).

Figure 3.4 Chemical structure of TMC. TMC can vary in degree of quaternisation (A),
and O-methylation (B). The various substitutions are randomly distributed throughout
the polymer and mono and di-methylation (incomplete quaternisation) may occur on the
amine unit also (B) (Verheul et al., 2008).

Figure 3.5 shows the typical structure and characteristic functional groups of TMC as
observed in 1H-NMR spectra. The degree of quaternisation (% DQ) and O-methylation
(OMe) can then be calculated using the following equations (Zarifpour, 2013):

𝑫𝑸 =

[(𝑪𝑯𝟑 )𝟑 ] 𝟏
× × 𝟏𝟎𝟎%
[𝑯]
𝟗
(Equation 3.6)

𝑶𝑴𝒆 =

[(𝑪𝑯𝟑 )] 𝟏
× × 𝟏𝟎𝟎%
[𝑯]
𝟑
(Equation 3.7)

where DQ is the degree of quaternisation, in mole percentage of free amine, [(CH 3)3] is
the integral of chemical shift of the hydrogens of trimethyl amino groups at 3.3 ppm,
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[(CH3)] the methylated hydroxyl groups at either 3.4 (OMe-6) or 3.5 (OMe-3) ppm and
[H] is the integral of H-1 peaks between 4.7 and 5.7 ppm, related to hydrogen atoms
bound to carbon 1 of the chitosan molecule, which is taken as the reference signal.

Figure 3.5 Chemical structure of TMC and 1 H-NMR chemical shifts associated to each
hydrogen (adapted from Verheul et al., 2008).

3.4 TEER-Permeation enhancement

Cs extracted from A. bisporus was assessed as an intestinal permeation enhancer using
Caco-2 monolayers via an electrical method known as transepithelial electrical resistance
(TEER, Ω cm2). TEER is measured across the monolayers using an EVOM® voltammeter
with a chopstick-type electrode (EVOM®, WPI, UK). It allows for the assessment of
transport of a molecule through tight junction (TJ) pores (paracellular route) (Hidalgo,
2001). Hydrophilic molecules must rely on transport between adjacent cells through the
paracellular pathway, unless they are substrates for membrane transporters and so are not
likely to transverse lipid rich cell membranes (Upadhyay, 2014). A schematic
representation of paracellular and transcellular transport is shown in Figure 1.2.
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In essence, the cell membrane can be thought of as an electrical insulator, in which the
lipophilic components that constitute the cell membrane are responsible for maintenance
of the membrane’s electrical potential, in addition to inhibiting the movement of water.
The tight junctions (TJs), on the other hand, possess open pores that allow the passage of
water and ions through fluid filled routes and as such can be considered as electrical
conductance pathways. An electrical potential difference, which is measurable as
electrical resistance, is created due to the TJs of the monolayers of epithelial cells
restricting the movement of ions (Anderson and Van Itallie, 2009). With a decrease in
TEER, in conjunction with an increased ionic conductance, an increase in paracellular
permeability of ions across a monolayer is indicated rather than transcellular
permeability. Even in the presence of ion channels, significantly lower resistance and
concordantly higher conductance to ion flow is seen in the paracellular space, as opposed
to the cell membranes.
TEER has been applied to study the permeation enhancing effects of compounds such as
polyacrylic acid, polycarbophil and Cs, over recent years (Aungst, 2000; Liu et al., 2008;
Maher, Mrsny and Brayden, 2016). The latter has been shown to exhibit a reversible time
and dose dependant decrease in TEER values in Caco-2 cells, indicating its ability to open
the TJs (Ranaldi et al., 2002). The effect of Cs on TJs was confirmed by increasing the
permeation coefficient of mannitol when applied in conjunction with 0.1-0.5 w/v % Cs
solution for 60 min, compared to cells treated with mannitol in the absence of Cs (Dodane,
Khan and Merwin, 1999). Additionally, observations by Sonaje et al. (2012) have also
suggested that the opening of TJs by Cs at 0.2 mg/mL is transient and reversible in Caco2 cell monolayers, further indicating it as an effective permeation enhancer.
It has been shown that specific MWs of Cs significantly influence its permeation
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enhancement (Chae, Jang and Nah, 2005). For example, studies by Opanasopit et al.
2007, showed that, as the MW of Cs is increased from 20 to 460 kDa, the reduction in
TEER significantly decreased in the order: 20 < 45 < 200 < 460 kDa, observed in Caco2 cell lines.

3.5 Selenium speciation

As the bioavailability of Se is highly dependent on its speciation, organic formats are
typically sought after when proposing a health supplement (Rayman, 2000). Typically,
Se is supplemented with SeMet, produced from Saccharomyces cerevisiae, a strain of
yeast which, when cultivated with minimal S in the presence of inorganic Se, possesses
the ability to accumulate up to 1400 µg SeMet per g of dried sample (Suhajda et al.,
2000). The high yield of Se from selenised yeast is one of the main factors for its
employment. However, an alternative source of Se has been investigated in recent years,
the edible mushroom A. bisporus.
The Irish mushroom industry produces in the region of 200,000 tonnes of spent
mushroom substrate (SMS) every year (Teagasc Mushroom Stakeholder Consultative
Group, 2013). Naturally, A. bisporus, contains an average of >1 µg Se/g dw (Savic et al.,
2012). However, when cultivated in substrates containing Se in either inorganic or
organic forms, they exhibit much higher concentrations, ranging from 354 ± 0.19 to 707
± 37.3 µg of Se per g of dried sample (Gergely et al., 2006; Savic et al., 2012). Previous
studies conducted in DIT identified high levels of SeCys2 (≈60 µg/g) in A. bisporus
samples supplied by Monaghan mushrooms (Vozza, 2013). However, identification of
the source and total Se content in the fruiting bodies was beyond the scope of the research,
at that time. Regardless, the levels of SeCys2 alone reflected Se fortification had occurred
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during cultivation and that these Irish mushrooms may potentially offer an alternative
source of Se to S. cerevisiae.
In order to use Se species sourced from A. bisporus in the NP formulation, it is first
necessary to isolate fractions of Se from the fruiting bodies of the mushrooms and identify
the species present. However, to date, no robust method for complete extraction and
analysis of Se from food sources has been developed (Thiry et al., 2012). Careful
optimisation of extraction procedures is an essential requirement for Se speciation
analysis of solid samples, in order to achieve high extraction efficiencies that also
mitigate interconversion of the original species present (Dumont, Vanhaecke and
Cornelis, 2006). It is generally recognised that a single step extraction is insufficient for
Se liberation due to the varied matrix associations of Se in real samples (Pyrzyńska,
1996). For example, hot water extraction has been employed as a Se leaching solution for
three edible wild mushroom species (Macrolepiota procera, Lepista luscina and Boletus
luridus). However, it was shown that merely 47% of the total Se content present in the
sample (present in water soluble proteins) could be recovered (Huerta, Sánchez and SanzMedel, 2005).
As many Se species are protein bound, several authors have utilised strong acids in
extraction procedures, in order to increase liberation of Se from various matrices (Casiot
et al., 1999; Wrobel et al., 2003). Additionally, proteolytic enzymes have been employed
for extracting SeAAs incorporated into proteins due to their ability to cleave peptide
bonds (Montes-Bayón et al., 2006). Also, inorganic forms of Se have been found to
become entrapped physically or chemically into cell walls and as such, acids and nonproteolytic enzymes such as driselase have been used in Se extraction (Infante, Hearn and
Catterick, 2005).
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In this work, Se species were extracted from Se supplemented A. bisporus samples, using
protease enzymes, under microwave energy following the procedure detailed by (Ward,
Connolly and Murphy, 2012). Once optimised, the entire procedure was subjected to a
validation protocol, based on approved guidelines (EMEA, 1995), to assess its suitability
for routine work.

3.5.1 HPLC-DAD

High Performance Liquid Chromatography (HPLC) is a powerful technique for
separating complex mixtures and quantitating their components. HPLC equipment can be
as simple as a specialised pump, a means of permitting sample injection, a specialised
column and a suitable detector. In this work, a HPLC system coupled with a diode array
detector (DAD) was employed for Se species quantification. A DAD detects the
absorption in the UV to visible region of the spectrum. While a UV-VIS detector has only
one sample-side light-receiving section, a beneficial feature of a DAD is that it has
multiple (1024) photodiodes to obtain information over a wide range of wavelengths at
one time. DADs differ from conventional UV-VIS detectors in that, light from the lamps
is shone directly onto the flow cell, light that passes through the flow cell is dispersed by
the diffraction grating, and the amount of the dispersed light is estimated for each
wavelength in the DAD (Figure 3.6).
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Figure 3.6 Schematic representation of a DAD optical system (picture acquired from
www.crawfordscientific.com).

3.6 Summary

This chapter has presented the experimental techniques used throughout this thesis and
provided relevant information and theory about each of the techniques employed.
Experimental procedures were described, with specifications and parameters used given
for each relevant procedure replicated throughout this thesis. The following chapter (4)
will present the results of the optimisation and the characterisation of unloaded chitosan
NPs that were formulated to ascertain formulation constituents and quantities that were
requisite to hit target physicochemical and morphological properties. Finally, the specific
detail on the applications of each technique will be described in the experimental section
of the subsequent chapters (5, 6, 7 & 8), which are presented in the form of papers.
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4.1 Introduction

Cs is a linear polysaccharide, prepared by N-deacetylation of chitin, the second most
abundant biopolymer in nature (next to cellulose) (Prochazkova, Vårum and Ostgaard,
1999). Cs holds a unique positive charge when dissolved in acid media (owing to the
primary amines present on its backbone), is biocompatible, non-immunogenic,
nontoxic and biodegradable, making it a choice component for oral drug delivery
systems and attractive for biomedical applications (Agnihotri, Mallikarjuna and
Aminabhavi, 2004; Bezerra et al., 2008; Saini et al., 2014). Cs nanoparticles (NPs)
are emerging polymeric bioactive carriers that have received attention for nutrient
delivery (Luo et al., 2010; Akhtar, Rizvi and Kar, 2012; Chen et al., 2013; Fathi,
Martín and McClements, 2014; Sarvaiya and Agrawal, 2015).
Specifically, Cs NPs can be made using a variety of techniques, such as complex
coacervation (Diop et al., 2015), co-precipitation (Bhattarai et al., 2006),
polyelectrolyte complexation (Kouchak and Azarpanah, 2015), solvent evaporation
(Nagpal, Singh and Mishra, 2010), emulsification solvent diffusion (Fathi, Martín and
McClements, 2014), micro-emulsion (El-Shabouri, 2002) and ionotropic gelation
(IG) (Yan et al., 2012; Ramasamy et al., 2014; Wu et al., 2014). The latter has been
considered more favourable for the stability of the cargo, owing to the ease with which
the NPs can be produced under mild operating conditions (room temperature, low
stirring rates) and mild solvents (dilute acids and bases) (Koppolu et al., 2014).
This research work has used the IG technique for the preparation of Cs NPs, by
ionically cross-linking Cs with a counter ion sodium tripolyphosphate (TPP)
(Sureshkumar et al., 2010). IG is based on the interaction between the negatively
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charged phosphate groups of TPP and the positively charged amino groups of Cs
Figure 4.1. When the concentrations of the cationic polymer Cs and oppositely
charged anionic polyelectrolytes are at appropriate pH values to induce sufficient
protonation/ionisation charge, electrostatic crosslinking can occur resulting in the
generation of NPs (Calvo et al., 1997).

Figure 4.1 Schematic representation of cross-linking between Cs and TPP
(adapted from Sureshkumar et al. (2010)).
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There are several process variables known to affect the properties of Cs NPs produced
via the IG technique, the most commonly studied being:
1.

The pKa of Cs itself and the target BA to be encapsulated (modulated through the
formulation media pH) (Fonte et al., 2014)

2.

The mass ratio of Cs to its oppositely charged crosslinker/counter ion (Gupta and
Karar, 2011)

3.

The stirring rate and stabilisation time the formulation is subjected to during the
crosslinking process (Grenha, 2012)

4.

The DDA and MW of the Cs used (Aktaş et al., 2005)

Research studies, regarding the encapsulation of bioactive nutrients within a Cs based
NP delivery system, include the binding of curcumin (CUR) onto Cs NPs through
passive diffusion, which produced a significant 3 fold reduction in the plasma
concentration of Plasmodium yoelii infected mice, compared to the rapidly
metabolised intact CUR drug (Akhtar, Rizvi and Kar, 2012). In another study, the oral
administration of Cs insulin loaded Cs NPs formed via the complex coacervation
method, was shown to be effective in lowering the blood glucose level of alloxaninduced diabetic mice, showing promising effects as a potential insulin carrier system
in animal models (Mukhopadhyay et al., 2013). In 2008, Kwon, showed successful
systemic administration of the anticancer drug, paclitaxel, encapsulated in Cs NPs in
SCC7 tumour-bearing mice, resulting in sensitive tumour-detection ability, ultimately
leading to simultaneous early-stage cancer diagnosis, drug delivery, and therapy
(Kwon, 2008).
It is worth noting that the success of these NPs applicability strongly depends on the
physicochemical properties of the produced NPs, such as particle size, ZP and PDI
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(des Rieux et al., 2006). Despite the simplicity of IG, controlling the process for the
reproducible, systematic, production and prediction of NP size, ZP and PDI is a
difficult task, attributable to the large number of aforementioned variables that can
affect the final product (Landriscina, 2015). Successful translation of NPs from bench
to bedside, depends on overcoming obstacles in terms of scalability and
reproducibility (Dong et al., 2013). Consequently, several attempts have been made
to optimise this methods outcome, for example, the variations in Cs molecular weight,
Cs concentration, Cs to TPP weight ratio and solution pH value have been investigated
for their effects on NP size, ZP and PDI (Pan et al., 2002; Jonassen, Kjøniksen and
Hiorth, 2012; Rampino et al., 2013; Kleine-Brueggeney et al., 2015). Often these
studies employ a OFAT approach for NP process optimisation and, although useful in
preliminary screening of factors and/or identification of the working ranges for these
factors, limited knowledge of the process can be gained by this approach. In contrast,
statistically designed experiments that vary several factors simultaneously are more
efficient when studying two or more factors aiming for optimisation (Ferreira et al.,
2007). RSM is a collection of mathematical and statistical techniques for designing
experiments, that: evaluates the relative significance of several independent variables
and their interactions, allows for building of regression models and determines the
optimum conditions for desirable responses, minimising the number of experiments
(Anarjan et al., 2011; Xue et al., 2015). While OFAT experiments are more
commonly adopted in the literature, designed experiments offer several advantages
over the OFAT counterparts (Politis et al., 2017):
•

First, RSM reduces the number of experimental runs typically required to gather
the same information as OFAT, thus reducing resource requirements.
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•

Second, RSM is useful in detecting interdependencies of variables that would not
be typically identified during OFAT experiments

•

Third, RSM improves the prediction of a response through use of gathered
information from a larger parameter space (Abdel-Hafez, Hathout and Sammour,
2014).

•

Fourth, RSM provides an iterative approach to experimental design where the
previous knowledge will contribute to the design specification of the next
experiment.

Recently, RSM experimental designs such as the Central composite and Box–
Behnken have been investigated for NP formulation optimisation (Hao et al., 2012;
De Carvalho et al., 2013; Zolgharnein, Shahmoradi and Ghasemi, 2013). The CCD is
a suitable approach to understand the effects of formulation variables (independent
factors) and the interactions between factors on the responses (dependent factors).
Commonly employed CCDs take factors at five levels (two-level factorial design
points, axial or star points, and centre points), resulting in a fully rotatable design (Hao
et al., 2012).
In this work, the mass ratios of Cs:TPP ranging from 4:1-27.5:1 were selected for
investigation, as these high and low levels were identified from previous preliminary
studies as feasible ranges for Cs NP production (Khalid, 2014). Further investigation
of these variables allowed for supplementary information on the characteristics of Cs
NP formation and their dependency on the Cs and TPP interaction. Overlaid contour
plots were used for optimisation purposes to produce NPs at a targeted diameter of
200-300 nm. The formulated NPs were characterised by DLS, SEM and FTIR
spectroscopy.
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4.2 Materials and Methods

4.2.1 Materials
The Cs compound PROTASAN™ UP (CL113) was purchased from NovaMatrix,
FMC Corporations, Norway. Sodium tripolyphosphate, technical grade, 85%, sodium
acetate anhydrous, for molecular biology, ≥99%, acetic acid, ACS reagent, ≥99.7 were
obtained from Sigma Aldrich, Ireland. Ultrapure water was obtained from a Milli-Q
(Millipore Corporation, USA) water purification system and was used for all aqueous
solution preparations throughout.

4.2.2 Central composite design

CCD (Bulmer, Margaritis and Xenocostas, 2012) was used to (i) determine the
optimum concentration ratio of Cs to cross linker, TPP and (ii), produce NPs with the
optimum physicochemical properties recommended for oral delivery (~300 nm
particle size, PDI < 0.5 and ZP > 30 mV). DoE software (Minitab™ 17, Pennsylvania,
USA) produced a two factor design with 5 levels. Centre points were replicated 5
times in order to estimate the experimental error and curvature associated with the
design. The formulation variables, concentration of CL113 (mg/mL) and
concentration of TPP (mg/mL), in addition to their high and low levels were identified
from previous preliminary studies (Khalid, 2014).
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A second order polynomial model (Equation 4.1) was used to approximate the
response surface:
Ri = b 0 + b 1 A + b 2 B + b 11 A 2 + b 22 B 2 + b 12 AB+ ε
(Equation 4.1)
where Ri is the measure of the response associated with each factor level combination,
b0 is an intercept, b1…b22 are the regression coefficients, A and B are the independent
variables, and A2, B2 and AB denote the quadratic terms and interactive term
respectively and  the error term. The responses selected were size, PDI and ZP with
the following criteria of minimise, minimise, and maximise adopted respectively. The
translation of coded levels into the actual variables natural units of measurement
(concentration (mg/mL) of CL113 and TPP) are denoted in Table 4.1.
In this experiment, the desirability function was created to give equal weight to
particle size, PDI and ZP, with EE% not included.
Table 4.1 Variables and levels employed in the CCD design (α=1.414)

Coded level
A: CL113 (mg/mL)
B: TPP (mg/mL)

-α
1.10
0.04

-1
1.20
0.10

0
1.45
0.25

1
1.70
0.40

+α
1.80
0.46

4.2.3 Preparation of unloaded Cs:TPP NPs

Cs solution (10 mg/mL) was prepared by adding 100 mg of CL113 to 10 mL of sodium
acetate-acetic acid buffer (pH 3) and stirring at 700 rpm for 4 hrs. Once fully
dissolved, the Cs solution was then filtered through a 0.22 μm syringe filter (Millex
Millipore) and diluted to experimental requirements with pH 3 buffer. Cs:TPP NPs
were then formed according to the ionotropic gelation process (Calvo et al., 1997)
with slight modifications. Aqueous TPP solution (10 mg/mL) was prepared and
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diluted with H2O to experimental requirements and subsequently added via burette
droplet addition to the Cs solution. The NPs formed were then left to stabilise for a
further 30 min whilst the stirring speed of the solution was maintained at 700 rpm.
After stabilisation, NPs were then transferred to a 20 kDa MWCO (Vivaspin 20,
Sartorius) centrifugal filter and isolated by centrifugation at 3000 rpm for 30 min.
Filtered H2O (equivalent in volume to the recovered supernatant) was then added to
the purified NPs and the suspension was subsequently sonicated at 35 % amplitude
for 30 s with 5 s pulse intervals. Physicochemical properties of the NPs (size, PDI and
ZP) were then determined using a Malvern Zetasizer NanoZS (Worcestershire, UK),
under the conditions described in Chapter 3, Section 3.2.1.

4.2.4 Fourier transform infrared spectroscopy (FTIR)

FTIR spectra of CL113, TPP and Cs:TPP NPs were acquired via a Spotlight 400 series
spectrometer (Perkin Elmer, USA), using the attenuated total reflectance spectroscopy
method (ATR-FTIR), in the range of 650-4000 cm-1. Prior to analysis, NP samples
were lyophilised using a FreeZone 6 L bench top freeze dry system (Labconco, USA)
at -40 °C for 20 hrs. The dried solids were then placed on the ATR crystal prism
(ZnSe), and 32 scans were acquired at 4 cm−1 resolution with background subtraction
(Vongchan et al., 2011).

4.2.5 Morphology assessment of formulated NPs- SEM

SEM analysis was used to ascertain the morphology of the formed CS:TPP NPs, under
conditions described in Chapter 3, Section 3.2.2.
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4.3 Results and Discussion

4.3.1 CCD

The observed values for all 13 experiments encompassed by the CCD are presented
in Table 4.2. Minimum and maximum values obtained for particle size, PDI, and ZP
were (194, 850 nm), (0.396, 0.799) and (24, 47.3 mV) respectively.
Table 4.2 CCD design matrix and corresponding results for dependant va riables.

Batch

A:CL113 (mg/mL)

B:TPP (mg/mL)

1
2
3
4
5
6
7
8
9
10
11
12
13

1.10
1.45
1.45
1.45
1.45
1.45
1.80
1.45
1.20
1.20
1.70
1.45
1.70

0.25
0.46
0.25
0.25
0.25
0.04
0.25
0.25
0.40
0.10
0.10
0.25
0.40

Size
(nm)
233
203
186
194
194
850
274
189
199
608
661
220
233

PDI
0.500
0.420
0.412
0.421
0.406
0.723
0.396
0.535
0.430
0.799
0.543
0.461
0.411

ZP
(mV)
34.0
24.3
52.5
47.3
44.1
31.0
38.5
41.5
24.0
28.0
29.0
40.0
27.0

The significance of independent variables and their interactions was assessed by
statistical software (Minitab™,17) to generate regression models. Through
bidirectional elimination (testing at each step for variables to be included or excluded),
non-significant terms were removed from the model in order to calculate regression
equations with significant terms only (Wang et al., 2013). The calculated regression
coefficients and standard errors for size, PDI and ZP of the reduced models are shown
in Table 4.3, in which coefficients related to the independent variables with significant
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t-values (p ≤0.05) were used. Higher significant effects of the independent variable
on the response are indicated by a lower p-value.
As discussed in Chapter 3 (Section 3.3), RSM allows for the construction of a
mathematical model to identify the optimum level of each factor to produce a target
response (Reddy et al., 2017). As such, the application of CCD to map the response
(particle size (nm), PDI and ZP (mV)) over the experimental domain studied, was
used to identify and tune an optimal formulation with desirable properties (des Rieux
et al., 2006) for oral delivery and is explored in the following section.

Regarding the size of the NPs, the model shows that two linear [concentration of
CL113 (A) and TPP (B)] and two quadratic [(AA) (BB)], terms were significant (p<
0.05). Size was mostly affected by the quadratic effects of the B*B term, whereby a
positive correlation was observed such that, at minimum and upper levels of B, size
increased. It is also worth noting that, the linear term of B showed a negative
coefficient, indicating that B has a negative effect on size until a turning point is
reached, after which the B*B term has a positive impact on size. This is in agreement
with the contour plot (Figure 4.2, B) and findings by Calvo et al. (1997), which
showed that intermediate concentrations (ratio of Cs:TPP of 5:1) of TPP gave rise to
smaller NPs compared to lower and higher concentrations. Additionally, they found
that formation of NPs was only possible at specific concentrations of Cs and TPP,
with a maximum concentration of 3 mg/mL and 0.75 mg/mL respectively (Calvo et
al., 1997).
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Table 4.3 The normalised estimated regression coefficients and standard errors, for
size, PDI and ZP of the reduced models. All parameters statistically significant
(p<0.05).

Estimated regression Coefficients for size (nm)
Term
Coef
SE Coef
Constant
196.83
9.79
A: CL113 mg/mL
25.4
10.9
B: TPP mg/mL
-307.9
10.9
2
A : CL113
72.6
16.5
mg/mL*CL113 mg/ml
B2: TPP mg/mL*TPP
345.6
16.5
mg/mL
𝑹𝟐𝒂𝒅𝒋 =99.04 %
Model summary
R2 = 99.36 %
Estimated regression Coefficients for PDI
Term
Coef
SE Coef
Constant
0.4532
0.0167
A: CL113 mg/mL
-0.0743
0.0230
B: TPP mg/mL
-0.1635
0.0230
2
B : TPP mg/mL*TPP
0.1399
0.0345
mg/mL
A*B: CL113
0.1161
0.0452
mg/mL*TPP mg/mL
𝑹𝟐𝒂𝒅𝒋 = 86.98 %
Model summary
R2 = 91.32 %
Estimated regression Coefficients for ZP (mV)
Term
Coef
SE Coef
Constant
45.10
1.91
A:CL113 mg/mL
1.82
2.13
B:TPP mg/mL
-2.72
2.13
A2: CL113
-11.22
3.22
mg/mL*CL113 mg/ml
B2: TPP mg/mL*TPP
-19.77
3.22
mg/mL
𝑹𝟐𝒂𝒅𝒋 = 78.44 %
Model summary
R2 = 85.62 %
As PDI reflects the NP size distribution (whereby samples with a wider range of
particle sizes have higher PDI values and vice versa), it is highly desirable that NP
formulations consist of monodisperse populations, to ensure that the system can
deliver its cargo over a sustained period of time (Nagpal, Singh and Mishra, 2010).
Table 4.3 shows that PDI was mostly affected by the linear effect of B (TPP
concentration mg/mL), i.e. PDI decreases as B increases one unit from median levels.
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Consequently, the quadratic terms of B*B showed a positive correlation, signifying
that PDI increases at upper and lower levels of B. This agrees with the contour plot
(Figure 4.2, C). This finding supports the work of other authors that observed the free
primary amino groups of Cs decreasing upon the addition of TPP, indicating the
formation of monodisperse Cs:TPP via anionic and cation linkages of both
polyelectrolytes (Masarudin et al., 2015).
In terms of ZP, the two quadratic terms [(A*A), (B*B)] were found to have a negative
effect on ZP, whereas the linear terms were shown to have a positive effect on ZP.
Table 4.3 shows the quadratic effect of TPP on the highest effect on ZP, indicating
that, at concentrations above and below median levels, a decrease in ZP is observed.
The positive correlation observed for the linear term of B indicates that, at one unit
above median level, ZP is increased signifying curvature in the model and a maximum
value for ZP can be achieved at this level. Figure 4.2A indicates that the optimum
value (maximum) for ZP can be found within the range of variables studied: ≈ 1.5
mg/mL Cs to 0.25 mg/mL TPP (Ratio 6:1). This is in agreement with other authors’
findings, as several studies investigating the optimum ratio of Cs to TPP have
indicated that a ratios of 4:1 – 8:1 give rise to the most stable NP complexes (Pan et
al., 2002; Kouchak and Azarpanah, 2015), attributable to sufficient quantities of TPP
that allow for the formation of crosslinked NPs, yet are not in an excess of that which
would result in complete neutralisation of the cationic charge on the free primary free
amines of Cs (Huang, Cai and Lapitsky, 2015)
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Contour Plot of PDI vs TPP mg/mL, CL1 1 3 mg/mL
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Figure 4.2 Contour plots for Zeta potential (mV) (A), PDI (B), and size (nm) (C) vs TPP (mg/mL), CL113 (mg/mL)

4.3.2 Optimisation of CL113 and TPP concentrations for Cs:TPP NP
formation

Overlaid contour plots for the fitted polynomials predicting the change of PDI, ZP and
particle size with Cs and TPP concentration were employed in order to identify optimum
conditions for the formulation, whereby NPs with sizes between 200-300 nm, PDI <0.5
and ZP >30 mV could be produced. Figure 4.3 details the results and shows that
increasing concentrations of Cs ≈ 1.68-1.8 mg/mL and intermediate TPP concentrations
≈ 0.20-0.37 mg/mL give rise to a region in which NP target properties can be achieved.

Figure 4.3 Overlapped contour plots for the fitted polynomials predicting the change
of PDI, Zeta potential and particle size with Cs and TPP concentration. The feasible
zone with PDI< 0.5, Zeta< 30 (mV) and Size> 200 (nm) is indicated in white.

By employing the constructed models from the CCD evaluation, response optimisation
could be used to establish an optimum NP formulation. In this approach, the value of each
response for a given combination of controllable factors is first translated to a number
between zero and one, known as individual desirability (Bezerra et al., 2008). An optimal
minimum (size (nm)), minimum (PDI) and maximum (ZP (mV)) forecast has been
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obtained with the present models and is presented in Figure 4.4, indicating that when the
variable settings of CL113 mg/mL and TPP mg/mL are set at ratio ≈ 6:1 (1.53 mg/mL
and 0.27 mg/mL respectively), NPs with the desired properties are produced. The 95%
confidence interval ranges that these conditions would produce are presented in Table
4.4. This is in agreement with previous authors’ findings (Janes, Calvo and Alonso, 2001;
Antoniou et al., 2015).

Figure 4.4 Desirability profiles for the optimisation problem, maximising the Zeta
potential and minimising particle size and PDI of the particles.

To verify the validity of the proposed models, n = 4 replicates of the optimised
formulation was prepared, and each experimental response was compared with the
predicted one. Table 4.4 shows the validation results of the model, whereby NPs
presented sizes of 161.3 ± 43 nm, PDI of 0.391 ± 0.022, ZP of 41.5 ± 3.1. No statistically
significant values (p>0.05) for predicted and measured responses (Size, PDI and ZP) were
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observed, indicating that the models fit the data satisfactorily. Lastly, by employing a
CCD, many additional experiments (in addition to time consuming laborious laboratory
studies) were eliminated in comparison to a OFAT approach.
Table 4.4 95% confidence intervals of the particle characteristics that optimal
conditions would produce under the present experimental conditions of uncertainty .

Response
Size
PDI
ZP

Fit
181.5
0.4247
44.5

SE fit
9.6
0.0175
1.9

95% CI
(159.4, 236.6)
(0.3843, 0.4651)
(40.2,48.8)

4.3.3 Characterisation of unloaded Cs:TPP NPs - FTIR

Figure 4.5 shows the FTIR spectra of (A) TPP, (B) Cs and (C) Cs:TPP NPs and the
characteristic peaks associated with TPP and Cs are presented in Table 4.5.
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Figure 4.5 FTIR spectra of (A) TPP, (B) Cs and (C) Cs:TPP NPs. N=3 .

By observing the intermolecular interaction of Cs:TPP NPs via FTIR (Figure 4.5, C), it
can be seen that the spectrum is different to that of the Cs matrix. If interaction between
the Cs and TPP has occurred, it will lead to frequency shifts or splitting in absorption
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peaks (Gan et al., 2005). For example, the peaks at 1514 cm-1 in the Cs spectrum have
been shifted to 1529 cm-1, indicating electrostatic interaction between the phosphate
groups of TPP and the amino groups present in the Cs NP matrix (Papadimitriou et al.,
2008). Additionally, the broadening and the reduced absorbance of the peak at 3272 cm 1

indicate hydrogen bonding has been enhanced (Luo et al., 2010). The crosslinked Cs

also showed a peak for P = O at 1155 cm–1.
Table 4.5 FTIR analysis of characteristic peaks associated with TPP and Cs .

NH Stretch / OH in pyranose ring

TPP
Wavelength
(cm-1)
1121, 886
Chitosan
Wavelength
(cm-1)
3240

CH2 in CH2OH group

2879

C=O in NHCOCH3 group (amide I)

1625

NH2 in NHCOCH3 group (amide II)

1514

CH3 in NHCOCH3 group

1376

C-O-C (glycosidic linkage)

1063

Bond
P=O
Bond
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Reference
(Bhumkar and Pokharkar, 2006)
Reference

(Luo et al., 2010; Mohammed,
Williams and Tverezovskaya,
2013)

4.3.4 Scanning electron microscopy (SEM)

Figure 4.6 shows the SEM image of unloaded Cs:TPP NPs. Spherical, monodisperse
particles were observed and the particle size of the NPs after spin coating was in good
agreement with the DLS measurements taken on the freshly prepared NPs.

Figure 4.6 SEM image of unloaded Cs:TPP NPs.
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4.4 Conclusion

In this work, Cs:TPP NPs have been produced via ionotropic gelation. As one of the most
influential variables that dominates the size, PDI, ZP and morphology of ionotropic
formed Cs NPs has been established to be Cs:TPP mass ratios (Almalik et al., 2013), a
CCD statistical design was employed to generate a mathematical model that identified
the optimum ratio of Cs:TPP for NPs with properties reported to be beneficial for oral
drug delivery (des Rieux et al., 2006). The results of the CCD design identified that, at
approximate concentrations of Cs (1.68 - 1.8 mg/mL) and intermediate concentrations of
TPP (0.20 - 0.37 mg/mL), a feasible region was produced in which NP target properties
could be achieved. The physicochemical properties of the NPs produced from the
validation of the CCD study were assessed by DLS, showing that, under optimum
conditions of Cs:TPP (6:1), NPs with sizes of 161 ± 43 nm, PDI of 0.39 ± 0.02, ZP of 42
± 3 could be produced. Evidence for the formation of NPs via ionotropic gelation was
acquired via FTIR analysis, through identification of key functional groups on Cs and
TPP and identifying their shifts in the crosslinked matrices. The morphology of the NPs
was then assessed by SEM analysis, showing that spheroidal, well distributed particles
were formed. The findings provide an overview to produce Cs NPs with desirable
physicochemical properties for successful use in drug delivery.
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Abstract
Selenomethionine is an essential amino acid with a narrow therapeutic index and
susceptibility to oxidation. Here it was encapsulated into a nanoparticle composed of
chitosan cross-linked with tripolyphosphate for oral delivery. The formulation was
optimised

using

a

three-factor

Box-Behnken

experimental

design.

The

chitosan:tripolyphosphate ratio, chitosan solvent pH, and drug load concentration
were independently varied. The dependent variables studied were encapsulation
efficiency, particle size, polydispersity index (PDI) and zeta potential (ZP). For
optimisation, encapsulation efficiency and zeta potential were maximised, particle
diameter was set to 300 nm and PDI was minimised. A 0.15mg/mL concentration of
selenomethionine, chitosan solvent pH of 3, and chitosan:tripolyphosphate ratio of 6:1
yielded optimum nanoparticles of size 187±58nm, PDI 0.24±0.01, ZP 36±6mV, and
encapsulation efficiency of 39±3%. Encapsulation efficiency was doubled to 80±1.5%
by varying pH of the ionotropic solution components and by subsequent coating of
the NPs with zein, increasing NP diameter to 377±47nm, whilst retaining PDI and ZP
values. Selenomethionine-entrapped nanoparticles were not cytotoxic to intestinal and
liver cell lines. Accelerated thermal stability studies indicated good stability of the
nanoparticles under normal storage conditions. In simulated gastrointestinal and
intestinal fluid conditions, 60% cumulative release was obtained over 6 hours.
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Abbreviations
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5.1 Introduction

Selenium is an essential micronutrient in human and animal nutrition (Rayman, 2000),
that exists in a wide array of different formats, both organic and inorganic, better
known as speciation. Selenomethionine (SeMet), the selenium analogue of
methionine, is the predominant form of organic Se found in foods from the Brassica
and Allium families (Reilly et al., 2014). SeMet is used for oral supplementation due
to its capacity to be non-specifically incorporated into body proteins in place of
methionine (Rayman, Infante and Sargent, 2008). The potential health benefits of
selenium are dependent on its chemical species, and several studies have suggested a
possible role in cancer prevention (Nie et al., 2016), increased immunological status
(Narayan et al., 2015) and increased fertility (Shanmugam et al., 2015). SeMet may
also to have a number of benefits regarding oncology treatments due to its modulation
of the therapeutic efficacy and selectivity of anticancer drugs (Evans, Khairuddin and
Jameson, 2017), capacity to provide protection of normal tissues from the toxicities
associated with chemotherapy and radiation treatments, in addition to enhancing their
anti-tumour effects (Chintala et al., 2012; Mix et al., 2015; Panchuk et al., 2016). It
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may also have some potential in degenerative disease by decreasing oxidative stress
of small molecule antioxidants used as a buffer for free radicals in brain tissue (Song
et al., 2014; Reddy et al., 2017). However, the oral delivery of SeMet can be
challenging due to the distinctive electronegativity and atomic radius of the selenium
atom (i.e. larger radius and lower electronegativity than sulphur,) that makes it easier
for low valence state Se compounds to be more readily oxidised compared to their
sulphur counter parts (Xu, Cao and Zhang, 2013). SeMet is readily oxidised (Davies,
2016) and, even though it is less toxic than inorganic selenium (Se), it still has a low
therapeutic index (Takahashi, Suzuki and Ogra, 2017). Oral delivery formulations of
SeMet therefore need to consider the balance between doses that exert beneficial
effects and those which may potentially be toxic.
Inorganic Se species such as selenite (SeO32-) and elemental selenium (Se0), together
with methylseleninic acid, have been formulated to nano-enabled delivery systems
which exhibited improved bioactivity with reduced cytotoxicity in vitro (Zhang,
Wang and Xu, 2008; Forootanfar et al., 2014; Loeschner et al., 2014). Nanoparticles
(NPs) can be more biologically active due to their enhanced surface area per mass
compared with larger-sized particles of the same chemistry (Oberdörster et al., 2005).
By using NPs as a drug delivery vehicle, it might be possible to enhance a range of
characteristics for a given bioactive, including increased protection and stability (Nair
et al., 2010) and suitability to increase bioavailability by non-parenteral routes of
administration including oral, pulmonary and topical applications (Helson, 2013).
The natural polymer chitosan (Cs) is a mucopolysaccharide, closely related to
cellulose and obtained by deacetylation of the compound chitin, predominantly found
in the exoskeletons of crustaceans (Nagpal, Singh and Mishra, 2010). Cs has been
used for the development and formulation of nanoparticles by ionotropic gelation due
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to its physicochemical and biological beneficial properties (H. Zhang et al., 2015;
Mohammed et al., 2017). Benefits include improved adherence to mucosal surfaces,
increased drug residence time (Ryan et al., 2012), and protection of the bioactive drug
from intestinal proteases (Ryan et al., 2013; Amaro et al., 2015). In acidic medium,
Cs can be dissolved, due to protonation of the amine residues present in the polymer
backbone. Ionotropic gelation allows for the formation of NPs from Cs via
crosslinking with oppositely-charged electrolytes under mild conditions in which
amino acids and peptides will remain reasonably stable (Janes, Calvo and Alonso,
2001; Wang et al., 2011; Chen et al., 2013).
Zein a GRAS approved prolamine-rich protein derived from maize, has been used in
the formulation and coating of peptide oral delivery systems (Y. Zhang et al., 2015),
to increase encapsulation efficiency (Luo and Wang, 2014) and improve the control
of gastric release of labile bioactives (Luo et al., 2010; Paliwal and Palakurthi, 2014).
By exploiting the physical interactions between protein and polysaccharide (in this
instance zein and Cs), it is possible to improve and broaden the physical and chemical
stability properties of the NP delivery systems (Benshitrit et al., 2012). However, the
formulation, characterisation and development of these multi-component systems can
be more challenging than single component systems and as such, it is important to
comprehensively optimise the formulation process. To the best of our knowledge,
there are currently no reports which describe the formulation of biological Se species
such as SeMet into a NP delivery system. The potential optimisation of this
formulation could be significant, given that SeMet more effectively increases human
and animal selenium levels and is less toxic than inorganic Se (Garousi, 2015).
In situations where several variables may influence system properties, a useful
technique to identify the relationships between a given response and independent
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variables (or factors) and optimise the system, is Response Surface Methodology
(RSM) (Anderson and Whitcomb, 2005). RSM is a more efficient approach to
experimentation than one factor at a time (OFAT) experiments since it: 1) reduces the
number of experimental runs typically required to gather the same information as
OFAT, thus reducing resource requirements, 2) is useful in detecting
interdependencies of variables that would not be typically identified during OFAT
experiments and 3) improves the prediction of a response through use of gathered
information from a larger parameter space. The Box-Behnken design (BBD) is an
RSM for process optimisation with an independent quadratic design where factor
combinations are considered at 3 levels: the midpoints of edges of the process space
and the centre (Traynor et al., 2013; Zolgharnein, Shahmoradi and Ghasemi, 2013).
After polynomial models for each of the different responses in a study have been
completed, a desirability function may be constructed in order to estimate minima or
maxima, provided such optima are within the design space (Bezerra et al., 2008).
In this study, SeMet was formulated into nanoparticles consisting of Cs and zein using
ionotropic gelation. After evaluating the main variables which affect encapsulation
efficiency, particle size and drug loading, a systematic approach (RSM) was used to
optimise the formulation of nanoparticles suitable for oral delivery. A three-level,
three-factor BBD was utilised to build polynomial models for the three responses and
a desirability function was then constructed to optimise the system. Optimised SeMet
NPs were prepared based on the predicted optimum levels of the independent
variables of the factorial design. To ensure stability of the optimised formulation after
lyophilisation, a cryoprotectant (trehalose) was also included (Danish et al., 2017a).
The physicochemical properties, storage stability, cytotoxicity, and the release profile
in a simulated intestinal buffer were assessed.
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5.2 Materials and Methods

5.2.1 Materials
The chitosan PROTASAN™ UP (CL113) was purchased from NovaMatrix, FMC
Corporations, Norway. DL-selenomethionine, D(+)-Trehalose dihydrate, and zein, of
≥99% purity, were obtained from ACROS Organics™, Fisher Scientific, Ireland.
Ultra-pure water 18mΩcm-1 was obtained from a Millipore simplicity 185 model
instrument, UK, and was used for all aqueous solution preparations throughout. All
other reagents, chemicals and solvents were of analytical grade from Sigma Aldrich,
Ireland.

5.2.2 Optimisation of nanoparticle formulation physicochemical
properties
A BBD was used to optimise the formulation and EE% of SeMet into the nanoparticle.
Selected physicochemical properties for oral delivery for the NPs were particle size
~300 nm, PDI < 0.5 and ZP > 30 mV (des Rieux et al., 2006). A three level, three
factor BBD (Zhao et al., 2013; Maleki Dizaj et al., 2015) of 15 random order
experiments was designed using Minitab™ 17 (Pennsylvania, USA). The 3
independent variables were, (X1) the pH of the Cs solvent - the isoelectric point (pI)
of SeMet, (pH-pI) (X2), the load concentration of SeMet and (X3) the ratio of Cs:TPP,
while (Y1) Particle size, (Y2) PDI, (Y3) ZP and (Y4) EE% were the dependent
variables. The variable ranges (Table 5.1) were based on an exploratory study.
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Each dependant variable was independently assessed by linear regression using a 2nd
degree polynomial model with 1st order interactions (Equation 5.1).
Y i = b 0 + b 1 X 1 + b 2 X 2 + b 3 X 3 + b 12 X 1 X 2 + b 13 X 1 X 3 + b 23 X 2 X 3 + b 11 X 1 2 + b 22 X 2 2 +
b 33 X 3 2 +ε

(Equation 5.1)
where Yi is the measure of the response associated with each factor level combination,
b0 is an intercept, b1-b33 are the regression coefficients, X1-X3 are the coded
independent variables and the XiXj and Xi2 (i,j = 1, 2, 3) denote the interactive and
quadratic terms, respectively. The linear regression and the significance (p<0.05) test
of independent variables and their interactions was assessed by statistical software
(Minitab™,17) to generate regression models. Through bidirectional elimination
(testing at each step for variables to be included or excluded), non-significant terms
were removed from the model in order to calculate regression equations with
significant terms only (Wang et al., 2013). Desirability functions to optimise all
responses were built the weighted geometric mean of individual desirabilities
presented in Table 5.1.
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Table 5.1 Variables and levels employed in the BBD with desirability function for
optimisation of nanoparticle formulation.
Factor (Independent variables)

Levels used, (Actual
coded)

X 1 = pH of the Cs solvent – the pI of SeMet (pHpI)
X 2 = SeMet concentration (mg/mL)

0.5

1.5

2.5

0.05

0.15

0.25

X 3 = ratio of Cs:TPP

4:1

6:1

8:1

Dependent Variables

Composite desirability

Y 1 = Size (nm)

Target of 300nm

Y 2 = PDI
Y 3 = ZP (mV)
Y 4 = Encapsulation efficiency (EE%)

Minimise
Maximise
Maximise

Response surface plots, statistical testing of the linear models and identification of
optimum formulations via feasibility and grid searches was performed to study the
optimal area (Barrentine, 1999). Finally, repetitions (N=4) of the optimal point found
were conducted experimentally to validate the study.

5.2.3 Preparation of SeMet loaded Cs:TPP nanoparticles

SeMet-entrapped NPs were produced using a modified ionic gelation method (Calvo
et al., 1997). Briefly, Cs was dissolved in buffered pH medium (3, 4 or 5 pH) at a
concentration of 3 mg/mL and filtered through a 0.22 μm syringe filter (Millex
Millipore, UK) to remove undissolved Cs. A known amount of SeMet was then added
to the Cs solution prior to crosslinking to obtain a final load concentration 0.05, 0.150
or 0.250 mg/mL. TPP was added dropwise to the solution under stirring at 700 rpm
and room temperature to yield final mass ratios of Cs:TPP NPs of 4:1, 6:1 or 8:1. All
of these experimental parameters (pH, concentrations and ratios) were prepared
according to the BBD design. The NP suspension was stirred at 700 rpm for 30 min
at room temperature for further crosslinking. After stabilisation, NPs were then
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transferred to a 30 kDa molecular weight cut off (Vivaspin 20, Sartorius) centrifugal
filter and isolated by centrifugation at 3000 rpm for 30 min. Filtered H2O (equivalent
in volume to the recovered supernatant) was then added to the isolated NPs and
sonicated at 35 % amplitude for 30 s with 5 s pulse intervals. Physicochemical
properties of the NPs were then determined as per Section 2.4, using a Malvern
Zetasizer NanoZS (Worcestershire, UK) and the supernatant was retained for EE%
determination as outlined in Section 2.7. The optimised formulation has a mass ratio
6:1 (Cs:TPP), Cs media (pH 5), and a final SeMet load concentration of 0.15 mg/mL.

5.2.4 Increase of Ionisation/Protonation states to increase EE% Formulation I
After optimising the general physicochemical properties via BBD (Section 2.2), the
ionic gelation component preparation procedure was modified with the aim of
increasing the EE%. Formulation I was produced as described in Section 2.3 with one
exception: SeMet and TPP were dissolved and diluted with NaOH (0.01 M) prior to
crosslinking. The rationale for the pH adjustment was to induce higher electrostatic
interactions (i.e. maximise the cationic component of Cs and the anionic component
of SeMet) between SeMet and Cs during the crosslinking process.

5.2.5 Coating NPs with zein to increase EE%

NPs were prepared as per formulation I (ratio 6:1 (Cs:TPP), Cs media (pH 3),
TPP/SeMet NaOH solution (pH 11) and a final load concentration of 0.15 mg/mL),
with the following modifications: after the NPs had stabilised, 8 mL of absolute EtOH
were added dropwise to the formulation whilst the stirring speed of the solution was
maintained at 700 rpm for 30 min at room temperature. Zein (10 mg/mL dissolved in
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80 % EtOH and filtered) was added dropwise to yield zein:Cs mass ratios of 0.5:1,
1:1 and 2:1, stabilised at 700 rpm for 30 min and isolated as per Section 2.3. The NP
formulations were then concentrated under vacuum (175 mbar) at 40 °C until EtOH
was completely removed. To ensure stability of the optimised formulation after
lyophilisation, 10 mL of the cryoprotectant trehalose 5 % w/v in H2O was added to
each formulation and lyophilised for 36 hr (Danish et al., 2017a).

5.2.6 Particle size, PDI and surface charge

Freshly prepared NP solutions were used for physicochemical analysis (Luo et al.,
2010). The mean particle size and PDI of the NP formulations were determined by
dynamic light scattering (DLS). The ZP values were measured with the use of laser
doppler velocimetry (LDV). Both DLS and LDV analysis were performed in triplicate
at 25 °C with a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser
(Malvern Instruments Ltd., UK), using a folded capillary cuvette (Folded capillary
cell-DTS1060, Malvern, UK). The values presented herein were acquired from three
separate experiments, each of which included three replicates; N=3.

5.2.7 Scanning electron microscopy (SEM)

NP morphology was evaluated by scanning electron microscopy (SEM) (Hitachi,
SU6600 FESEM, USA), at an accelerating voltage of 20 kV, unless otherwise stated,
using the secondary electron detector. The fresh NP solutions were then spin coated
onto Si wafers, dried at room temperature and then sputter coated with 4 nm Au/Pd
prior to imaging (Mukhopadhyay et al., 2013).
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5.2.8 Fourier transform infrared spectroscopy (FTIR)

FTIR spectra of CL113, TPP, Cs:TPP NPs, SeMet and SeMet loaded Cs:TPP NPs
were acquired via a Spotlight 400 series spectrometer (Perkin Elmer, USA), using the
attenuated total reflectance spectroscopy method (ATR-FTIR), in the range of 6504000 cm-1. Prior to analysis, NP samples were lyophilised using a FreeZone 6 L bench
top freeze dry system (Labconco, USA) at -40 °C for 20 hr. The dried solids were then
placed on the ATR crystal prism (ZnSe), and 32 scans were acquired at 4 cm −1
resolution with background subtraction (Vongchan et al., 2011).

5.2.9 Encapsulation efficiency of SeMet in Cs:TPP nanoparticles

The EE% of SeMet in the NPs was determined by the separation and quantification
of SeMet left in the supernatant. This was performed by ultracentrifugation at 3000
rpm, 4 °C for 30 min. SeMet in the supernatant was quantified by reverse phase high
performance liquid chromatography (RP-HPLC), as previously described (Ward,
Connolly and Murphy, 2012) with the following modifications. Samples were
analysed with a Waters 2998 HPLC and Photodiode Array Detector, (Waters, USA),
using a Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7 μm, (Agilent Technologies,
UK). Isocratic elution was carried out at a flow rate of 0.4 mL/min, column
temperature 45.0 ± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid
(97.9:2.0:0.1). Samples were monitored according to their UV absorbance at 218 nm.
The encapsulation efficiency was calculated by Equation 5.2 (Xu and Du, 2003):

𝑬𝑬% =

𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕 − 𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑿 𝟏𝟎𝟎
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕

(Equation 5.2)
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5.2.10 MTS assay

The potential cytotoxicity of pure SeMet, SeMet loaded NPs and unloaded NPs
(coated with zein) were examined on Caco-2 human epithelial cells, and HepG2
human liver hepatocellular cells. Both cell lines are routinely employed to assess the
potential toxicity of orally delivered compounds (Gleeson et al., 2015; Brayden et al.,
2015). Caco-2 and HepG2 cells, were seeded at a density of 2 x 104 cells/well and
cultured on 96 well plates in Dulbecco's Modified Eagle Medium (DMEM) and
Eagle's Minimum Essential Medium (EMEM) respectively, supplemented with 10 %
foetal bovine serum, 1 % L-glutamine, 1 % penicillin-streptomycin and 1 % nonessential amino acids at 37 °C in a humidified incubator with 5 % CO2 and 95 % O2.
Time points were selected with the intention to mimic in vivo conditions for each cell
type. As the maximum time NPs will be exposed to the intestine, a 4 hr exposure time
was used in Caco-2 cell lines (Neves et al., 2016), to mimic the liver, a 72-h exposure
time was used for HepG2 cell lines (Brayden, Gleeson and Walsh, 2014). Triton X100™ (0.05%) was used as a positive control. The concentrations of the test
compounds applied were 25, 50 and 100 uM. After exposure, treatments were
removed

and

replaced

with

MTS

(3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). Optical density (OD)
was measured at 490 nm using a microplate reader (TECAN GENios, Grodig,
Austria). Each value presented was normalised against untreated control and
calculated from three separate experiments, each of which included six replicates.
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5.2.11 Accelerated stability analysis

NPs were suspended at a concentration of 0.1 mg/mL, in aqueous KCl solution (10
mM) and stored at accelerated conditions: 60 °C for 720 min, 70 °C for 300 min and
80 °C for 120 min (Danish et al., 2017b). The particle size, PDI and zeta potential
were measured using the Nanosizer ZS (Malvern Instruments Ltd, UK) over time
intervals to determine the degree of degradation. The generated data was then
analysed via R software (R Core Team, 2016). The temperature dependence of the
kinetic parameters of SeMet-loaded NPs stability was measured by calculating the
observed rate constants. This was plotted in an Arrhenius representation and apparent
activation energy, Ea and reaction rate constant, kref were calculated according to
Equation 5.3:

𝑷 = 𝑷𝒐 + 𝒆

𝒍𝒏(𝒌)−

𝑬𝒂 𝟏 𝟏
( −
)
𝑹 𝑻 𝑻𝒓𝒆𝒇

𝒕
(Equation 5.3)

where P is the property (particle size, PDI or ZP) at time t, Po is the initial property
conditions, k is the apparent zero order reaction constant, Ea is the energy of
activation, R is the universal gas constant, T is the temperature of the experiment in
Kelvin (K) and Tref is the reference temperature (343 K).

5.2.12 In vitro controlled release studies

SeMet release from the NPs was carried out using a dialysis bag diffusion technique
(Hosseinzadeh et al., 2012) over 6 hr (Calderon L. et al., 2013; Yoon et al., 2014).
Freeze dried SeMet loaded NPs were suspended in 5 mL H2O and sonicated at 35 %
amplitude for 30 s with 5 s intervals and placed into a Float-A-Lyzer®G2 dialysis
membrane with a pore size of 25 kDa (Spectrum Laboratories, USA). The sample was
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placed into 40 mL of simulated gastric fluid (SGF) or simulated intestinal fluid (SIF)
specified according to the British Pharmacopoeia (Pharmacopoeia, 2016). SGF was
composed of 0.1 M HCL and SIF was composed of 1 volume of 0.2 M trisodium
phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without
enzymes (British Pharmacopoeia Commission, 2016). Samples were placed in a
thermostatic shaker at 37 ºC and agitated at 100 rpm. At predetermined time points, 1
mL of release fluid was analysed and replaced with simulated fluid to maintain sink
conditions.
SeMet release was measured by RP-HPLC (Section 5.2.9). Equation 5.4 was used to
determine the % drug release:

𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =

𝑪(𝒕)
∗ 𝟏𝟎𝟎
𝑪(𝒍)
(Equation 5.4)

where 𝐷𝑟𝑢𝑔𝑟𝑒𝑙 is the percentage of SeMet released, C(l) represents the concentration
of drug loaded and C(t) represents the amount of drug released at time t, respectively.
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5.3 Results and Discussion

5.3.1 Response Surface Modelling – Box Behnken design

The observed values for all 15 experiments described by the BBD yielded minimum
and maximum values for Size (Y1) (152, 318 nm), PDI (Y2) (0.218, 0.554), ZP (Y3)
(26.0, 42.7 mV) and EE% (Y4) of, (24.7, 41.4 %). The reduced models resulting from
the analysis are presented in Table 5.2. Response Y1 showed no significant terms in
the model, suggesting that there was no evidence in the sample population that could
prove the association of the independent variables with particle size. This finding is
unsurprising, as the NPs produced in this study fell within a narrow target region (152,
318 nm) and the regions of interest chosen in this study (e.g. Cs:TPP 4:1-8:1, pH 35), to produce the Cs NPs, have been well established for yielding particle sizes within
100-400 nm range (Hassani et al., 2015; Sipoli et al., 2015; Mohammed et al., 2017).
Responses Y2-Y4 (PDI, ZP and EE% respectively) all showed a curvature with regards
to X1-X3, as quadratic or interactive effects of some independent variables were
statistically significant in all the models.
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Table 5.2 Normalised variable estimated coefficients (Coef) with associated
standard error (SE Coef.) and unnormalised reduced regression equations for Y 2 -Y 4 .
Y2 (PDI)

Y3 (ZP)

Term

Coef

Constant
X1 (pH-pI)
X2 (SeMet
(mg/mL))
X3 (Ratio
of Cs:TPP)
X1*X1
X2*X2
X3*X3
X1*X2
X1*X3
X2*X3

0.3083
0.0515

SE
Coef
0.0063
0.0039

0.0084

0.0039

0.0521

0.0039

-0.0613
0.1040
0.0645
-0.0175
0.0165
-0.0402

0.0057
0.0057
0.0057
0.0054
0.0054
0.0054

R2adjusted

98.66%

Equation
5.5

Y2 = 0.592 +
0.212 X1 - 1.565
X2 - 0.1495 X3 0.06 X1*X1
+ 10.40 X2*X2
+0.01611 X3*X3 0.175 X1*X2
+0.00825 X1*X3 0.2012 X2*X3

Y4 (EE%)

Term

Coef

Constant
X1 (pH-pI)
X2 (SeMet
(mg/mL))
X3 (Ratio
of Cs:TPP)
X1*X1
X2*X2
X3*X3
X1*X2
X1*X3
X2*X3

35.534
6.405

SE
Coef
0.293
0.300

-

-

1.245

0.300

-2.626
-

0.419
-

R2adjusted

98.65%

Equation
5.6

Y3 = -1.21 +
6.405 X1 +
8.49 X3 - 0.6588
X3*X3

Term

Coef

Constant
X1 (pH-pI)
X2 (SeMet
(mg/mL))
X3 (Ratio
of Cs:TPP)
X1*X1
X2*X2
X3*X3
X1*X2
X1*X3
X2*X3

31.731
6.113

SE
Coef
0.814
0.599

-

-

0.487

0.599

3.821
-3.529
-

0.879
0.879
-

R2adjusted

90.82%

Equation
5.7

Y4 = -2.06 + 5.35
X1 +
10.83 X3 + 3.821
X1*X1
- 0.882 X3*X3

In Table 5.2 (Equation 5.5), PDI was mostly affected by the quadratic effects of
X2*X2, which showed a positive correlation such that, at -1 and +1 levels of X2, the
PDI increased. It is also worth noting that the linear term of X2 showed a negative
coefficient, indicating that X2 has a negative effect on PDI until a turning point is
reached, whereafter X2*X2 has a positive impact on PDI. Similar findings were
reported by Masarudin et al., (2015), who found that ratios of Cs:TPP less than 3:1
and greater than 12:1, resulted in a significant increase of the formed NPs PDI values
(>0.75). Additionally, they found that the NPs produced at ratios between (median
levels) the aforementioned upper and lower bounds resulted in NPs with PDI values
ranging from 0.15-0.32. A contour plot based on the regression model is presented in
Figure 5.1(A) and highlights this, showing that, at medium load concentrations of 0.15
mg/mL and medium/low ratios of Cs:TPP (4.75:1 to 5.5:1), a minimum value for PDI
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can be achieved. Conversely, as the concentration of TPP passes median levels PDI
increases, which may be attributable to TPP inducing cross-linking between the
nanoparticles and thus the presence of smaller aggregates within the solution (Hu et
al., 2008; Antoniou et al., 2015a). Furthermore, the reduction of PDI as the
concentration of TPP approaches median levels, has been shown to relate with the
increased availability of TPP molecules to interact with the free amino groups of Cs,
thus allowing for additional incorporation of the anion within the NP Cs chains
(Huang and Lapitsky, 2017). Although PDI can be minimised at these particular
levels, it is worth noting that the PDI values for all formulations fell within optimum
values for oral delivery (Wong, Al-Salami and Dass, 2017).
The results presented in Table 5.2 (Equation 5.6) show that ZP was not affected by
X2, although it was affected by X1 (pH-pI) and X3 (Cs:TPP), indicating that the pH of
the formulation medium and the electrostatic forces between the ionizable groups of
Cs and TPP determine the net charge of the produced particles. It is likely that this is
a direct consequence of the binding between the anionic phosphate groups of TPP
with the positively charged amino acid moieties of Cs (Rampino et al., 2013), for
example, a positive correlation was observed, such that ZP increased with increasing
ratios. In addition, X1 also showed a prominent effect on ZP, whereby an increase in
ZP is observed as X1 increases. The contour plot representing the reduced regression
model (Figure 5.1(B)), demonstrates that low X1 levels (pH 5 - 4.2) and low ratios of
Cs:TPP (4.0/4.5:1) are the areas where NPs of ZP <30mV were obtained (with a
minimum of 27 mV). As X1 increases (approximately pH 3.5), an increment in ZP
was observed and maximum values of >39 mV are achieved between X3 (ratio) of
4.5:1 - 7.5:1. This is in agreement with previous studies by Antoniou et al., (2015),
that showed at Cs: TPP mass ratios of 7:1, the ZP of the produced NPs decreased
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almost linearly with increasing pH of the formulation medium. As it has been shown
that high ZP (either negative or positive), requires higher energy for bringing two
particles in contact with each other (Dora et al., 2010), this pH-responsive behaviour
can be attributed to the protonation of the primary amino groups present on the Cs
chain, resulting in an increase of electron density and repulsion forces between the
crosslinked Cs chains (Lai and Guo, 2011). For example, at pH 3.5, the charge
interaction between these two molecules becomes strong enough, and stable Cs NPs
are obtained. At pH approaching the pI of Cs, reduced availability of protonated amine
residues (-NH3+) present on the Cs polymer backbone chain results in a lower surface
charge of the formed NPs (Huang, Cai and Lapitsky, 2015).
EE% was not affected by load concentration (X2) but was mostly affected by the pH
of the Cs media (pH-pI (X1)) (Table 5.2, Equation 5.7), demonstrating the notable
effect of SeMet loading with the charge of both polyelectrolytes (Cs and TPP) and
their subsequent interaction during the crosslinking process. As can be seen, a
negative correlation was observed, indicating that, as X1 increases, the EE%
decreases, most likely attributable to the reduced protonation of the primary amines
present on Cs (Umerska, Corrigan and Tajber, 2014). It is also worth noting that the
quadratic term X1*X1 showed a positive coefficient, indicating X1 had a negative
effect on EE% until a turning point was reached, where after X1 had a positive impact
on EE%. He et al., (2017), reported that by exploiting the ionic nature of insulin
through modulation of the formulation media, the EE% of insulin into Cs:TPP NPs
could be significantly enhanced, going from 37 to 94 %. This is evident in the contour
plot produced by the regression model (Figure 5.1(C)) showing that, at maximum X1
levels (approximately 2.5 unit distance from pI of SeMet) and minimum to
median/high ratios of Cs:TPP (4:1 - 7.5:1), maximum EE% (>40 %) can be achieved,
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indicating that pH plays a significant role in the EE%. These findings agree with those
of other research groups (Janes, Calvo and Alonso, 2001; Antoniou et al., 2015b), that
reported a strategy to increase ionisable proteins (such as bovine serum albumin
(BSA) and insulin) EE% (>80%) within a Cs NP matrix, by dissolving the load protein
at a pH above its isoelectric point. By doing this, deprotonation of the hydroxy groups
present on the load cargo occurs, inducing a predominantly negative state and thus
has a higher affinity to Cs and increased EE%. Several other studies have mirrored
these findings, showing that the electrostatic interactions between the acidic groups
present on insulin and the amino groups of Cs play a role in the association of insulin
to the Cs-NPs by mediation of the ionic interaction between both macromolecules
(Pan et al., 2002; Mattu, Li and Ciardelli, 2013).

Figure 5.1 Contour Plot of (A) PDI against ratio of Cs:TPP (X 3 ) and SeMet (mg/mL)
(X 2 ), with pH-pI (X 1 ) held at median level (1.5), (B) ZP against pH -pI (X 1 ) and the
ratio of Cs:TPP (X 3 ) and (C) EE% against pH-pI (X 1 ) vs ratio of Cs:TPP (X 3 ) for the
RSM models presented in Table 5.2.
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5.3.2 Optimisation

Employing the models constructed with the BBD evaluation in Table 5.2, response
optimisation was employed in order to establish a formulation strategy to yield NPs
with minimum PDI values, ZP of ≥30 mV and maximum EE% (des Rieux et al.,
2006). As the range of NP sizes within all experimental runs fell within recommended
target values for oral delivery, this response was excluded from the optimisation
analysis.
Figure 5.2 shows the optimisation plot of the desired responses and indicates that,
when the variable settings of X1, X2 and X3 are fixed at 2.5 (pH-pI), 0.15 (mg/mL)
and 6 (Cs:TPP), respectively, NPs with the desired properties can be produced.
Additionally, the 95 % confidence interval ranges of the predicted NP properties that
these conditions would produce are presented in Table 5.3.

Figure 5.2

Desirability profiles for optimisation of the formulation

parameters; X 1 (pH-pI), X 2 (load concentration) and X 3 (Ratio of Cs:TPP) maximising ZP and EE%, whilst minimising PDI.
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To verify the validity of the proposed models, n = 4 replicates of the optimised
formulation were prepared, and each experimental response was compared with the
predicted one. Table 5.3 shows the validation results of the model, whereby NPs
presented sizes of 187 ± 58 nm, PDI of 0.284 ± 0.044, ZP of 39.7 ± 2.6 mV and a max
EE% of 39 ± 3 %.
Table 5.3 95% confidence interval for particle characteristics that optimal
conditions would produce under the present experimental conditions of uncertainty.

Response
Y2 (PDI)
Y3 (mV)
Y4 (EE%)

Fit
0.299 ± 0.007
42.2 ± 2.0
41.7 ± 1.0

95 % CI
(0.282, 0.317)
(41.6, 42.7)
(39.5, 43.8)

Actual values
0.284 ± 0.044
39.7 ± 2.6
39 ± 3

No statistically significant values (p>0.05) for predicted and measured responses (Y2Y4) were observed, indicating that the models fit the data satisfactorily and has
adequate precision for the prediction of NP ZP, PDI and EE% in the chosen space of
independent variables (in the domain of levels chosen for the independent variables).
Additionally, several consuming and laborious laboratory studies were eliminated in
this study by using the BBD, rather than a OFAT approach.

5.3.3 EE% optimisation I: protonation and ionisation

The results from the BBD were promising in terms of the NPs produced and their
physicochemical properties. However, even when optimised, EE% remained low at
approximately 40 %. A second study was undertaken with the aim of maximising the
EE%, by controlling the ionisation process, given that this property primarily
influenced the encapsulation efficiency in the desirability profile (Figure 5.2). In the
previous BBD, it was noted that the highest EE% of SeMet within Cs:TPP NPs was
obtained when the pH of the Cs medium was maintained at pH 3 and the SeMet load
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was dissolved within it prior to crosslinking. The fundamentals of ionotropic gelation
exploit the opposing charges between the protonated amine residues found on the
glucosamine residue unit of Cs against the deprotonated hydroxyl groups on TPP
(Janes, Calvo and Alonso, 2001). In order to increase the EE%, a modulation of the
ionisation state of SeMet was achieved by dissolving it (and TPP) in a basic solution
prior to crosslinking with Cs. The rationale for this approach is the observation that
the pKa for the acid moiety of SeMet is pH 2.6, whereas the pKa for the basic moiety
is at pH 8.9 (Foulkes, 2003) and as such, further electrostatic interactions can be
induced at time of complexation (Qi et al., 2010). The effect of dissolving the TPP
and SeMet in 0.01 M NaOH (pH 12) rather than H2O prior to crosslinking in the
optimised formulation (ratio Cs:TPP 6:1, SeMet load concentration of 0.15 mg/mL
and Cs medium pH of 3) was investigated, as a means to elicit greater interaction
between Cs and SeMet and subsequently increase EE%. N= 3.
By altering the pH of the formulation, the EE% increased from 39 ± 3 % to 66 ± 1 %,
whilst the physicochemical properties of the NPs remained within the target range for
oral delivery (Table 5.4) (des Rieux et al., 2006). This was most likely attributed to
the electrostatic interactions between the now further ionised TPP and SeMet groups
and protonated amine residues found on the glucosamine unit of Cs. This is consistent
with the work by Pan et al., (2014) which showed curcumin (CUR) successful
encapsulation (>90%) into casein NPs, through deprotonation of CUR at pH 12,
enabling for its re-association and thus subsequent encapsulation into the NP matrix.
Table 5.4 Size, PDI, ZP and EE% results for formulation I. N=3.
SeMet NPs Ratio 6:1, SeMet in NaOH (0.15 mg/mL load conc.), Cs in pH 3
SIZE (nm)
PDI
ZP (mV)
EE (%)
227 ± 17
0.448 ± 0.049
32 ± 1
66 ± 4
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5.3.4 Improved Encapsulation Efficiency using zein

The results from the first EE% optimisation study (Table 5.4) were promising, in
terms of increasing EE% in addition to maintaining the desired NP physicochemical
properties. Nevertheless, the maximum EE% obtained by modifying the pH remained
at 66 ± 4 %. Therefore, a subsequent step, involving the coating of the optimised NPs
with zein (at varying zein:Cs mass ratios), was pursued as a means to increase the
encapsulation efficiency of SeMet into the Cs: TPP NPs.
As shown in Table 5.5, as the ratio of zein in the formulation increased, the EE%
improved. At 0.5:1, zein:Cs, the average EE% achieved was 75 % and approximately
5 % increments in EE% were observed with subsequent increments of zein:Cs. The
physicochemical properties of the NPs (PDI and ZP) were still within the target range
for oral delivery for formulations with zein:Cs ratios ≤1:1, although an increase in NP
size was observed upon increasing zein concentrations. At a ratio of 2:1, zein:Cs, the
physicochemical properties of the NPs were less than ideal, as large particle sizes (721
nm average) and high PDI values (0.783) were yielded, most likely as a consequence
of a denser and thicker coating (Luo et al., 2010) provided by the partial deposition
of the negatively charged protein on the particle surface, thus reducing the total net
charge and inducing particle swelling (Rampino et al., 2013). For example, as the zein
concentration increases, so does the viscosity of the dispersion, which can affect the
nucleation process leading to the production of larger sized NPs (Zhong and Jin,
2009). Similar results have been observed by others, whereby, an increase in zein
concentration led to an increase in particle size of 6,7-dihydroxycoumarin loaded zein
NPs (Podaralla and Perumal, 2012) or alpha-tocopherol loaded zein NPs, stabilised
with Cs (Luo, Teng and Wang, 2012). Lastly, the ZP of this formulation was the
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lowest observed (average of + 6 mV), which may be attributed to the increasing zein
concentration, causing increased masking of the free positively charged amino groups
of Cs (Krauland and Alonso, 2007). It is also possible that agglomeration occurred as
a result of the reduced electrostatic repulsion between the NPs in suspension (Liu and
Gao, 2009).
Table 5.5 Physiochemical results for SeMet loaded NPs (Ratio 6:1, SeMet in NaOH
(0.15 mg/mL load), Cs in pH 3) coated with zein. Size, PDI, ZP and EE% are
presented for each NP using different mass ratio combinations of zein and Cs. N=3.

Zein:Cs
0.5:1
1:1
2:1

Size (nm)
319 ± 19
377 ± 47
721 ± 108

PDI
0.221 ± 0.040
0.325 ± 0.136
0.783 ± 0.281

ZP (mV)
27 ± 6
35 ± 6
6±4

EE (%)
74 ± 1
81 ± 1
85 ± 1

5.3.5 Characterisation Fourier transform infrared spectroscopy
(FTIR)
Figure 5.3 shows the FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP
NPs and (E) SeMet:Cs:TPP:zein NPs. The zein spectrum (Figure 5.3, A) shows
characteristic peaks at 3289, 2929, 1644, 1515 and 1233 cm-1 corresponding to NH
stretching vibrations, CH stretching, amide I (C=O stretch), amide II (C-N and C-NH/ in plane bending) and amide III respectively (Podaralla and Perumal, 2012).
Characteristic peaks for the phosphate ion (P=O) in TPP (Figure 5.3, B) were observed
at 1121 cm-1 and 886 cm-1, respectively (Rampino et al., 2013). Cs spectra (Figure
5.3, C) showed characteristic peaks at 3240, 2879, 1625, 1514, 1376 and 1063 cm -1.
corresponding to NH Stretch / OH in pyranose ring, CH2 in CH2OH group, C=O in
NHCOCH3 group (amide I), NH2 in NHCOCH3 group (amide II), CH3 in NHCOCH3
group and C-O-C (glycosidic linkage) respectively (Luo et al., 2010; Mohammed,
Williams and Tverezovskaya, 2013).
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Figure 5.3 FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP NPs and
(E) SeMet:Cs:TPP:zein NPs. Spectra are offset for clarity.

The FTIR spectrum of SeMet:Cs:TPP NPs (Figure 5.3, D) is different to that of the
Cs matrix, as a result of intermolecular interactions of the constituent components. If
interaction between the Cs and TPP had occurred, it will lead to frequency shifts or
splitting in absorption peaks (Gan et al., 2005). For example, the peaks at 1514 cm-1
in the Cs spectrum have been shifted to 1560 cm-1, indicating electrostatic interaction
between the phosphate groups of TPP and the amino groups present in the Cs NP
matrix (Papadimitriou et al., 2008). Additionally, the broadening and the increased
absorbance of the peak at 3272 cm-1 indicate hydrogen bonding has been enhanced
(Luo et al., 2010). The band observed at 1644 cm−1 in the zein FTIR spectrum
(assigned to N-H bond), has been shifted to 1648 cm−1 in the zein/Cs NPs spectrum
(Figure 5.3, A and E respectively), indicating an interaction among the zein and Cs
chains, possibly through hydrogen bonding among the amino groups present on both
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Cs and zein chains (Müller et al., 2011). Another indication of Cs:zein interaction
arises from the amide III bands at 1406 cm-1, not visible in the zein spectrum, but now
visible in the zein/Cs NPs (Figure 5.3, A and E respectively) spectrum, most likely as
a result of the C-N stretching and out of plane N-H deformation being highly sensitive
to structural changes (Sessa, Mohamed and Byars, 2008).
Lastly, the formation of zein/Cs NPs (E) is also characterised by the appearance of a
band at 1041 cm−1 (assigned to C-O-C (glycosidic linkage)), which was observed in
Cs/SeMet NPs (D) at 1028 cm−1 but not observed in the zein spectrum (A), supporting
the presence of Cs within the NP matrix (Figure 5.3) (Müller et al., 2011). The
crosslinked Cs also showed a peak for P = O at 1151 cm–1 (Bhumkar and Pokharkar,
2006), further indicating electrostatic interaction between Cs and TPP (Figure 5.3, E).
No significant SeMet peaks in either Cs/TPP/SeMet or Cs/TPP/SeMet/zein NPs
spectra were observed, most likely due to the fact, that only 0.07 % of the dried
formulation is contributed by SeMet and it is consequently masked by the other
formulation components.

5.3.6 Scanning electron microscopy

Figure 5.4 shows the SEM images of uncoated and zein coated Se loaded NPs. The
particle size of the NPs after spin coating was in good agreement with the DLS
measurements taken on the freshly prepared NPs. Spherical, well distributed particles
for both coated and uncoated SeMet loaded NPs were observed. However, it is
interesting to note that the zein coated NPs displayed a smoother surface than that of
the uncoated. This may be attributed to the use of the acetic acid buffer used during
the formulation process, as similar results have been observed in spin-cast zein films
prepared from an aqueous ethanol solvent compared to an acetic acid solution,
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indicating that a rough and hydrophilic surface was acquired for the former, whilst the
zein film produced from an acetic acid solution appeared to be smooth, featureless
and more hydrophobic (Shi, Kokini and Huang, 2009; Y. Zhang et al., 2015).

Figure 5.4 SEM image of (A) SeMet:Cs:TPP NPs and (B) SeMet:Cs:TPP NPs coated
with zein.

5.3.7 Accelerated stability analysis of SeMet-loaded NPs coated with
zein
The principle aim of accelerated stability testing is to provide reasonable assurance
that a pharmaceutical or food consumable will remain at an acceptable level of quality
throughout its timespan in the market place (Waterman and Adami, 2005; Bajaj et al.,
2012). Real-time, retained sample, cyclic temperature and acceleration, are the four
categories into which stability testing procedures fall (Bhagyashree et al., 2015). In
the latter, the product is subjected to elevated temperatures and/or humidity well
above ambient values, to determine the temperature at which product failure (i.e.
degradation) will occur.
The Arrhenius equation, upon which the interpretation of accelerated stability testing
is based, allows for the determination of the activation energy and consequently, the
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degradation rate of a product at lower temperatures (i.e. ambient, refrigerated etc.). In
this instance, the data acquired can then be used to project the shelf life of the product
in a much shorter time than that of real time assessments (Ali et al., 2013;
Bhagyashree et al., 2015). This is a beneficial approach to stability testing, as it results
in a greatly reduced product development schedule.
Figure 5.5 shows the kinetic behaviour of the NP properties: size (A), PDI (B) and ZP
(C) at temperatures ranging from 60-80 °C. The stability of the NPs decreased with
increasing temperature. Little change was detected for all properties at 60 °C, over the
course of 720 min, whereas a more pronounced increment in size and PDI and a
decrease in ZP was observed at 70 °C after 300 min. At 80 °C, destabilisation of the
NP complexes was evident across all properties, whereby size increased from
approximately 300 nm to > 800 nm, PDI from approximately 0.2 to >0.9 and ZP
reduced from approximately 32 mV to < 18 mV, indicating that aggregation of the
NPs had occurred (Wu, Zhang and Watanabe, 2011).
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Figure 5.5 (1) Particle size, (2) PDI and (3) ZP analysis of SeMet loaded NPs
exposed to (a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720
min, respectively. N=3.
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The one-step nonlinear regression analysis of the kinetic experiments shows that
particle size and PDI fit to a zero-order kinetic behaviour, with an Arrhenius
dependence of ln (kref@70 °C) = 1.66 ± 9.44 min−1 and Ea = 452.57 ± 570.59 kJ/mol
for size, and a ln (kref@70 °C) = 0.029 ± 0.014 min−1, and an Ea = 182.31 ± 42.64
kJ/mol for PDI respectively. In terms of ZP, an apparent first order mechanism fits
the data better than that of an apparent zero order model, with an Arrhenius
dependence of ln (kref@70 °C) = 0.038 ± 0.010 min−1 and Ea = 205.71 ± 25.65 kJ/mol.
Additionally, as can be seen in Figure 5.6, a linear correlation is evident between 1/T
and ln k, indicating that the formulations will be stable under normal storage
conditions. This was expected, as previous reports have shown that zein coatings can
increase the colloidal stability of iron phosphate NPs (Van Leeuwen, Velikov and
Kegel, 2014) and, when stabilised with Cs, results in high thermal resistance of the
NPs over prolonged periods of time (Luo et al., 2013).

Figure 5.6 Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies
of SeMet loaded NPs. N=3.
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5.3.8 Cytotoxicity assessment of SeMet-loaded NPs

The potential cytotoxicity of SeMet in its native form and unloaded or SeMet loaded
NPs coated with zein, at different test concentrations (25, 50 and 100 uM), were
examined on Caco-2 human epithelial cells, and HepG2 human liver hepatocellular
cells, using the MTS assay. As the NPs will become exposed to the intestinal epithelia
following oral delivery (leading to its facilitated transport and uptake), time points
were selected with the intention to mimic in vivo conditions for each cell type, to
assess the potential cytotoxicity of the formulated NPs (Gleeson et al., 2015; Brayden
et al., 2015). Caco-2 cells were exposed for 4h (Figure 5.7(A)) and HepG2 cells for
72h (Figure 5.7(B)). In Caco-2 exposures, no cytotoxicity was observed for unloaded
or SeMet loaded NPs, in comparison to the negative control, across all tested
concentrations. For HepG2 exposures, no cytotoxicity was observed for unloaded or
SeMet loaded NPs coated with zein. Additionally, the lower concentrations (25 and
50 uM) of native SeMet showed no cytotoxicity to either cell line, whereas a reduction
in HepG2 cell viability (Figure 5.7(B)) for native SeMet, at the 100 uM test
concentration, was observed (approx. 66% cell viability).
Similar results were observed by Takahashi, Suzuki and Ogra, 2017, whereby SeMet
showed no significant change on the viability of Caco-2 cell lines, although it did
show marginal toxicity to HepG2 cells at concentrations > 80 ug/mL after prolonged
exposure (48 hr). This finding is also in agreement with other works that showed
SeMet toxicity occurred at concentrations ≥40 uM in various hepatoma cell lines
(Kajander et al., 1991). It has previously been shown that Cs nanoparticles can
enhance the delivery of inorganic Se compounds whilst reducing its toxicity (C. Zhang
et al., 2015).
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In this work, SeMet loaded NPs elicited no significant reduction in viability of either
cell line at equivalent concentration (100 uM), indicating that, by encapsulating SeMet
within the Cs NP matrix, the cytotoxic effects of pure SeMet, can be reduced.

Figure 5.7: Cytotoxicity assessment of
coating and

SeMet,

unloaded NPs with zein

SeMet loaded NPs with zein coating, exposed for (a) 4h in Caco -

2 cell lines and (b) 72h in HepG2 cell line at SeMet equivalent concentrations (25
uM, 50 uM and 100 uM). Triton™ X-100 (0.05%) was used as positive control and
percentage (%) of MTS converted was compared to untreated control. 1 -Way
ANOVA with Dunnetts’s post-test *** p< 0.001, ** p< 0.01, Each value presented
was normalised against untreated control and calculated from three separate
experiments, each of which included six replicates. N=3.
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5.3.9 In vitro release studies

In vitro techniques are advantageous for modelling potential interactions between NPs
and the in vivo environment of the GI tract. Simulated gastric fluid and membrane
analysis models enable assessment of in vivo environments without the use of human
cell lines (Gamboa and Leong, 2013). Figure 5.8 shows the cumulative release profile
of SeMet loaded NPs coated with zein, after subjection to 2 hr in an SGF environment
(pH 1.2) representative of the stomach, followed by a compartmental change to SIF
(pH 6.8), representative of the intestine, for 4 hr. As can be seen, 25±1 % of SeMet
was released after 2 hr in SGF, followed by 33 ±3 % in SIF for 4 hr. No significant
difference in the release profile of SeMet loaded NPs without zein coating was
observed (data not shown). However, it was necessary to keep zein in the formulation
due to the increase in EE (≥ 80 %).
The target site of absorption of SeMet is the jejunum, in the small intestine. Therefore,
it is important to withstand the acidic environment of the stomach. Three basic
mechanisms that are typically applied to describe the release of drugs from polymeric
particles, are swelling/erosion, diffusion, and degradation (Liechty et al., 2010). In
this work, the total cumulative release of SeMet from the zein coated NPs, after 6 hr
in simulated gastrointestinal tract environments, was 58 %, indicating that degradation
of the NP was slow and thus the mechanism may be diffusion/relaxation oriented. As
such, the release kinetics of SeMet NPs, under the SGF and SIF sequential controlled
release experiments, were fitted using the following diffusive models derived from
swellable systems (Siepmann and Peppas, 2011; Danish et al., 2017a).
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For the SGF:
𝑴𝒕
= 𝒌𝒔𝟏 ∗ √𝒕𝒊𝒎𝒆 + 𝒌𝒔𝟐 ∗ 𝒕𝒊𝒎𝒆
𝑴∞
(Equation 5.8)
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at
infinite time, and ks1 and ks2 are the diffusive and relaxation rate constants
respectively.
For the SIF:
𝑴𝒕 𝑴𝟏𝟐𝟎
−
= 𝒌𝒊𝟏 ∗ (√𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) + 𝒌𝒊𝟐 ∗ (𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎)
𝑴∞
𝑴∞
(Equation 5.9)
where M120 is the predicted diffused mass at the time of changing from SGF to SIF
(120 min), ki1 and ki2 are diffusive and relaxation rate constants.
Table 5.6 Swellable model parameters for kinetic release studies SeMet NPs. ks
represents the stomach compartment and ki the intestinal compartment, divided into
diffusion and relaxation mechanisms ( 1 and

2 ).

All parameters listed where

statistically significant, *P < 0.05.

Parameters
Ks2
Ki1
Ki2

Estimate
0.17082
0.69145
0.10817

Std. Error
0.04092
0.33863
0.02105

R2adj

t-value
4.175
2.042
5.140
0.984

Table 5.6 presents the fitted values for the rate constants in SGF (ks) and SIF (ki) for
SeMet NPs, with ks1, representing a diffusion mechanism and ks2 a relaxation
mechanism (Equation 5.8, 5.9). In terms of the stomach compartment (SGF, pH 1.2),
no statistically significant ks1 parameter was found, indicating that the primary
mechanism for release in the stomach was via relaxation, i.e. slower release,
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approaching zero-order kinetics. After 2 hr subjected to the SGF environment, a
compartmental change was employed to mimic the movement of the NPs to the
intestinal environment (SIF, pH 6.8), whereupon a combination of diffusion (ki1) and
relaxation (ki2) mechanisms were observed (p<0.05). Overall, the model employed
(Equation 5.8, 5.9) predicted the experimental data well, with an R2adj >0.98. These
results were expected, as polysaccharides generally undergo solvent penetration,
swelling and chain disentanglement and relaxation, resulting in their ultimate
dissolution (Fu and Kao, 2010). Additionally, this result is in agreement with previous
studies, reporting a diffusion and zero order kinetic profile for IPP and LKP loaded
Cs NPs, coated with zein (Danish et al., 2017a) and that of other researchers, who
observed that zein proved to be a good coating for NPs, whereby, the stronger the
interaction of the load material (in this instance phenolic monoterpenes) with that of
the wall material (zein) was evidenced by its controlled release over time (da Rosa et
al., 2015).

Figure 5.8 Release kinetics of SeMet NPs coated with zein after 2 hr in SGF (pH
1.2) and 4 hr in SIF (pH 6.8). The continuous line indicates the model prediction.
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5.4 Conclusion

In this study, SeMet-loaded Cs NPs were produced via ionotropic gelation. BBD was
used to identify optimum formulation variables that would result in NPs with
physicochemical properties thought to be suitable for oral delivery. BBD highlighted
the optimum conditions for NP production, although EE% remained relatively low.
By varying the formulation media pH, increased electrostatic interaction between the
crosslinking polyelectrolytes and drug were achieved, resulting in an increase in EE%.
Coating the NPs at a 1:1 mass ratio of Cs:zein, resulted in NPs with a doubled EE
accompanied by an increase in diameter. These NPs were then characterised via FTIR
analysis, which identified the presence of key functional groups of the native
components and identifying shifts in the crosslinked matrixes. SEM analysis showed
that spherical, well distributed particles were observed. MTS cytotoxicity studies
showed no decrease in cellular viability in either Caco-2 or HepG2 cell after 4 and 72
hr exposures, respectively. Accelerated thermal stability of the loaded NPs indicated
good stability under normal storage conditions. Lastly, after 6 hr exposure to
simulated intestinal buffers, the release profile of the formulation showed that ≤ 60%
of the drug had been released. These findings infer that encapsulation of SeMet into a
NP delivery system comprising food-derived components reveals an oral
administration approach for this molecule.
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loaded chitosan nanoparticles-coated with zein. Ready for submission to the Journal
of Food Hydrocolloids.
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Abstract
Organic forms of selenium, an essential micronutrient, such as selenoamino acids
(SeAAs), have been shown to possess antioxidant and anticancer properties. However,
their bioavailability is low, and they may be toxic above the recommended nutritional
intake level, and thus improved, targeted oral delivery methods are desirable. In this
work, the SeAAs, Methylselenocysteine (MSC) and selenocystine (SeCys2) were
encapsulated into nanoparticles (NPs) using the mucoadhesive polymer chitosan (Cs),
via ionotropic gelation with tripolyphosphate (TPP) and the NPs produced were then
coated with zein (a maize derived prolamine rich protein). Optimum NP
physicochemical properties for oral delivery were obtained at a 6:1 ratio of Cs:TPP,
with a 1:0.75 mass ratio of Cs:zein coating (diameter ~260nm, polydispersity index
~0.2, zeta potential >30mV). SEM analysis showed that spheroidal, well distributed
particles were obtained. Encapsulation Efficiencies of 80.7% and 78.9% were
achieved, respectively, for MSC an SeCys2 loaded NPs. Cytotoxicity studies of MSC
loaded NPs showed no decrease in cellular viability in either Caco-2 (intestine) or
HepG2 (liver) cells after 4 and 72 hr exposures. For SeCys2 loaded NPs, although no
cytotoxicity was observed in Caco-2 cells after 4 hr, a significant reduction in
cytotoxicity was observed, compared to pure SeCys2, across all test concentrations in
HepG2 after 72 hr exposure. Accelerated thermal stability testing of both loaded NPs
indicated good stability under normal storage conditions. Lastly, after 6 hr exposure
to simulated gastrointestinal tract environments, the sustained release profile of the
formulation showed that 62 ± 8 % and 69 ± 4% of MSC and SeCys2, had been released
from the NPs respectively.
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6.1 Introduction

In recent years, interest in preventative public health has increased through the
emergence of nutraceuticals, bioactive (BA) food compounds, shown to offer a wide
variety of physiological benefits in addition to reduced disease risks (Lagos et al.,
2015). By incorporating BA compounds (such as minerals or peptides) into food
systems, a potentially simple means of ameliorating the risk of disease, and the
subsequent development of an innovative functional food, can be achieved (Cencic
and Chingwaru, 2010). Unfortunately, the ability for such products to affect disease
prevention is highly dependent on the bioavailability and stability of these BA
compounds (Tavano et al., 2014). Given that a substantial amount of BA molecules
remain poorly available via oral administration, due to various factors such as, a lack
of stability in the environmental conditions encountered in food processes
(temperature, oxygen, light) and in the gastrointestinal tract (GIT) (pH, enzymes,
presence of other nutrients), a short gastric residence time of the dosage form, and a
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low permeability and/or solubility within the gut, all presenting a major formulation
challenge (Chen, Remondetto and Subirade, 2006).
Over the past few decades, encapsulation systems have been developed and employed
to overcome these limitations, based to their potential to more effectively deliver BA
agents to a selected target site of action (Vozza et al., 2016). Although several
synthetic polymers have been employed for use in various delivery applications in the
pharmaceutical industry, they are not suitable for deployment within the food industry
unless they have a generally recognised as safe (GRAS) status. Nanoparticle (NP)
delivery systems can offer an added advantage to the delivery of BA compounds, as
they possess a higher mobility and cellular uptake compared to systems of larger size.
As an illustration, He et al., (2012) found that particles 300 nm in size or less are ideal
for oral drug delivery since they are preferentially internalized by both enterocytes
and M cells and demonstrate higher intestinal transport compared to larger sized
particles. Etheridge et al. (2013) observed that the effect of particle size on cellular
intake can also be influenced by the constituent material and the particle geometry, a
consequence of reduced intestinal clearance mechanisms and an increase in the mass
to surface ratio interaction with the biological support.
Chitosan (Cs), a polysaccharide derived from chitin, the second most abundant
biopolymer (next to cellulose) in nature, has gained increasing popularity for
numerous biomedical applications and more specifically for use in NP deliver systems
(Kumari, Yadav and Yadav, 2010; Rodrigues et al., 2012; Mohammed et al., 2017)
Given the combination of its GRAS approved status and its well documented
biodegradable, biocompatible, and mucoadhesive properties, it is unsurprising that
this compound has been targeted for use in the delivery of BA cargos (Hejazi and
Amiji, 2003; Kumirska et al., 2011; Anitha et al., 2014). Due to the presence of
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primary amine groups in the Cs backbone, it can readily become protonated and thus
solubilised in acidic media, offering the ability to be cross linked with negatively
charged polyelectrolytes and under relatively mild reaction conditions, a technique
known as ionotropic gelation (Janes, Calvo and Alonso, 2001). Recent reports have
indicated the capacity of Cs NPs to improve the bioavailability of nutraceuticals such
as tea derived phenols, that are soluble yet poorly absorbed, through opening of tight
junctions and/or direct uptake by epithelial cells via endocytosis (Liang et al., 2017).
However, the oral administration of BA molecules contained within a Cs:NP matrix
remains a challenge, due to its lack of stability in the low pH media typically found in
the GIT (pH 1.2), in which rapid dissociation and thus degradation can lead to the
destruction of sensitive nutraceutical cargo (Yan et al., 2012).
Surface coating of Cs NPs has been proposed to confer increased protection to BA’s
as they pass through the GIT after oral consumption (Luo and Wang, 2014). Zein, a
GRAS approved prolamine rich protein derived from maize, has been employed for
the coating of Cs:NP oral delivery systems in recent years due to its ability to increase
the encapsulation efficiency (EE%) of BAs and to improve their controlled release in
the GIT (Luo et al., 2010; Luo and Wang, 2014; Paliwal and Palakurthi, 2014). This
coating strategy harnesses both the protein (zein) and polysaccharide (Cs) properties
in a combined NP delivery system in which a broader range of physical, chemical and
colloidal stability can be achieved (Benshitrit et al., 2012).
Selenium (Se), is an essential micronutrient in human and animal nutrition (Rayman,
2000) that exists in a wide array of different forms, both organic and inorganic.
Selenite and selenate salts are the most common inorganic forms, whereas
selenoamino acids (SeAAs), such as selenocystine (SeCys2), selenomethionine
(SeMet), and methylselenocysteine (MSC) are the most commonly found forms in
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foods from the Agaricus, Brassica and Allium families (Montes-Bayón et al., 2006;
Maseko et al., 2013; Reilly et al., 2014). Although essential, Se possesses a low
therapeutic index in which there is a fine line between beneficial and toxic doses.
Generally, organic Se shows a greater bioavailability than that of the inorganic forms,
in addition to showing a higher threshold for toxicity (Amoako, Uden and Tyson,
2009). Health benefits of MSC and SeCys2 have been linked to the body’s endogenous
antioxidant defence system, protecting cellular components such as cell membranes,
lipids, lipoproteins and DNA from oxidative damage by free radicals, reactive oxygen
and reactive nitrogen species (Ponnampalam et al., 2009). As oxidative damage is
linked to the development of cardiovascular and neurodegenerative diseases as well
as cancers, several experimental in vivo studies of the effects of administration of Se
compounds have been undertaken (Valko et al., 2007; Lobo et al., 2010; de Souza et
al., 2014). SeCys2 has been shown to reduce tobacco-derived nitrosamine-induced
lung tumour growth and enhance hepatic chemoprotective enzyme activities in mice
(Fan et al., 2013), whereas MSC has been shown to offer selective protection against
organ specific toxicity induced by clinically active antitumor agents, cisplatin,
oxaliplatin, and irinotecan in rat models (Cao et al., 2014).
However, organometals such as MSC and SeCys2 are readily oxidised (Wasowicz et
al., 2003; Davies, 2016) and although less toxic than inorganic Se, the adequate
physiological range between deficient and excess doses is narrow, being one order of
magnitude (0.1–1.0 µg/g diet) in experimental animals (Takahashi, Suzuki and Ogra,
2017). Additionally, the site of target for SeAAs is the jejunum, in the small intestine
(Cousins and Liuzzi, 2018). Therefore, it is important that the composition of the
formulation offers a sufficient ability to withstand the acidic environment of the
stomach whilst retaining the stability of the cargo. As such, the potential optimisation
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of the delivery of these compounds in a NP formulation could be significant, given
that both these organic species can more effectively increase both human and animal
selenium levels and are less toxic than inorganic selenium (Garousi, 2015).
This study builds directly on previous work (Vozza et al., 2018, Chapter 5) in which
the production of Cs:TPP NPs via ionotropic gelation, using selenomethionine
(SeMet) as a prototype encapsulant, was investigated. In that study, a Design of
Experiments (DoE) approach was employed to establish optimum formulation
conditions that would produce SeMet loaded NPs suitable for oral delivery. The
conditions of mass ratio 6:1 (Cs:TPP), with TPP dissolved in NaOH (0.1 M) and Cs
dissolved in acetate buffer (pH 3) prior to crosslinking, produced NPs with
physicochemical properties (Size ~ 300 nm, PDI <0.5 and ZP >30 mV) suitable for
oral delivery (des Rieux et al., 2006). By coating the NPs with zein, the encapsulation
efficiency (EE%) was significantly improved from < 65% to >80%. In this work, the
optimised formulation conditions, as previously identified by DoE, were employed to
encapsulate SeCys2 and MSC, based on the rationale that SeCys2 (with a pKa of 4.7
(Lacourciere and Stadtman, 1999)), and MSC (with a pKa of 4.9 (Mishra, Priyadarsini
and Mohan, 2007)), contain comparably ionisable groups to SeMet. As such, it was
hypothesised that by employing the previously established DoE parameters to the
current Cs:TPP NP formulation of MSC and SeCys2, similar formulations (e.g.
physicochemical properties and EE%) as those achieved for the SeMet loaded NPs
could be produced. Once prepared, the cryoprotectant trehalose was employed, to
ensure stability of the optimised formulations after lyophilisation (Danish, 2017a).
NPs were then extensively assessed for their physicochemical properties,
morphology, thermal stability, cytotoxicity and in vitro controlled release, utilising
the methods developed in the previous studies (Vozza et al., 2018, Chapter 5).
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6.2 Material and Methods

6.2.1 Materials
The chitosan compound PROTASAN™ UP (CL113) was purchased from
NovaMatrix, FMC Corporations, Norway. D (+) - Trehalose dihydrate, and zein, of
≥99 % purity, were obtained from ACROS Organics™, Fisher Scientific, Ireland.
Seleno-DL-cystine (>98 % purity) and Se-methyl-seleno-L-cysteine (>98 % purity),
were purchased from Sigma Aldrich, Ireland and LKT laboratories, UK, respectively.
Ultra-pure water 18mΩcm-1 was obtained from a Millipore simplicity 185 model
instrument, UK, and was used for all aqueous solution preparations. All other
reagents, chemicals and solvents were of analytical grade, from Sigma Aldrich,
Ireland.

6.2.2 Formulation of MSC and SeCys2 loaded Cs NPs – coated with
zein
Cs:TPP NPs were formed according to (Vozza et al, 2018, Chapter 5) with the
following modifications. Aqueous TPP solution (3 mg/mL) was prepared in NaOH
(0.01 M), with a Se species (SeCys2 or MSC) concentration of 400 ug/mL.
Subsequently, this mixture was added in equal volumetric proportions to CL113
solution (3 mg/mL) via burette droplet addition. The NPs formed were then left to
stabilise for a further 30 min whilst the stirring speed of the solution was maintained
at 700 rpm. Once the NPs had stabilised, absolute EtOH (8 mL) was added dropwise
to the formulation whilst the stirring speed of the solution was maintained (700 rpm,
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30 min). Filtered Zein (2 mL, 5.625 mg/mL), dissolved in aqueous EtOH (80% v/v),
was then added dropwise to the solution to yield Zein:Cs NPs of mass ratio 0.75:1.
All formulations were left to stabilise at 700 rpm for 30 min, then transferred to a 20
kDa MWCO (Vivaspin 20, Sartorius) centrifugal filter and isolated by centrifugation
at 3000 rpm for 30 min. Filtered EtOH (80% v/v) (equivalent in volume to the
recovered supernatant) was then added to the purified NPs and subsequently sonicated
at 35% amplitude for 30 s with 5 s pulse intervals. The NP formulations were then
concentrated under vacuum (175 mbar) at 40 °C until EtOH was completely removed.
To ensure stability of the optimised formulation after lyophilisation, 10 mL of the
cryoprotectant trehalose 5 % w/v in H2O were added to each formulation and they
were lyophilised for 36 hr (Danish, 2017a).

6.2.3 Physicochemical characterisation of MSC and SeCys2 loaded
Cs NPs coated with zein
Dynamic light scattering (DLS) was used to determine the mean particle size and
polydispersity index (PDI) of the NP formulations. Laser doppler velocimetry (LDV)
was used to measure the zeta potential (ZP). Both DLS and LDV analysis were
performed with a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser
(Malvern Instruments Ltd., UK), using a folded capillary cuvette (Folded capillary
cell-DTS1060, Malvern, UK), at 25 °C. The values presented herein were acquired
from three separate experiments, each of which included three replicates. N=3
(Chapter 3, Section 3.2.1).
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6.2.4 Scanning electron microscopy (SEM)
SEM analysis was used to visualise the morphology of the NPs formed’ at an
accelerating voltage of 20 kV, using a secondary electron detector (Hitachi, SU6600
FESEM, USA). NP solutions were spin coated onto Si wafers, dried at room
temperature and then sputter coated with 4 nm Au/Pd prior to imaging
(Mukhopadhyay et al., 2013), (Chapter 3, Section 3.2.2).

6.2.5 Encapsulation efficiency (EE%)

The EE% of Se (MSC or SeCys2) in the NPs was determined by the separation and
quantification of Se left in the supernatant. This was performed after
ultracentrifugation of the formed NPs (3000 rpm, 4 °C, 30 min). Reverse phase high
performance liquid chromatography (RP-HPLC), was employed to quantify
unencapsulated Se in the supernatant, as previously described (Ward, Connolly and
Murphy, 2012) with the following modifications. Samples were analysed with a
Waters 2998 HPLC coupled to a Photodiode Array Detector, (Waters, USA), using a
Pursuit 5 C18, 250 x 4.6 mm column, (Agilent Technologies, UK). Isocratic elution
was carried out at a flow rate of 0.8 mL/min, column temperature 45.0 ± 5.0 °C with
a mobile phase of water/methanol/trifluoroacetic acid (97.9:2.0:0.1). Samples were
monitored according to their UV absorbance at 218 nm. The encapsulation efficiency
was calculated using Equation 6.1 (Xu and Du, 2003), (Chapter 3, Section 3.2.3):

𝑬𝑬% =

𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕 − 𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑿 𝟏𝟎𝟎
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
(Equation 6.1)

203

6.2.6 Cellular viability assay (MTS)

The potential cytotoxicity of the different SeAA (MSC and SeCys2) loaded NPs,
coated with zein, were examined on Caco-2 human epithelial cells, and HepG2 human
liver hepatocellular cells, using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)

assay.

Caco-2

and

HepG2, were seeded at a cell density of 2 x 104 cells/well and cultured on 96 well
plates in Dulbecco's Modified Eagle Medium (DMEM) and Eagle's Minimum
Essential Medium (EMEM) respectively, supplemented with 10% foetal bovine
serum, 1% L-glutamine, 1% penicillin-streptomycin and 1% non-essential amino acids
at 37°C in a humidified incubator with 5% CO2 and 95% O2. The assay was carried
out using 4 h exposure times for the test compounds on Caco-2 cells (Neves et al.,
2016) and 72 h on HepG2 cells (Gleeson et al., 2015), using Triton X-100™ (0.05%)
as a positive control. The time points were selected to mimic in vivo conditions for
each cell type. The concentrations of the test compounds applied were 25, 50 and 100
uM. After exposure, treatments were removed and replaced with MTS. Optical
density (OD) was measured at 490 nm using a microplate reader (TECAN GENios,
Grodig, Austria). Each value presented was normalised to that of untreated control
and calculated from three separate experiments, each of which included six replicates
(Chapter 3, Section 3.3.1).

6.2.7 Stability studies

Accelerated stability studies of MSC and SeCys2 loaded NPs, were conducted to
determine the change in physicochemical properties (particle size, PDI and ZP) stored
at accelerated conditions: 60°C for 720min, 70°C for 300min and 80°C for 120min
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(Danish, 2017a). In brief, aqueous KCl solution (10 mM) was used to suspend the
NPs at a concentration of 0.1 mg/mL and the degree of degradation was measured
using the Nanosizer ZS (Malvern Instruments Ltd, UK) over different time intervals.
R software (R Core Team, 2016) was used to analyse the generated data.
The temperatures dependence of the kinetic parameters of MSC or SeCys2 loaded NPs
stability were measured by calculating the observed rate constants. This was plotted
in an Arrhenius representation and apparent activation energy, Ea and reaction rate,
kref were calculated according to Equation 6.2:

𝑪 = 𝑪𝒐 + 𝒆

𝒍𝒏(𝒌)−

𝑬𝒂 𝟏 𝟏
( −
)
𝑹 𝑻 𝑻𝒓𝒆𝒇

𝒕
(Equation 6.2)

where C is the property (particle size, PDI or zeta potential) at time t, Co is the initial
property conditions, k is the apparent zero order reaction constant, Ea is the energy of
activation, R is the universal gas constant, T is the temperature of the experiment (K)
and Tref is the reference temperature (343 K), (Chapter 3, Section 3.3.2.).

6.2.8 Release studies

In vitro release studies of MSC and SeCys2 from the NPs were conducted using a
dialysis bag diffusion technique (Hosseinzadeh et al., 2012) over 12 hr (Calderon et
al., 2013; Yoon et al., 2014). In brief, freeze dried loaded (MSC or SeCys2) NPs were
suspended in H2O (5 mL) and probe sonicated (Branson Ultrasonics; Ultrasonic
processor VCX-750W, USA) at 35 % amplitude for 30 s with 5 s intervals and placed
into a Float-A-Lyzer®G2 dialysis membrane (DM) with a pore size of 25 kDa
(Spectrum Laboratories, USA). The DM was then placed into 40 mL of simulated
gastric fluid (SGF) for 2 hr, followed by a compartmental change to simulated
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intestinal fluid (SIF) for 4 hr. The composition of SGF was 0.1 M HCl and SIF
comprised of a 3:1 mixture of 0.2 M trisodium phosphate dodecahydrate and 0.1 M
HCl (adjusted to pH 6.8), without enzymes (British Pharmacopoeia Commission,
2016). Samples were then placed in a thermostatic shaker (37 ºC, 100 rpm) and, at 7
equidistant predetermined time points, release fluid was removed (1 mL) and replaced
with fresh simulated fluid to maintain sink conditions.
The % of drug (MSC or SeCys2) released was measured by RP-HPLC (Section 6.1).
Equation 6.3 was used to determine the % drug release:

𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =

𝑫(𝒕)
∗ 𝟏𝟎𝟎
𝑫(𝒍)
(Equation 6.3)

where Drugrel % is the percentage of drug released, D(l) represents the concentration
of drug loaded and D(t) represents the amount of drug released at time t, respectively
(Chapter 3, Section 3.3.3.).
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6.3 Results and Discussion

6.3.1 Particle size, PDI and Zeta potential and EE%

The Se species (MSC or SeCys2) used to load the NPs did not have a significant effect
on any of the NP properties (size (nm), PDI, ZP (mV) and EE (%) as shown in Table
6.1. The effects of zein and zein:Cs ratio on particle characteristics and Se species
EE% are also presented in Table 6.1.
Table 6.1 Physicochemical analysis of SeAA loaded Cs NPs, coated with zein, at
mass ratios of 1:1 and 1:0.75 (Cs:zein).

Se Species
SeCys2
MSC

Size (nm)
335.2 ± 34.5
333.6 ± 15.8

Se Species
SeCys2
MSC

Size (nm)
262.1 ± 11.1
271.2 ± 21.4

Se Species
SeCys2
MSC

Size (nm)
205.9 ± 14.3
226.5 ± 40.1

Zein:Cs 1:1
PDI
0.346 ± 0.070
0.374± 0.054
Zein:Cs 0.75:1
PDI
0.243 ± 0.061
0.211 ± 0.148
Zein:Cs 0:1
PDI
0.271 ± 0.042
0.280± 0.034

ZP (mV)
23.8 ± 2.6
23.0±3.4

EE%
82.1± 1.2
83.2 ± 2.5

ZP (mV)
31.5 ± 1.0
32.2 ± 1.3

EE%
78.9 ± 1.5
80.7 ± 0.7

ZP (mV)
36.6 ± 2.0
38.6 ± 2.4

EE%
61.9 ± 2.8
61.5 ± 1.0

Zein was shown to significantly increase NP size (nm) and EE (%), in a linear fashion
with respect to increasing mass ratio to Cs (Figure 6.1). For example, it was observed
that the average size of MSC or SeCys2 loaded Cs NPs, before zein coating, increased
from 227 ± 40 (weight ratio of 0:1), to 334 ± 16 (weight ratio of 1:1) and 206 ± 14
(weight ratio of 0:1), to 352 ± 35 nm (weight ratio of 1:1), respectively.
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Similar observations were made by Zhang et al. (2014) where zein to sodium
caseinate (SC) mass ratios of 1:0.625–1:1.25, resulted in an increase in particle size
from 176.85±1.06 nm to 204.75± 1.62 nm, most likely a consequence of NP coating.
Additionally, this finding may be due to the larger size of zein (relative to TPP), and
is consistent with our previous observations for SeMet loaded Cs NPs coated with
zein (Vozza et al., 2018, Chapter 5) and that of others, whereby, an increase in zein
concentration led to an increase in particle size of 6,7-dihydroxycoumarin loaded zein
NPs (Podaralla and Perumal, 2012) or alpha-tocopherol loaded zein NPs, stabilised
with Cs (Luo et al., 2011), evidenced by a denser and thicker coating of zein around
the Cs NP.
Interval Plot of Size (nm), PDI, ZP (mV), EE (%)
95% CI for the Mean
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Figure 6.1 Interval plot showing the effect of Se Species and Cs:zein mass ratios on
NP physicochemical properties (Size (nm), PDI, ZP (mV) and EE (%).

PDI reflects the particle size distribution of dispersions, ranging from homogenous
(0.0) to heterogeneous (1.0) (Win and Feng, 2005). For a NP formulation to be orally
active, it is generally recognised that PDI values should be no greater than 0.5 (Avadi
et al., 2010). In this work, The PDI of the formulations (with or without zein coating)
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remained below 0.4 and neither Se species nor addition of zein significantly affected
the size distribution of the NPs formed, indicating that they could be suitable for oral
delivery (des Rieux et al., 2006).
Additionally, to establish an industrially viable delivery system, it is recommended
that a high degree of the drug cargo be encapsulated within the NP complex (> 80 %)
(Sinead Bleiel, AnaBio Technologies Ltd, private communication). As can be seen in
Table 6.1, the Se loaded Cs NPs, showed a higher EE (> 79%) for all formulations
with zein coating (0.75-1:1 mass ratio), compared to < 62% for uncoated formulations.
This is most likely attributable to zein facilitating the incorporation of a higher
proportion of the SeAAs into the NP matrix. In other work, bovine serum albuminin
has been encapsulated within hydrophobic polymers such as poly-lactic-co-glycolic
acid (PLGA) and poly-ε-caprolactone (PCL), providing evidence that EE%, can
greatly depend on the interactions between the polymer (in this instance Cs), protein
(zein), and organic solvent (Lamprecht et al., 2000).
Conversely, an inverse relationship was observed for ZP (mV), whereby the surface
charge of the NPs reduced upon increasing the zein:Cs mass ratio. This trend is
conceivable, as, as the concentration of zein increases, a higher proportion of the
positively charged primary amines (-NH3+) present in Cs, become neutralised during
complexation with the negatively charged carboxyl (COO-) groups of zein
(Mukhopadhyay et al., 2013) and thus a reduction in ZP occurs.
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6.3.2 Scanning electron microscopy (SEM)

SEM provides information on both the size and morphology of nanoscale particles,
factors which may influence the colloidal and chemical stability of a given NP
formulation. Figure 6.2 shows the SEM images of uncoated NPs (1, A, B), zein coated,
MSC (2, A, B) and SeCys2 (3, A, B) loaded NPs. The uncoated NPs showed uniform
spheroidal morphologies and the particle size, after spin coating, was in good
agreement with that determined by DLS (Figure 6.2, (3 (A), (B)), and consistent with
the works of several others (Luo et al., 2011; Park, Park and Kim, 2015).

Figure 6.2 SEM images of uncoated NPs (1 (A), (B)). MSC loaded NPs - coated
with zein (2 (A), (B)) and SeCys 2 loaded NPs - coated with zein (3 (A), (B)).

Interestingly, the NPs coated with zein showed a slightly irregular surface
morphology, with a denser core and brighter shell structure (Figure 6.2 (1 (A), (B))
and 2 (A), (B)) inferring that zein produces a less dense coating when compared to Cs
NPs alone. This may be attributable to the electrostatic interaction of the negatively
charged carboxyl groups of zein facilitating a thin layer membrane around the
positively charged amines residues of Cs (Luo et al., 2011).
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In terms of the particle size, comparing between SEM and DLS measurements,
slightly larger sizes were observed under SEM imaging (approx. 80-120 nm larger),
which may be due to the rapid evaporation of residual ethanol (present in the final
suspension media) during the spin casting process and subsequent flattening of the
particles on the grid (da Rosa et al., 2015).

6.3.3 Stability studies

Figure 6.3 shows the kinetic behaviour of the MSC loaded NP properties: size (A),
PDI (B) and ZP (C), at temperatures ranging from 60-80 °C.
(1)

(2)

c

c

c

1.0
0.8
0.6

3.6
3.4
3.2
3.0

0.4
0.2

300

600
500
400

b

300

a

a
1.0
0.8
0.6
0.4

600
500
400
300

b
1.0
0.8
0.6
0.4

PDI

b

3.6
3.4
3.2
3.0

log(Zp)

600
500
400

Particle Size [nm]

(3)

0.2

a
3.6
3.4
3.2
3.0

0.2
0 5 10 15 20 25

Time [min]

0

5 10 15 20 25

Time [min]

0

5 10 15 20 25

Time [min]

Figure 6.3(1) Particle size, (2) PDI and (3) ZP analysis of MSC loaded NPs exposed
to (a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720 min,
respectively. N=3.

The stability of the NPs decreased with increasing temperature. Little change was
detected for all properties at 60 °C, over the course of 720 min, whereas a more
pronounced influence on size and PDI and a decrease in ZP was observed at 70 °C
after 300 min. At 80 °C, destabilisation of the NP complexes was evident according
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to all properties, whereby size increased from approximately 350 nm to > 700 nm,
PDI from approximately 0.2 to >0.9 and ZP reduced from approximately 32 mV to <
18 mV, indicating that aggregation of the NPs had occurred (Wu, Zhang and
Watanabe, 2011).
A linear relationship is evident between 1/T and ln k, indicating that the formulations
three physical chemical properties follow Arrhenius law (Figure 6.4).
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Figure 6.4 Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies
of MSC loaded NPs.

The one-step nonlinear regression analysis of the kinetic experiments at Tref the
reference temperature (70°C) shows that the particle size and PDI of MSC loaded NPs
fit to a zero-order kinetic behaviour, with an Arrhenius dependence of ln (kref@70 °C)
= 4.45 ± 6.28 min−1 and Ea = 340.32 ± 139.20 kJ/mol for size, and a ln (kref@70 °C)
= 0.0112 ± 0.0124 min−1, and an Ea = 314.30 ± 109.00 kJ/mol for PDI respectively
(Figure 6.4). Regarding ZP, an apparent first order mechanism fits the data better than
an apparent zero order model, with an Arrhenius dependence of ln (kref@70 °C) =
0.047 ± 0.011 min−1 and Ea = 157.25 ± 19.95 kJ/mol.
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Similar kinetic behaviour was observed for the SeCys2 loaded NPs properties (size
(A), PDI (B) and ZP (C)) at temperatures ranging from 60-80 °C (Supplemental
Figure S6.1). Again, as temperature increased destabilisation of the NPs occurred,
whereby size and PDI fit to a zero-order kinetic behaviour, with an Arrhenius
dependence of ln (kref@70 °C) = 5.22 ± 6.04 min−1 and Ea = 301.87 ± 112.99 kJ/mol
for size, and a ln (kref@70 °C) = 0.0267 ± 0.0101 min−1, and an Ea = 200.53 ± 34.10
kJ/mol for PDI respectively. Likewise, ZP, followed an apparent first order
mechanism better than that of an apparent zero order model, with an Arrhenius
dependence of ln (kref@70 °C) = 0.043 ± 0.007 min−1 and Ea = 175.70 ± 15.12 kJ/mol.
Lastly, a linear correlation is evident between 1/T and ln k, further indicating that the
formulations will be stable under normal storage conditions (Supplemental Figure
S6.2).
As there was no significant difference observed between the Se species (MSC or
SeCys2) used to load the NPs on the formulations stability, it can be concluded that
the contributing factors are determined by the Cs:zein complex rather than the specific
loaded SeAA. This is expected, as the complexation of protein (in this instance zein)
with polysaccharide (Cs) systems, involves non-covalent interactions that can change
the interfacial behaviour and stability of food colloids (Ghosh and Bandyopadhyay,
2012).
For example, by harnessing Cs’ thermal stability and combining it with zeins’
aromatic side groups and double bonds, it is possible to greatly increase the stability
of labile nutraceuticals against thermal degradation and oligomerization (Luo et al.,
2013). Zein coated tablets exhibit stronger resistance to abrasion, high humidity and
high temperatures than a variety of commercial sugar-coated tablets (Zhang et al.,
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2015). Moreover, it has been reported that the bi-layer approach for encapsulation of
bioactives leads to a better control of the NP interface structure, charge, thickness and
permeability, and substantially enhanced stability (Hu and McClements, 2014).
Notably, the net attractive and net repulsive strength character of protein–
polysaccharide non-covalent physical interactions can vary substantially, depending
primarily on environmental conditions such as pH, ionic strength, and temperature
(Semenova et al., 2014). In this work, the conditions (presence of salt) used to prepare
the NPs, in addition to the strong bonding between the zein and Cs complex may have
been a contributing factor to the enhanced stability of the formulation and is consistent
with our previous observations (Vozza et al., 2018, Danish et al., 2017b).

6.3.4 Cellular viability

Se loaded NPs become exposed to the intestinal epithelia following oral delivery,
leading to its facilitated transport and uptake. Therefore, the potential cytotoxicity of
the different Se species were examined on Caco-2 human epithelial cells, and HepG2
human liver hepatocellular cells. Both cell lines are routinely used to assess
cytotoxicity of orally delivered molecules (Gleeson et al., 2015; Brayden et al., 2015).
The MTS assay was used to assess the cytotoxicity of both MSC and SeCys2 in native
format and within the NP formulation (loaded and unloaded), at different test
concentrations (25, 50 and 100 uM).
Supplementary figures show the cytotoxicity assessment of MSC loaded NPs on
Caco-2 (S6.3 (A)) and HepG2 cell lines (S6.3 (B)). In terms of Caco-2, no cytotoxicity
was observed for all test formulations (native, loaded and unloaded NPs), after 4 hr
exposure, in comparison to the negative control, across all tested concentrations (S6.3
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(A)). The same response was observed for the HepG2 cell exposures for 72h (S6.3
(B)). These results are in accordance with the observations of Barrera et al., (2013),
who observed no apparent cytotoxicity on Caco-2 cells after a 72 hr exposure of MSC
(0.2-100 uM) and Marschall et al., (2016), who reported no obvious cytotoxicity
HepG2 cells incubated with MSC (2.5-200 uM) after 48 hr exposure.
Regarding SeCys2 (native, loaded and unloaded NPs), although no cytotoxicity was
observed in Caco-2 cells after 4 hr exposure (Figure 6.5 (A)), a significant reduction
in cell viability was observed for both native and equivalent loaded NPs across all test
concentrations, with native SeCys2 resulting in a reduction of ≥ 63% cell viability at
50 and 100 uM test concentrations (Figure 6.5 (B)). Similar results were observed by
Takahashi, Suzuki and Ogra (2017), who reported that SeCys2 elicited no significant
change in the viability of Caco-2 cell lines after 6 hr, although it did show significant
toxicity to HepG2 cells at 100 uM, comparable to that of the inorganic form selenite,
after prolonged exposure (48 hr).
Organic Se species, such as SeAAs have been reported to be less toxic than inorganic
Se species and as such the high toxicity of SeCys2 is quite surprising (Suzuki et al.,
2010; Takahashi, Suzuki and Ogra, 2017). As the toxicity of SeCys2 has been shown
to be comparable to that of selenite, it has been proposed by others that the cellular
overload of metabolites (such as selenide moieties (-Se-) and (HSe-) produced during
selenoprotein formation or excretion (Rayman, Infante and Sargent, 2008; Marschall
et al., 2016) is responsible for this effect. Most likely, the reduction of SeCys2 to
SeCys in the cell results in the generation of a highly reactive and sensitive to
oxidation selenyl group (-SeH), whose relatively low pKa of 5.2 promotes the
formation of (-Se-) at physiological pH (Iwaoka, 2014). As can be seen in Figure 6.5
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(B), the encapsulation of SeCys2 within the Cs:zein NP matrix conferred protection to
the HepG2 cells after 72 hr exposure, indicating that, at the tested concentrations used
in this study, the cytotoxic effects of pure SeCys2 can be reduced.
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Figure 6.5 Cytotoxicity assessment of

SeCys 2 ,

unloaded NPs and

SeCys 2 loaded NPs, exposed for (a) 4h in Caco2 cell lines and (b) 72h in HepG2 cell
line at 25 uM, 50 uM and 100 uM concentrations. Percentage (%) of MTS converted
was compared to untreated control. 1-Way ANOVA with Dunnett’s post-test *** p<
0.001. Each value presented was normalised against untreated control and calculated
from three separate experiments, each of which included six replicates. N=3.

Lastly, the unloaded NPs showed no significant effect on Caco-2 cells over the range
of test concentrations, nor HepG2 at test concentrations of 25 and 50 uM. However,
at 100 uM, a significant increase in cell viability was observed, indicating that the
formulation elicits an enhanced proliferative effect at this concentration. This may be
attributable to a combination of zein’s demonstrated cytocompatibility with NIH 3T3
and human liver cells (HL-7702) in terms of cell adhesion and proliferation (Dong,
Sun and Wang, 2004), and an increase in fibroblast production caused by the presence
of Cs (Rajam et al., 2011).
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6.3.5 Release studies

Three basic mechanisms that are typically employed to describe the release of drugs
from polymeric particles are, swelling/erosion, diffusion, and degradation (Liechty et
al., 2010). The prominence of each can depend on the conditions of the environment.
Therefore, the release kinetics of MSC NPs were monitored sequentially in SGF and
SIF controlled release experiments.
Figure 6.6 shows the cumulative release profile of MSC and SeCys2 loaded NPs,
coated with zein, after subjection to 2 hrs in an SGF environment (pH 1.2)
representative of the stomach, followed by a compartmental change to SIF (pH 6.8),
representative of the intestine, for 4 hrs. As can be seen, 37 ± 11 % of MSC was
released from the NP after 2 hr in SGF, followed by 25 ± 8 % release in SIF for 4 hr.
Regarding SeCys2, 45 ± 4 % was released from the NPs after 2 hr in SGF, with a
subsequent release of 24 ± 4 % after subjection to a SIF environment (4 hr).
Despite the high-water solubility of the SeAAs, there was good control of drug release
in the simulated physiological environment of stomach and small intestine. On
exposure to the dissolution fluids (SGF and SIF), the Cs complex will become
hydrated forming a viscous gel layer that slows down further seeping-in of dissolution
fluids towards the core of the NP (Miladi et al., 2015). The subsequent Cs swelling
under these conditions allows for the drug release to follow a diffusion oriented
mechanism, which is then typically trailed by the mechanical erosion of the swollen
Cs hydrogel (Mohammed et al., 2017). In tandem, subsequent hydration and swelling
of the system is heavily dependent upon whether or not the Cs erodes further. With
this in mind, it was observed that the release of both SeAAs from the Cs:zein NPs was
pH dependent, indicative of Cs solubility in acidic media (Yuan et al., 2013).
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SGF

SGF

SIF
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Figure 6.6 Release kinetics of MSC and SeCys2 loaded NPs, coated with zein, aft er
2 hr in SGF (pH 1.2) and 4 hrs in SIF (pH 6.8). Solid lines are a fit to the model of
Equations 6.4 and 6.5. The continuous line indicates the model prediction.

As two different simulated fluids were used for this study, representing the pH
environment in the stomach (SGF) and the jejunum target site in the intestine (SIF),
their release profile was modelled using a swelling, Peppas equation (6.4) and (6.5)
(Siepmann and Peppas, 2011; Danish, 2017a).
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For the SGF:
𝑴𝒕
= 𝒌𝒔𝟏 ∗ (√𝒕𝒊𝒎𝒆) + 𝒌𝒔𝟐 ∗ 𝒕𝒊𝒎𝒆
𝑴∞
(Equation 6.4)
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at
infinite time, and ks1 and ks2 are the diffusive and relaxation rate constants
respectively.
For the SIF:
𝑴𝒕 𝑴𝟏𝟐𝟎
−
= 𝒌𝒊𝟏 ∗ (√𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) + 𝒌𝒊𝟐 ∗ (𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎)
𝑴∞
𝑴∞
(Equation 6.5)
where M120 is the predicted diffused mass at the time of changing from SGF to SIF
(120 min), ki1 and ki2 are diffusive and relaxation rate constants.
The release of SeCys2 and MSC from the nanoparticles was best fitted with a
combination of diffusion and relaxation mechanisms. The fits of the model are
illustrated by solid lines in Figure 6.6. Table 6.2 presents the fitted values for the rate
constants in SGF (ks) and SIF (ki) for both Se loaded (MSC and SeCys2) NPs, divided
into diffusion and relaxation mechanisms (1 and 2) (Eq. 6.4, 6.5).
For SeCys2 loaded NPs, subjected to the simulated stomach environment (SGF, pH
1.2), no statistically significant ks1 parameter was found, indicating that the primary
mechanism for release in the stomach was via relaxation, i.e. slower release,
approaching zero-order kinetics. After 2 hr subjected to the SGF environment, a
compartmental change was employed to mimic the movement of the SeCys2 NPs to
the intestinal environment (SIF, pH 6.8), whereupon a combination of diffusion (ki 1)
and relaxation (ki2) mechanisms were observed (p<0.05). In contrast, a combination
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of ki1 and ki2 mechanisms in the stomach (SGF) was observed for the release of the
MSC loaded NPs and no statistically significant ki1 parameter was found for the
intestinal compartment, indicating that, in the small intestine (jejunum), at pH 6.8,
relaxation is the primary mechanism of release for MSC.
These findings corroborate previous studies, reporting a diffusion and zero order
kinetic profile for IPP and LKP loaded Cs NPs, coated with zein (Danish et al., 2017a)
and that of other researchers, who observed that zein proved to be a good coating for
NPs, whereby, the stronger interaction of the load material (in this instance phenolic
monoterpenes) with that of the wall material (zein) was evidenced by its controlled
release over time (da Rosa et al., 2015).
Table 6.2 Swellable model parameters for kinetic release studies of MSC and
SeCys2 loaded NPs, coated with zein. ks represents the stomach compartment and
ki the intestinal compartment, divided into diffusion and relaxation mechanisms ( 1
and 2 ). All parameters listed where statistically significant, ( ∗P < 0.05).

SeCys2 loaded NPs
Estimate (min-1/2)
0.26±0.08
1.86±0.28
-0.023±0.05

Coefficients
ks2
ki1
ki2
MSC loaded NPs

Estimate (min-1/2)
-1.65±0.75
0.46±0.08
0.14±0.05
0.95

Coefficients
ks1
ks2
ki2
2
R adjusted

In terms of significant differences between the common release parameters of the two
SeAAs (Ks2 and Ki2, Table 6.2), MSC was found to exhibit a lower release rate in
SGF than SeCys2, with a release of 37 ± 11 % observed for MSC vs 45 ± 4 % for
SeCys2. This may be attributable to a number of different factors, for example the
difference in the polar surface area (PSA) between the two compounds (MSC PSA =
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63.32 A2 vs SeCys2 PSA = 126.44 A2) allowing for MSC to become more physically
entrapped into the NP matrix. Additionally, the electrostatic attractions between the
NP matrix and SeCys2 becomes amplified at pH 1.2, whereby the SeCys2 charged
state predominantly exists with both amine residues going to NH3+ (Rivail da Silva et
al., 1997; Kotrebai et al., 2000), facilitating increased electrostatic repulsion with the
primary amines of Cs. As other authors have observed that swelling rates, swelling
capacity and release rates of drugs varying in hydrophobicity were pH dependent,
because of the presence of charged groups on the drug molecules in varying pH release
media (Katas, Raja and Lam, 2013; Bouman et al., 2016), it is reasonable to suggest
that this may be the attributing factor to the faster release observed with SeCys 2. No
significant difference in the release profile of either MSC or SeCys2 loaded NPs
against those without zein coating, was observed (data not shown), indicating that the
release profile is influenced by the interaction of the active with Cs:TPP and is not
significantly influenced by the zein coating. This may be related to the formulation
media conditions employed in this study for TPP (pH 12) prior to crosslinking with
Cs, which has been shown to decrease drug release rates. For example, Ajun et al.,
(2009) observed that aspirin’s release rate from Cs NPs could be reduced from 64 to
40 % within 8 hr by increasing the basicity of the TPP media pH from 3 to 8.4,
allowing for the production of high density structured NPs and consequently, the
drugs slower release. Nonetheless, whether zein affected the release profile or not, it
remained necessary to keep zein in the formulation to ensure an EE (≥80 %) for the
encapsulated SeAAs.
Lastly, the release profile of SeMet, previously assessed in Chapter 5 (Section 5.9,
Figure 5.8), was compared to those of both MSC and SeCys2, SeMet was found to
release in SGF at a slower rate than the other SeAAs, with a total release of 25±1 %
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after 2 hr in the SGF environment, vs 37 ± 11 % and 45 ± 4 % for MSC and SeCys 2
respectively. Conversely, in the SIF environment SeMet was the fastest releasing
SeAA, showing release of 33 ± 3 % vs 25 ± 8 for MSC and 24 ± 4 for SeCys 2
(Supplemental Table S6.1). From the Henderson–Hasselbalch equation it can be
derived that any drug-like molecule (weak acid or base) will be predominantly ionised
if the pH of the system is about two pH units higher than its pKa. Vice versa, at two
pH units lower than its pKa the drug will be predominantly (99%) protonated. The
pKas for the SeAAs are 4.66 < 4.93 < 5.53 (SeCys2, MSC, SeMet) (Supplemental
Table S6.1) suggesting that the observed variance in release rates is attributable to
their chargeable properties and interactions with the protonated 1º amines of Cs
(Makhlof, Tozuka and Takeuchi, 2011). For example, SeCys2, the fastest releasing
SeAA in SGF (45 ± 4%), would be the most protonated (pKa = 4.66) at pH 1.2,
allowing for increased electrostatic repulsion between its two -NH3+ moieties and that
of Cs, thus driving the release from both the surface and within the NP structure.
Conversely, SeMet with a pKa of 5.5 showing the slowest release in SGF (25 ± 1)
(Supplemental Table S6.1), would be the least protonated out of the SeAAs allowing
for less repulsion between its -NH2 and -NH3+ and thus a slower release in SGF. As
the target site for the SeAAs is the jejunum, sufficient ability of the NP to withstand
the acidic environment of the stomach is important, with the findings showing that
SeMet loaded NPs are the most resistant in this instance, followed by MSC and
SeCys2.
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6.4 Conclusion

In this study, SeAA loaded Cs NPs, were produced via ionotropic gelation. NPs with
optimum properties for oral delivery were formed by coating the produced NPs at a
1:0.75 mass ratio of Cs:zein, resulting in MSC loaded NPs with sizes of 271.2 ± 21.4
nm, PDI 0.211 ± 0.061, ZP 32.2 ± 1.3, EE% of 80.7 ± 0.7 and SeCys2 loaded NPs of
262.1 ± 11.1 nm, PDI 0.243 ± 0.148, ZP 31.5 ± 1.0 and EE% 78.9 ± 1.5. SEM analysis
showed that spheroidal, well distributed particles were observed. MTS cytotoxicity
studies on MSC loaded NPs showed no decrease in cellular viability in either Caco-2
(intestine) and HepG2 (liver) cell lines after 4 and 72 hr exposures, respectively. For
SeCys2 loaded NPs, no cytotoxicity was observed in Caco-2 cell lines after 4 hr,
however a significant reduction in cytotoxicity was observed, when compared to pure
SeCys2, across all test concentrations on HepG2 after 72 hr exposure. Accelerated
thermal stability of both loaded NPs indicated good stability under normal storage
conditions. Lastly, after 6 hr exposure to simulated GIT environments, the sustained
release profile of the formulation showed that 62 ± 8 % and 69 ± 4 of drug had been
released from MSC and SeCys2 loaded NPs respectively. These findings infer that, by
encapsulating SeAAs into a NP delivery system, improved oral administration of this
molecule may be achieved, which could be of beneficial use for the supplementation
of food products with these essential nutrients.
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Figure S6.1(1) Particle size, (2) PDI and (3) ZP analysis of SeCys 2 loaded NPs
exposed to (a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720
min, respectively. N=3.
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MSC,
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loaded NPs, exposed for (a) 4h in Caco2 cell lines and (b) 72h in HepG2 cell line at
25 uM, 50 uM and 100 uM concentrations. Percentage (%) of MTS converted was
compared to untreated control. 1-Way ANOVA with Dunnett’s post-test *** p<
0.001, ** p< 0.01, Each value presented was normalised. against untreated control
and calculated from three separate experiments, each of which included six
replicates. N=3.
Table S6.1 Release (%) of SeAAs in SGF and SIF.

SeAA loaded
NP

% Release in
SGF

% Release in
SIF

SeMet
MSC
SeCys2

25 ± 1
37 ± 11
45 ± 4

33 ± 3
25 ± 8
24 ± 4
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%
Cumulative
release
58 ± 2
62 ± 9
69 ± 4

pKa

5.53
4.93
4.66

7 POTENTIAL OF MUSHROOM BYPRODUCTS FOR NUTRIENT DELIVERY
APPLICATIONS: PRODUCTION AND
CHARATERISATION OF CHITIN FROM
AGARICUS BISPORUS AND ITS
DERIVATISATION TO CHITOSAN AND
TRIMETHYL CHITOSAN
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Abstract
In this work, chitin (CT) was extracted from A. bisporus using alkali reflux, yielding
6.6 ± 2.2 % of dried mushroom powder determined to be CT. The CT produced
showed equivalent purity and degree of acetylation (DA%) (≈ 100%) to a commercial
standard, as determined by

13

C NMR. The extracted CT was then derivatised to

Chitosan (Cs), via microwave irradiation and conventional thermal heating methods,
the optimum method for conversion being identified as microwave treatment (yield
of 55 vs 33 %). The Cs produced using microwave irradiation showed equivalent
purity and degree of deacetylation (DDA%) (≈86 %) to that of commercial fungal Cs
and that of an ultrapure Cs typically employed for use in bioactive delivery
formulations, as identified by 1H-NMR and FTIR spectroscopy. The extract was then
chemically modified to water soluble trimethyl chitosan (fTMC), for assessment as a
permeation enhancer, showing equivalent degrees of quaternisation (≈ 44 %) with low
O-methylation values (≈ 25 %), as determined by 1H-NMR. Lastly, fTMC was
assessed for permeation enhancing effects via the trans-epithelial electrical resistance
(TEER) assay on human epithelial colorectal adenocarcinoma cell (Caco-2)
monolayers, showing a time reversible reduction in TEER of ≈ 75 vs ≈ 90 against a
well-established permeation enhancer, sodium caprate used as positive control. The
findings indicate that A. bisporus can be considered as a good source of CT that can
be easily isolated without aggressive treatments, subsequently deacetylated for the
production of Cs and chemically modified to fTMC, supporting the proposition that
these by-products have potential use for many different practical applications.
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Keywords
Fungal extracts, chitin, microwave treatment, chitosan, Trimethylchitosan,
permeation enhancer.
Abbreviations
CT, Chitin; Cs, Chitosan; CL113, PROTASAN™ UP; DA%, Degree of Acetylation;
DDA%, Degree of Deacetylation; TMC, Trimethyl chitosan; DDQ%, Degree of
quaternisation; cTMC, commercial TMC, fTMC, fungal TMC; TEER, trans
epithelial electrical resistance assay.

7.1 Introduction

Chitin (CT) is a polysaccharide consisting of adjacent monosaccharides, 2(acetylamino)-2-deoxy-d-glucose, bonded by glycosidic bonds in a linear or branched
fashion, and is the second most abundant polymer found in nature (next to cellulose)
(Rathke and Hudson, 1994). CT is insoluble in most regular solvents owing to the
presence of acetyl, amino and hydroxyl groups in the polysaccharide chain, that
generate hydrogen bonds (inter and intramolecular), and cause a high degree of
aggregation (Pillai, Paul and Sharma, 2009). Today, CT, chitosan (Cs) and Cs are
produced on a commercial scale for a variety of applications, e.g. cosmetics,
pharmaceuticals, and wastewater treatment, with a market value of $2.0 billion (BCC
research, 2016). However, CT insolubility affects the scaling up of the processes to
produce CT-based products (Hamed, Özogul and Regenstein, 2016; Yang et al., 2016;
Aranaz et al., 2018).
Cs is a linear, semi-crystalline polysaccharide composed of (1, 4)-2-acetamido-2deoxy-β-D-glucan (N-acetyl D-glucosamine) and (1,4)-2-amino-2-deoxy-β-D-glucan
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(D-glucosamine) units, that are not widely present in nature (Duarte et al., 2002). Cs
is typically produced from CT by chemical hydrolysis under severe alkaline
conditions, by removing the acetyl groups from the molecular chain of CT, which
results in a high degree of the chemically reactive group (NH2) being left on the
compound (Cs), thus allowing for its solubilisation in acidic aqueous solutions
(Ospina Álvarez et al., 2014). The ratio of N-acetyl-D-glucosamine to D-glucosamine
is what determines whether the polymer can be considered Cs or CT, whereby, if more
than 60% of the partially deacetylated CT exists as D-glucosamine, it is considered
Cs (de Alvarenga, Pereira de Oliveira and Roberto Bellato, 2010). For Cs this ratio
percent is known as the degree of deacetylation (DDA%) (whereas for CT this ratio
percent is known as the degree of acetylation (DA%)) and is an important property to
consider in Cs production, as it determines its solubility properties, biodegradability
and immunological activity (Tolaimate et al., 2000; Pillai, Paul and Sharma, 2009).
A considerable amount of work on Cs and its chemically modified derivatives, for
potential use in drug delivery systems, has been published over the past 20 years (Felt,
Buri and Gurny, 1998; Prabaharan, 2008; Xing et al., 2018). Cs, in contrast to all other
polysaccharides, holds a unique cationic character, owing to the primary amino groups
present on its backbone. It has been used for the development and formulation of
nanoparticles for drug delivery due to properties such as controlled drug release,
mucoadhesion, in situ gelation, transfection and permeation enhancement (PE)
properties (Bernkop-Schnürch and Dünnhaupt, 2012; Katas, Raja and Lam, 2013;
Huang, Cai and Lapitsky, 2015). In terms of drug delivery properties, it has previously
been reported that Cs with a higher DDA%, has the ability to achieve higher
encapsulation of bioactives, due to the increased level of functional groups present
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that can complex with reactive groups on the bioactive (BA) of interest (Xu and Du,
2003).
At present, crustacean shells are considered the most convenient available source for
the commercial production of CT (Hamed, Özogul and Regenstein, 2016). However,
due to seasonal availability and environmental pollution, the industrial isolation of CT
from this source faces some challenges. For example, calcium carbonate, proteins,
lipids and pigments associated with crustacean CT requires aggressive, successive,
acid (HCL), alkali (KOH) and bleaching treatments (decolourising agent) at high
temperatures, for purification (Barikani et al., 2014). Consequently, the final product
produced can often undergo chemical changes such as the deacetylation and
depolymerisation of CT thus reducing its overall quality and reproducible
functionality (Kardas et al., 2012). Moreover, the release of waste containing alkali
and degradation products into the surrounding environment has been identified as a
contributing source of environmental pollution (Kaur et al., 2014). Enzymatic
hydrolysis has also been reported as a method of Cs production, but it is not as
commonly employed as chemical hydrolysis due to its higher cost (Kim and
Rajapakse, 2005).
PROTASAN™ CL113, a commercial Cs, derived from crustacean shells and sold by
NovaMatrix, FMC Corporations, has been previously promoted for its ability to
encapsulate and deliver food derived bioactives such as Retinyl Palmitate (a vitamin
A isomer) and possesses the following physicochemical properties: molecular weight
(MW) of 110-150 kDa, DDA% ≥80 % and minimal metal contamination (Fernández‐
Gutiérrez et al., 2015). It has also been used to slow and control the drug release
profile of Triclosan (an efficient anti-malarial drug) (Maestrelli, Mura and Alonso,
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2004) and salmon calcitonin (a potential osteoarthritic drug) (Ryan et al., 2013) owing
to both its known mucoadhesive and enhancer properties and its demonstrated
effectiveness in optimally controlling drug release rate. In fact, to date, much of the
research involving its employment as a nanocarrier, has been of Cs of animal origin
(crustaceans) (Hamed, Özogul and Regenstein, 2016). However, high batch to batch
variability

and

climate

change

(David

Brayden,

TRANS-INT,

private

communication) of Cs from these sources have been reported, resulting in
formulations with variable physicochemical properties and with potential for inducing
allergic responses (Smets and Rüdelsheim, 2018). Hence, an alternative Cs produced,
for example from edible A. bisporus mushrooms, could be well placed for
pharmaceutical applications, particularly if available with batch to batch
reproducibility and high control over its molecular characteristics, such as molecular
weight and DDA%.
During white mushroom (A. bisporus) cultivation, by-products are generated,
whereby between 5 and 20% of fruiting bodies with misshaped cups and stalks do not
meet the specifications set by retailers and are not utilised for human consumption
(Figure 7.1). In the USA alone, mushroom production results in nearly 50,000 metric
tons of mushroom material per year, with no suitable commercial application
(Philibert, Lee and Fabien, 2017). Notably, however, under mild conditions, media
optimisation and green conversion of agricultural industrial wastes, CT and Cs can be
obtained from mushrooms and fungi and present an alternative to other uses of this
by-product (Kulshreshtha, Mathur and Bhatnagar, 2014). Extraction of CT, which the
European Food Safety Authority (EFSA) approved as a food additive in 2010, can
potentially offer alternative revenue with significant economic potential (Tetens,
2010).
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Mariod (2016) reported that, for the isolation of CT from different marine sources,
chemical treatments like deproteinisation with hot alkali (1 M NaOH at 65–100 ˚C for
1–72 hr), demineralisation with acid to eliminate calcium carbonate (0.275–2 M HCl
at near 100 ˚C for 1–48 hr) and decolouration to remove pigments are necessary. The
fungal approach, however, has the advantage of easy handling, harvesting and control
to produce high quality Cs, through enhanced control of environmental and nutritional
conditions used during cultivation (Ghormade, Pathan and Deshpande, 2017).
Feofilova (2010) extensively reviewed the contributions of the structural and matrix
components of fungal cell walls, such as chitin/chitosan, glucans, proteins, lipids,
uronic acids, etc, reporting that, for isolation of CT, the chemical treatments used are
milder than that as reported for marine sources.

Figure 7.1 Mushroom by-products and nonconforming mushroom bodies, not
currently utilised for human consumption.
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The most common procedure for obtaining Cs is based on the alkaline deacetylation
of CT with strong alkaline solution at high temperature (Castelli et al., 1996), while
other procedures include alkali treatment at high temperature and high pressure
(autoclave) (Abdou et al., 2008), and enzymatic N-deacetylation (Martinou et al.,
1995). Recently, microwave irradiation as a non-conventional energy source has
received increasing attention in organic chemistry, due to its ability to accelerate
reactions, provide high batch-to-batch consistency, scalability and to increase the
yield of product, in comparison to conventional heating (Singh, Kumar and Sanghi,
2012). By exploiting the rapid energy transfer from the functional groups (-OH and NH2 groups) during dielectric heating using microwave energy, the reaction rate can
be greatly enhanced, allowing for rapid breakage of covalent and glycosidic linkages
between the glucosamine residues and thus faster production of Cs (Wasikiewicz and
Yeates, 2013). Sagheer et al., (2009) studied the production of Cs from crustacean
sources using microwave irradiation and found the reaction time was significantly
reduced (15 min vs 10 hr), in addition to producing Cs with DDA and MW values
higher than those of Cs produced by conventional methods.
A particularly interesting application for Cs is its employment as a permeation
enhancer (PE) for enhanced delivery of biopharmaceuticals, that are generally labile,
large, hydrophilic and usually require parenteral administration (Boateng, Okeke and
Khan, 2015). Oral delivery, considered the “gold standard” drug delivery method (in
terms of patient compliance and reduced adverse effects related to injections) is an
often sought-after alternative to methods such as inhalation or parenteral delivery
(Gleeson, Ryan and Brayden, 2016). The limitation of delivering hydrophilic dugs
orally arises from the low permeability of the epithelial barrier, as a result of which
they must rely on active transport across the barrier, or passive transport between
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adjacent cells through the paracellular pathway, known as tight junctions (TJs),
present in the mucosal membrane (Upadhyay, 2014). Polymeric PEs, such as Cs, have
been studied to enable the safe passage of drugs with low bioavailability. However,
the pKa of 6.5 of Cs, and its low solubility, limits its application as a PE for mucosal
surfaces when the pH is above 6.5 (Sonia and Sharma, 2011).
N-trimethyl chitosan (TMC) is a quaternary derivative of Cs, in which partial
trimethylation of the primary amine results in a permanent, pH independent positive
charge and thus aqueous solubility at neutral pH. The degree to which TMC can act
as a PE has varied in a number of reports, partially due to differences in the
physicochemical properties of the Cs precursor (Benediktsdóttir, Baldursson and
Másson, 2014). The structure of TMC can vary in O-methylation, DA%, degree of
trimethylation (DQ) and MW and often, the potential mechanism of action for TMC
as a PE, is suggested to be a consequence of mucoadhesion, arising from charge
interactions between polymer and mucosal membrane (Mourya and Inamdar, 2009).
Furthermore, it has been postulated that TMC can be used for the enhancement of
antigen delivery for vaccines via nasal delivery, due to the increased interaction of the
antigen with the epithelial cell barrier and thus increased antigen uptake (Amidi et al.,
2010).
To date, a vast number of researchers have derived TMC from commercially available
Cs derived from crustacean sources (Xu et al., 2010). Yet, to the best of our
knowledge, none have synthesised TMC from Cs of fungal origin, which presents an
opportunity that may address the variations typically associated with crustacean TMC
products. Fungal Cs (fCs) offers several advantages over its crustacean counterparts,
owing to the highly controlled environments in which it is cultivated, year-round
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growth that is not seasonally dependant and significantly less heavy metal association
than that of crustaceans (Muzzarelli et al., 2012). In this context, production and
purification of CT from the cell walls of waste fungal mycelium, and its subsequent
derivatisation to Cs and TMC, offer the advantage of being environmentally friendly
with potential for a more consistent product.
As such, the aim of this study was to extract CT from the edible basidiomycete
mushroom A. bisporus and to produce Cs with the same properties (DDA%, MW and
purity) to that of PROTASAN™ UP (CL113), a commercially available fungal
sourced Cs from Sigma Aldrich was also compared to the Cs produced in this work,
as an additional reference check point.
Following production of fCs with a satisfactory match to CL113, a further chemical
modification to TMC was performed to assess whether fungal derived TMC may offer
potential use as a PE and as an alternative to crustacean derived. The permeation
enhancing properties of this new fTMC were tested.

244

7.2 Materials and Methods

7.2.1 Materials
PROTASAN™ UP (CL113) was purchased from NovaMatrix, FMC Corporations,
Norway. Commercial CT (SACT) and Cs from fungal origin (SACs) was purchased
from Sigma Aldrich. Ireland. Acetic acid, ACS reagent, ≥99.7%, sodium hydroxide
solution 50 wt % in H2O, hydrochloric acid (HCL) 37 wt % in H2O were purchased
from Fisher Scientific, Ireland. All other reagents, chemicals and solvents were of
analytical grade from Sigma Aldrich, Ireland. Deionised water (dH2O) ≥18 MΩcm
was obtained using Millipore Simplicity® Water Purification System and used for all
manipulations unless otherwise specified.

7.2.2 Preparation of Mushroom Samples

A. bisporus samples were sourced from Tyholland Farm, Monaghan Mushrooms.
Mushroom bodies were freeze-dried, ground to a powder, sieved through a 500 uM
sieve and stored in a desiccator at room temperature for further analyses and
extraction. Extraction of CT was preformed according to the protocol of Sagheer et
al., (2009), with the following modifications. Dried mushroom powder (DMP) (10 g),
was suspended in NaOH (1 M, 300 mL) to give a final weight to volume ratio of 1:30.
The resultant slurry was then heated in a thermostatic chamber (80 °C) and agitated
at 120 rpm for 1.5 hr, thrice, to extract proteins, alkali soluble polysaccharides, and
small molecules (e.g. monosaccharides, phenolics, amino acids, and salts). The slurry
was then centrifuged at 5,500 rpm, for 20 min at 4 °C, to obtain alkaline insoluble
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material (AIM). The supernatant was discarded and the pellet subjected to the
previous digestion conditions (80 °C, 120 rpm for 1.5 hr). The AIM was then
centrifuged (5500 rpm, 20 min, 4 °C) and the pellet washed to neutrality (pH 7-7.4)
extensively by H2O. Once neutral, the AIM was washed twice with boiling absolute
ethanol (30 ml), resuspended in dH2O and freeze dried for approximately 36 hr
(FreeZone 6 L bench top freeze dry system (Labconco, USA)). The weight of the
dried product was recorded and then it was ground to a fine powder.
7.2.2.1 Extraction of chitin from A. bisporus

To obtain insoluble, crude fungal CT, the AIM was refluxed in 5 % acetic acid (20
mL) for 6 h at 95 °C and then centrifuged at 10,000 rpm for 20 min at 4 °C. The
resultant pellet was then washed with dH2O and ethanol as described in 7.2.2. CT, if
present, remained as an insoluble residue (crude CT), and was then freeze dried for
approximately 36 hours. The weight of the dried product was recorded and then
ground to a fine powder.
7.2.2.2 Chitosan preparation from crude CT

Two methods were employed to produce Cs, conventional and microwave
derivatisation. For the conventional method, crude CT (250 mg) was suspended in
concentrated KOH (50 mL, 45 w/v %) and heated on a boiling water bath under
constant agitation for 3.5 hr. The solution was then centrifuged (10,000 rpm, 30 min,
22 °C) to obtain a pellet of Cs. The Cs pellet was then washed extensively with H2O
until pH 7-7.4 was achieved and lyophilised for approx. 36 hr. For the microwave
method, crude CT (250 mg) was weighed into individual microwave vessels
(EasyPrep™, CEM, UK) followed by the addition of NaOH (9 mL, 30% w/v). Vessels
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were then placed under magnetic stirring for 30 min at 900 rpm to ensure homogenous
distribution throughout the solvent. Samples were then subjected to microwave
irradiation (MARS5, CEM, UK) for 15 mins, at 900 W followed by a 30 min cool
down period. The resultant Cs was then centrifuged (5500 rpm, 20 min, 22 °C) and
the pellet washed extensively until neutral pH was reached (7-7.4). The product was
then freeze dried for approximately 36 hr and the dried weight recorded.

7.2.3 CT-Determination of the degree of acetylation via

13

C-NMR

spectroscopy
Solid state

13

C-NMR is often used for quantifying and determining the degree of

purity of carbohydrates, in particular CT and Cs (Heux et al., 2000) and, as such, was
applied to determine the purity and DA% of the CT samples extracted from A.
bisporus. In the CT molecular structure, the amine group of the glucosamine residue
is acetylated and consequently shows two additional resonances in the

13

C-NMR

spectrum, one related to the carbonyl group at 175 ppm and the other one with the
methyl group at 25 ppm. These two signals are very distinctive as they occur at both
sides of the signals due to the backbone structure, making them easy to identify.
Spectra were recorded using a procedure published Heux et al., 2000 and the DA%
calculated using equation 7.1:

𝑫𝑨 (%) =

𝑨𝑼𝑪𝟐𝟓
× 𝟏𝟎𝟎
𝑨𝑼𝑪𝟏𝟕𝟓
(Equation 7.1)

where AUC25 relates to the methyl carbons on the glucosamine residue at 25 ppm and
AUC175 the carbonyl carbons at 175 ppm (Heux, et al 2000).
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7.2.4 Chitosan-Determination of the DDA% 1H-NMR spectroscopy

DDA% of Cs samples were determined using a procedure published by (de Oliveira
et al., 2014) with the following modifications: Cs (100 mg) was suspended in HCl (10
mL, 0.07 M) at room temperature (RT) and left to stir at 800 rpm overnight. Sodium
nitrate (15 uL, 1 M) was then added to the solution and then left to stir for four hours
at RT. NaOH (1 M) was then added drop wise until pH 10 was reached and the Cs
subsequently precipitated out. The Cs pellet was then recovered by centrifugation at
10,000 rpm for 15 min, washing extensively with dH2O, lyophilising and ion
exchanging with D2O three times. The Cs sample (approximately 10 mg) was then
transferred to a 2 mL Eppendorf and D2O (1.96 mL) was added along with DCl (40
uL, 20% w/v). The solution was then left to agitate for 30 min to ensure full dissolution
and was then transferred to a Colorspec™ NMR (Aldrich) tube for 1H NMR analysis.
Spectra were recorded on a Bruker Avance 400 spectrometer at 80°C after 128 scans
with a delay time of 4 seconds. An elevated temperature was used, with the aim of
shifting the HOD signal to a higher field, allowing for the quantification of the
glucosamine residue H-1 signals. The DDA% was than calculated using Equation 7.2
(Lavertu et al. 2003):

𝑫𝑫𝑨 (%) =

𝟏
(𝟏 − (𝟑 𝑯𝑨𝒄)
𝟏
(𝟔 𝑯𝟐𝟔)

× 𝟏𝟎𝟎
(Equation 7.2)

where HAc corresponds to the methyl protons of the acetyl group and H26 represents
the signal from protons H2, H3, H4, H5, H6, H6 of both monomers, through use of
the integral peak intensity values (Lavertu et al. 2003).
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7.2.5 Fourier transform infrared spectroscopy (FTIR)

The FTIR spectrum of the extracted Cs was acquired via a Spotlight 400 series
spectrometer (Perkin Elmer, USA), using the attenuated total reflectance spectroscopy
method (ATR-FTIR), in the range of 650-4000 cm-1. Prior to analysis, Cs samples
were lyophilised -40 °C for 36 hrs. The dried Cs solids were then placed on the ATR
crystal prism (ZnSe), and 32 scans were acquired at 4 cm−1 resolution with
background subtraction.

7.2.6 Chitosan molecular weight determination: gel permeation
chromatography (GPC)
For all samples, Cs solutions (4.0 mg/mL) were prepared by direct dissolution in
mobile phase (acetate buffer: 0.15 M acetic acid:0.1 M sodium acetate:0.2 mM
sodium azide) by agitating at 300 rpm, at room temperature for two days, and were
then filtered with a syringe filter (0.45 μm, Millipore). Analyses were performed at
room temperature using 2 X PL Aquagel-OH MIXED-H 8um 300 x 7.5mm columns
(Agilent, UK), at a flow rate of 1 mL/min and a sample injection volume of 20 μL.
GPC data was acquired using a Varian 350 refractive index detector coupled to a
Varian 210 solvent delivery module. A calibration curve was made by using GPC
dextran standards of known MW (25-670 kDa) at 2.0 mg/mL concentration.

7.2.7 Synthesis of trimethyl chitosan

During TMC synthesis, the number of positive charges on the polymer chain is
increased (Synman, D. et al., 2002) through the addition of methyl groups to the
primary amines present on Cs. The use of Iodomethane (MeI) and N-methyl-2-
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pyrrolidinone (NMP) allows quaternisation through the nucleophilic substitution of
the amine group with MeI and Sodium iodide (NaI). The N-quaternisation process
depends on the concentration of NaOH used, the reaction time and the reaction steps.
The initial TMC iodide salt is then dissolved in NaCl for exchange of iodide ions with
chloride (Sieval, et al, 1998) (Figure 7.2). Once produced, TMC can be assessed for
its ability to open cellular tight junctions (as determined in a transepithelial electrical
resistance (TEER) assay) and thus infer its potential usefulness as a PE.

Figure 7.2 The synthesis of N-trimethyl chitosan (TMC).

TMC chloride was synthesised by methylation of fungal (fTMC) or commercial Cs
(cTMC) with methyl iodide (MeI) in the presence of NaOH, as per Sieval et al.,
(1998), with slight modifications. In detail, a mixture of Cs (1 g), sodium iodide (2.4
g) and NaOH (5.5 mL, 15 % w/v) in N-methylpyrrolidinone (NMP) (40 mL) was
maintained in an oil bath under magnetic stirring at 60 °C for 30 min in the presence
of a Liebig condenser. Then, MeI (5.75 mL) was added to the mixture and the reaction
was continued for another 75 min. The product was then precipitated by the addition
of ethanol and isolated by centrifugation at 4000 rpm, 4 ºC, for 5 min. The pellet was
washed with diethyl ether, dried under vacuum and then resuspended in NMP (40
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mL), at 60 ºC and stirred continuously until the product dissolved. Once dissolved,
NaI (2.4 g), NaOH (5.5 mL, 15 % w/v) and MeI (3.5 mL) were added to the flask and
the reaction was left to proceed for 30 min. MeI (2 mL) and NaOH (0.3 g) pellets were
then added to the flask and the reaction was left to proceed for a further 60 min. The
product was then precipitated by the addition of ethanol and isolated by centrifugation
at (4000 rpm, 4 ºC, 5 min). Resultant pellets were then resuspended in an aqueous
NaCl solution (10 % w/v), to exchange iodide for chloride ions and the product was
reprecipitated with ethanol, isolated by centrifugation at (4000 rpm, 4 ºC, 5 min). The
final product was dissolved in H2O and centrifuged (5500 rpm, 4 ºC for 10 min) to
remove insoluble material (such as demethylated Cs residues N-(CH3)2). The resultant
supernatant was then dialysed against deionised water (changing buffer twice-daily)
for 3 days and freeze dried for 36 hr to obtain white purified TMC powder.
7.2.7.1 Water solubility of fTMC and cTMC

Aqueous solubility of the different polymers (fTMC and cTMC) was determined in
HPLC grade water (pH 7) solvent at room temperature. Samples were dissolved at
concentrations ranging from 1-10 w/v %, and the transmittance of the solutions at 500
nm was measured on an UV/VIS spectrophotometer (TECAN GENios, Grodig,
Austria). The polymers were considered insoluble when the transmittance was less
than 90% compared to the transmittance of the solvent (Verheul et al., 2008).

7.2.8 Determination of the degree of quaternisation and Omethylation by 1H-NMR
To determine the degree of quaternisation (% DQ) and O-methylation (OMe) the 1H
NMR spectrum of TMC was measured in D2O, using a 400 MHz spectrometer
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(Bruker-Biospin, Rheinstetten, Germany) at 80 °C. The % DQ and OMe was
calculated by the following equations (Zarifpour 2013):

𝑫𝑸 =

[(𝑪𝑯𝟑 )𝟑 ] 𝟏
× × 𝟏𝟎𝟎%
[𝑯]
𝟗
(Equation 7.3)

𝑶𝑴𝒆 =

[(𝑪𝑯𝟑 )] 𝟏
× × 𝟏𝟎𝟎%
[𝑯]
𝟑
(Equation 7.4)

where DQ is the degree of quaternisation, in mole percentage of free amine, [(CH3)3]
is the integral of chemical shift of the hydrogens of trimethyl amino groups at 3.3
ppm, [(CH3)] the methylated hydroxyl groups at either 3.4 (OMe-6) or 3.5 (OMe-3)
ppm and [H] is the integral of H-1 peaks between 4.7 and 5.7 ppm, related to hydrogen
atoms bound to carbon 1 of the Cs molecule, which is taken as the reference signal.

7.2.9 Transepithelial electrical resistance (TEER) measurements

Caco-2, human colon adenocarcinoma cell lines, are regarded as representative of the
small intestine (Brayden, Cryan, et al., 2015; Gleeson et al., 2015). When they are
grown on semipermeable filters, they spontaneously differentiate in culture to form
confluent, polarised, columnar cell monolayers (Woitiski et al., 2011). Therefore, they
have widely been selected as an in vitro model for evaluation of intestinal drug
absorption (Maher, Mrsny and Brayden, 2016). Caco-2 cells were seeded at a density
of 6x105 cells per well on 12-transwell plates with a microporous membrane. The cells
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
L-glutamine (1%), Penicillin and streptomycin (PEST) (1%), non-essential amino
acids (1%) and foetal bovine serum (10%), for 21 days until a confluent cell layer was
formed. The medium was replaced by Hank’s Balanced Salt Solution (HBSS) at the
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basolateral side and left to equilibrate for 1 hr before the start of the experiments.
Then, 0.5 ml solution of TMC (0.1 w/v), derived from commercial Cs (cTMC) or
fungal Cs (fTMC), was applied at the apical side of the cell monolayers. Sodium
caprate (0.1 % w/v) was used as positive control and Hanks balanced salt solution
(HBSS) as reference. The resistance of the membrane, measured without cells, was
used as blank. The TEER of the Caco-2 cells was measured with an Epithelial
Voltammeter (EVOM - World Precision Instruments Inc, USA), using the chopstick
method (Verheul et al., 2008), at certain time points (0, 10, 30, 60 90 min and 120
min) after addition of the stimuli. After 90 minutes, the cells were washed with HBSS
and incubation of the cells was continued in DMEM for 24 hrs at 37 °C, CO2 5% to
determine the recovery of the TEER.
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7.3 Results and Discussion

7.3.1 Percentage yield of chitin and chitosan

The CT in cultivated A. bisporus, is a stable characteristic of the species and there are
no significant differences between the CT content of pileus (cap) and stipes (stalk) of
fruiting bodies (Vetter, 2007). In this work, CT was found to account for 6.6 ± 2.2 %
of the DMP (Table 7.1), consistent with the observations of Vetter, (2007), who found
that 6.68 and 7.25 % of A. bisporus pileus and stipes, respectively, existed as CT.
After extraction of CT from the DMP used in this study, two derivatisation methods
were employed to produce Cs, which were conventional, and microwave assisted
(Section 7.2.2). As can be seen in Table 7.1, a significantly higher yield of Cs was
obtained for microwave derived Cs (55%) vs conventional (33%). Moreover, the
microwave method entails more than half the reaction time of conventional (45 min
vs 3.5 hr). The lower yield recovery from the conventional method may be attributable
to the highly basic solvent (KOH 45 w/v %) and the long reflux time (3.5 hr), causing
depolymerisation of the CT backbone (through hydrolysation of the amide bond of Nacetylglucosamine) allowing for its subsequent loss during the washing process
(Anwar, Anggraeni and Amin, 2017).
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Table 7.1 Yield and composition of material obtained during extraction of chitinous
material from A. bisporus samples. a CT yield expressed as percent of DMP, b Cs yield
expressed as percent of CT, c Cs conventionally derived, d Cs microwave derived.

Sample
DMP
AIM
CT
c
Cs
d
Cs

Yielda (%)
100
25 ± 4.7
6.6 ± 2.2
-

Yieldb (%)
100
33.3 ± 6.8
55.4 ± 5.6

In contrast to the applied, relatively simple and fast method for producing pure fCs
with microwave irradiation described in this work, the more common extraction of Cs
from crustaceans requires higher concentrations of sodium hydroxide at high
temperature and, in general, the whole procedure is costlier and time consuming
(Tajdini et al., 2010). Therefore, the fungi could be considered as a good alternative
source of Cs.

7.3.2

13

C-NMR -Chitin DA% determination

Figure 7.3 shows the 13C-NMR spectrum of the fungal CT, which exhibits eight main
peaks: sharp peaks at 173 and 22 ppm were assigned to the carbonyl and methyl
carbons, respectively; the peaks at 103, 82, 74, 72, 59 and 54 ppm were ascribable to
the resonances of C1, C4, C5, C3, C6, and C2 on the N-acetyl-D-glucosamine unit of
CT, respectively, also illustrated in Figure 7.3. The DA% of the extracted CT was
then calculated using the relative integrals of methyl or carbonyl groups related to the
carbon integrals of the polysaccharidic backbone (Equation 7.1,) and compared with
the commercial CT purchased from Sigma Aldrich (Table 7.2).
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Figure 7.3 Solid state

13

C-NMR Spectra of CT extracted from A. bisporus.

Well resolved, high purity spectra were observed for both commercial and extracted
CT, both having a DA of around 100%. No significant difference in DA was observed
between the commercial and extracted CT in this work (Table 7.2), and the high
degree to which it is acetylated indicates that the CT produced is a suitable candidate
for further derivatisation.
Table 7.2 DA% of extracted CT and SACT, calculated as per Equation 7.1.

Sample
SACT (commercial)
CT (extracted)

DA (%)
96 ± 4.5
101 ± 5

Extracted CT was also assessed to establish the crystalline form (α, β or γ) that was
present in the A. bisporus sample. The α form has chains arranged alternately
antiparallel; the β form has all chains parallel, while γ-CT is considered a form of α
CT with alternating parallel and antiparallel chains (Figure 7.4 (Kumirska et al.,
2011)). It has been shown that β-CT is much more amenable to deacetylation than the
α form (Abdou, Nagy and Elsabee, 2008), which is useful when trying to increase the
DDA% in order to attain requisite Cs properties for a given application. Notably, the
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signals assigned to C3 and C5 of the CT powder existed as a single peak, inferring
that the CT extracted from A. bisporus was in the β crystal form (Duan et al., 2013).
β-chitin has the unique feature of incorporating small molecules, including water, into
its crystal lattice to form crystalline complexes (Li, Revol and Marchessault, 1999)
and thus is more easily hydrated and soluble in water (Wan and Tai, 2013) The weaker
hydrogen-bonding from the parallel-chain structure of β-chitin may account for its
higher chemical reactivity (Kurita et al., 2005).

Figure 7.4 Schematic representation of the three polymorphic forms of CT (a) α CT. (b) β-CT. (c) γ-CT (adapted from Kumirska, Mirko X. Weinhold, et al. 2011).

7.3.3 1H-NMR -Chitosan DDA% determination
Figures 7.5 and 7.6, show the 1H-NMR spectrum of A. bisporus Cs, conventionally
and microwave derived, respectively. The peak present between 2.0-2.5 ppm
represents the methyl protons of the N-acetyl-glucosamine unit (Ac) and the peak
between 3.2-3.6 ppm denotes the H-2D proton of the glucosamine (H2, D) residues
(Hirai, Odani and Nakajima, 1991). Similar chemical shifts are observed for the nonanomeric protons (H2-H6, A and H3-H6, D) connected to the polymer backbone, due
to their similar electron densities, resulting in their signals partially overlapping,
causing a broad envelope of signals within the middle of the spectrum, in the range of
approximately 3.78-4.32 ppm (Kasaai, 2010). Lastly, the anomeric protons can be
seen at higher chemical shifts (approx. 5.33 and 5.01 for H1,D and H1,A respectively)
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(Lavertu et al., 2003), attributable to their deshielding glycosidic and ring oxygen
neighbours. Additionally, these proton bands possess the least resolution in the 1HNMR spectra, followed by H3, H4, H5, and H6, while, in contrast, the methyl protons
retain the highest resolution of all peaks (Kasaai, 2010).

Figure 7.5 1 H-NMR spectra of A. bisporus Cs (conventional extraction) at 80°C in
DCl 2 wt % in D 2 O.

Table 7.3 details the 1H-NMR calculated DDA% of the commercial chitosans (SACs
and CL113), which were found to be 85±4% and 81±4.5% respectively. The Cs
conventionally derived from the A. bisporus was found to have a similar DDA% of
75±6%, in comparison to the microwave extracted (86 ± 6) and, in addition, showed
less peak resolution than the microwave Cs samples. This may be attributed to the fact
that CT typically exists with associated minerals and proteins that may contain C=O
and NH functional groups, similar to those found in Cs (Brugnerotto et al., 2001).
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Figure 7.6 1 H-NMR spectra of A. bisporus Cs (microwave extracted) at 80°C in DCl
2 wt % in D 2 O.

Contamination of Cs with impurities such as these may have contributed to the
creation of interference peaks (in addition to change in position and intensity of the
signal bands (Brugnerotto et al., 2001; Kasaai, 2010) and the conventional method
may not possess the full capacity to remove these impurities. This is evident in the
1

H-NMR spectrum of the conventionally derived Cs (Figure 7.5), in which the signal

of the H1-A proton appears to have been overlapped by the solvent peak at
approximately 4.82 ppm and all other proton signals have been shifted slightly upfield
compared to those of the microwave Cs samples (Figure 7.6). Furthermore, the fast
and direct heating of reactants using microwave irradiation has been reported to not
only give higher yields, but to improve the purity of the desired products (Singh,
Kumar and Sanghi, 2012), as reflected in the 1H-NMR observations for microwave
derived Cs (Figure 7.6), whereby the H1-A proton is well resolved at 5.1 ppm. Due to
the reduction of chemicals usage, reaction time and significantly higher DDA%,
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purity and yields (Section 7.3.1) of Cs obtained via microwave derivatisation, it was
selected for use in the experiments from this point on.
Table 7.3 DDA% of SACs, CL113 and Cs extracted by conventional or microwave
method, calculated as per Equation 7.2.

Sample
SACs
CL113 (NovaMatrix)
Cs (A. bisporus)
Cs (A. bisporus

DDA (%)
81 ± 4.5
85 ± 4
75 ± 6%
86 ± 6

Derivatisation method
Conventional
Microwave

7.3.4 FTIR analysis of extracted chitin and chitosan

The structure of the extracted Cs was confirmed by FTIR analysis (Figure 7.7). Table
7.4 provides a comprehensive list of all FTIR spectral bands observed in both
commercial and extracted Cs and CT samples; it is worth noting the key peaks
associated with the analysis of both compounds, for example the characteristic peak
at ≈1550 cm-1 that is present in Cs (due to the presence of the primary amine on the
D-glucosamine unit) but not in CT.
CT was examined via FTIR (denoted A and B in Figure 7.7) in order to establish the
crystalline form (α, β or γ) that was present in the A. bisporus sample. Typically, αCT shows two characteristic bands between ~1660-1620 cm-1 (amide I splitting),
whereas β-CT displays one band in the amide I region only (Jang et al., 2004). As can
be seen, neither commercial or extracted CT displayed peak splitting in the amide I
region and, as such, were determined to be in the β crystal form (Raafat and Sahl,
2009), further corroborating the 13C-NMR observations (Section 7.3.4).
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Figure 7.7 IR spectra (off set for clarity) of CT and Cs obtained from, A; CT extracted from A. bisporus, B; Commercial CT (Sigma
Aldrich), C; Commercial SACs (Cs, Sigma Aldrich), D; Commercial Cs ( NovaMatrix, CL113), E; Cs extracted from A. bisporus.

Table 7.4 FTIR bands observed in A; CT extracted from A. bisporus, B; Commercial CT (Sigma Aldrich), C; Commercial SACs (Cs,
Sigma Aldrich), D; Commercial Cs (NovaMatrix, CL113), E; Cs extracted from A. bisporus.

Wavenumber (cm-1) frequency
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Figure 7.7

A

B

C

D

E

Sample

A. bisporus CT

SA CT

SACs

CL113

A. bisporus Cs

Bond Assignment

cm-1

cm-1

cm-1

cm-1

cm-1

NH Stretch, amine OH in pyranose ring

3271

3263

3262

3240

3261

CH2 in CH2OH group

2925

2929

*

2879

*

C=O in NHCOCH3 group (amide I band)

1632

1631

1621

1625

1627

NH2 in NHCOCH3 group (amide II)

*

*

1553

1514

1555

CH2 ending and CH3 deformation

1401

1401

*

*

*

CH3 in NHCOCH3 group

*

*

1375

1376

1375

CH in pyranose ring

*

*

1308

1315

*

C-O-C (glycosidic linkage)

*

*

*

1151

*

C-O-C (glycosidic linkage)

*

1078

1068

1063

*

C-O in secondary OH group

1026

1022

1024

*

1028

*
884

931
889

*
*

*
*

*
*

C-O in primary OH group
Pyranose ring skeletal vibrations
*not observed

Regarding Cs analysis, the spectra of all samples analysed (denoted C, D and E in Figure
7.7), both commercial and extracted, showed a broad absorption band in the range 3240
cm-1- 3271 cm-1 which is attributed to stretching vibrations caused by the primary amine
and pyranose ring hydroxyl groups (Kaya et al., 2014; Rumengan et al., 2014). Key
characteristic bands such as amide I band at 1620 cm-1 (carbonyl (C=O)) and amide II at
1550 cm-1 (amine (NH2 tensions) were also observed, which is in agreement with
literature findings (Abdou, Nagy and Elsabee, 2008; Kaya et al., 2014). The peaks around
2879, 1375 and 1068 cm-1 in the FTIR spectrum are due to the stretching vibrations of
aliphatic C– H, Amide III and C–O–C bonds, respectively, and are the main
characteristics of the Cs polysaccharide (Kaya et al., 2014; Rumengan et al., 2014).
Furthermore, FTIR spectral similarities between, SACs, CL113 and chitosan produced
from the A. bisporus samples in this work displayed a correlation percentage of 85.31%
and 74.93% respectively (Figure 7.7).

7.3.5 Molecular weight determination

MW is another important physical property of Cs and is typically determined via viscosity
measurements or gel permeation chromatography (GPC) (Baxter et al. 2005; Zielinska et
al. 2014). The size range of fungal derived Cs has been reported as 17-450 kDa by various
authors (Miyoshi et al. 1992; Niederhofer & Müller 2004; Badawy & Rabea 2009). In
terms of determining what size of Cs to use for a given application, low MW Cs is
considered to be 10-90 kDa, medium MW in the range of 90-310 kDa and high MW 310375 kDa (Zappino et al. 2015; Lal et al. 2012). In this work, GPC was employed to
determine the MW of CL113, SACs, fCs and fTMC, and all tested compounds fell within
the medium MW range (Table 7.5).
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Table 7.5 MW (kDa) of CL113, SACs, fCs and fTMC as determined by GPC , means
that do not share a letter are statistically different (p < 0.05) .

Sample
MW (kDa)

CL113
110.1±5.9a

SACs
165.5±39.9a,b

fCs
156.3±23.6 b

fTMC
198.8±16.6 c

It was observed that the MW of the produced fCs was significantly higher than that of
CL113 (156 vs 110 kDa). Additionally, there was a larger spread of variation in the
extracted fCs vs the CL113 (±24 vs ±6) respectively. This is expected, as CL113 is
certified to possess a MW of 110-150 kDa and as such is most likely fractionated before
sale in order to meet this requirement. Additionally, it has previously been shown that Cs
produced via microwave heating tends to have a higher molecular weight than
conventionally derived Cs (Sagheer et al., 2009) and this may also be an attributing factor
to the higher MW. A strategy to match the fCs further with CL113 in terms of MW would
be to depolymerise the chain with NaNO2 (Mao et al., 2004) and subsequently fractionate
it with semi-preparative GPC (Nguyen, Winnik and Buschmann, 2009). However, as
medium molecular weight Cs, intended for use as a drug delivery vehicle, is considered
ideal (Bowman and Leong, 2006), the fCs can be considered acceptable for use in future
NP formulations. Interestingly, the commercial SACs was found to possess the highest
MW in addition to the largest spread of variation (165±39 kDa) and although this product
has not been sold as an ultrapure, highly characterised, Cs, it is worth noting for other
researchers, considering its employment in various applications. Lastly, the MW of the
fCs was found to increase after synthesis to TMC, which was expected due to the addition
of methyl groups to the free amine residues of the Cs backbone (Verheul et al., 2008).
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7.3.6 TMC solubility

Table 7.6 shows the water solubility of the synthesised TMCs (derived from CL113 or
fungal Cs extracted from A. bisporus), both with and without centrifugal purification
(Section 7.2.7). As can be seen, a significant improvement in both cTMC and fTMC
aqueous solubility (1 vs 10 %, at pH 7) was observed by employing the centrifugal clean
up step (Section 7.2.7). This is an expected result, as any residual, insoluble, Omethylated (OCH3) and dimethylated (CH3)2 amines would be removed from the final
product, thus increasing solubility (Verheul et al., 2008).
Table 7.6 Results of Solubility of Synthesised TMC.

Conc. (%w/v)
1%
2%
4%
6%
8%
10%

Non-Purified
fTMC
cTMC
+
+
+
-

Purified
fTMC
+
+
+
+
+
+

cTMC
+
+
+
+
+
+

Interestingly, without the clean-up step, cTMC showed solubility up to 2 % w/v, whereas
fTMC to only 1 w/v %, most likely attributable to the higher MW of the fCs, which plays
an important role in the solubility of the final product, whereby typically, the lower the
MW, the higher the solubility (Sajomsang et al., 2010).

7.3.7 1H-NMR - TMC DQ % determination

Several studies have been performed to determine the optimal DQ% for solubilising TMC
in neutral aqueous media and for the trans epithelial delivery of low molecular weight
drug molecules and/or proteins (Mourya and Inamdar, 2009; Vongchan et al., 2011; de
Britto et al., 2012). For TMC to be soluble in neutral aqueous solvents, it is requisite that
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the DQ% be ≥ 28 % and, for trans epithelial delivery of both low molecular weight
compounds and proteins, a DQ% of about 40-50% is generally accepted to be optimum
(Benediktsdóttir, Baldursson and Másson, 2014). In this work, the calculated DQ%
(Equation 7.3) of fTMC and cTMC was found to be 45 ± 6 and 40 ± 4 respectively (Table
7.7) and repeated experiments showed good reproducibility, inferring the suitability of
the synthesised polymers to serve as absorption enhancers.
Table 7.7 Degree of quaternisation (DQ %) calculated as per Equation 7.3 and 7.4.

Sample
fTMC
cTMC

DQ (%)
45 ± 5.5
40 ± 3.5

OMe-6
25 ± 6.5
21 ± 2.5

OMe-3
18 ± 4.0
15 ± 2.0

In this work, chitosan was methylated with methyl iodide to yield TMC (Figure 7.2) and
the 1H NMR spectrum of the fTMC polymer is presented in Figure 7.8. The amino groups
in the C-2 position of Cs were methylated to form quaternary amino groups with fixed
positive charges on the repeating units of the TMC polymer chain. According to the
results of previous studies (Domard et al., 1987; Sieval et al., 1998), the peak at 3.8 ppm,
that was not detected in the 1H NMR spectrum of Cs (Figure 7.5 and 7.6), is attributable
to the nine hydrogen atoms of the methyl groups pertaining to trimethylated amino
groups, and the peaks between 4.9 and 5.9 ppm are assigned to the 1H protons, which
were taken as the reference signal.
An overview of the 1H-NMR results of the O-methylated TMCs is presented in Table 7.7.
Although O-methylation is a well-known side-reaction in TMC synthesis, that reduces
the aqueous solubility of the product, there are relatively few studies that report the extent
of this side reaction (Verheul et al., 2008). The spectrum of fTMC synthesised showed
O-methylation of the hydroxyl groups at the C-3 and C-6 of the glucosamine units (peaks
observed at 4.0 and 3.9 ppm, respectively) showing that OMe-6 and OMe-3 were 25 and
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18%, respectively (Equation 7.4). As the C-6 hydroxyl groups are less sterically hindered
than the hydroxyl groups on the C-3, a higher degree of methylation is observed (Verheul
et al., 2008).

Figure 7.8 1 H-NMR-spectra of fTMC with a DQ of approximately 45 % at 80°C in D 2 O.

7.3.8 TEER -TMC as a permeation enhancer

TEER measurements for intestinal membrane models such as Caco-2 human colon
adenocarcinoma cell monolayers can be used to predict their paracellular permeability.
When the tight junctions (TJs) are open, the TEER of Caco-2 cell monolayers is
significantly reduced due to the passing of ions via their paracellular route (Hidalgo, Raub
and Borchardt, 1989). TEER has been applied to study the permeation enhancer (PE)
effects of compounds such as polyacrylic acid, polycarbophil and TMC, over recent years
(Aungst, 2000; Liu et al., 2008; Maher, Mrsny and Brayden, 2016), the latter having been
shown to exhibit a reversible time and dose dependant decrease, thus indicating its ability
to open the TJs (Ranaldi et al., 2002).

267

The initial studies in this work looked to compare the TEER measurements across Caco2 cells incubated with fTMC and cTMC to the well-established PE, sodium caprate (C10)
(Brayden, Gleeson and Walsh, 2014) at 0.1 % w/v, vs HBSS as reference (Figure 7.9).
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Figure 7.9 TEER assessment of commercial (cTMC) and fungal (fTMC) derived TMC
(0.1% w/v) using C10 (0.1% w/v, 10mM) as a positive control. Error bars represent the
standard deviation of six measurements.

It was observed that a significant reduction to TEER occurred for both TMCs vs HBSS
alone, and no significant difference between cTMC and fTMC was apparent (50±4 % vs
47±6 %, respectively) at the test concentrations employed (0.1% w/v). It is has previously
been shown that a decrease of TEER, to a value not exceeding 50% of the initial reference
value (HBSS), is insufficient to permit paracellular transport of the marker substances
(Borchard et al., 1996). C10 at 0.1 % w/v (10 mM) comfortably achieved a reduction of
TEER to 94±4% (Figure 7.9). However, as concentrations of C10 exceeding 10 mM have
been shown to elicit substantial cytotoxicity (Gleeson et al., 2015), it was decided to
increase the TMC concentration for further investigation, whilst maintaining C10 (10
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mM) as positive control. Additionally, as the ultimate goal of this work was to produce
and assess fungal derived fTMC as a PE, it was decided that fTMC be solely evaluated
for further investigation.

Figure 7.10 presents the TEER assessment of fTMC ranging from 0.2-0.6 % w/v. As can
be seen, after 120 min incubation, the initial TEER value in Caco-2 cell monolayers
incubated with fTMC, across all test concentrations, decreased by ≥ 75 %. This is
consistent with reports from Kotzé et al., (1998), whereby increased TMC concentrations
(0.25-1.5 % w/v) lead to further decreases in TEER values, on Caco-2 monolayers. It has
recently been reported that exposure of C10 at 10 and 12 mM to Caco-2 monolayers
irreversibly reduced TEER ≈90% after 15 min (Brayden, Maher, et al., 2015). The
observations in this work are in line with those reported, as the greatest reduction in TEER
was again observed for C10 (94 %). However, this decrease in TEER value may be
attributable to a decrease in cell viability after long periods of incubation (Marušić et al.,
2013). To assess whether this was the case, all test compounds were removed from the
monolayers after the 120 min exposure and replaced with DMEM to determine the
recovery of the TEER after 24 hr. A recovery of TEER after the experiments would imply
that the cells were undamaged and functionally intact and, as the results in Figure 7.10
shows, the TEER of the fTMC monolayer partially recovered after removal of the
solutions (≥60 % of initial reference value), whereas that exposed to C10 did not (≈8 %).
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It has also been proposed that, due to the high viscosity and adhesive nature of TMC, the
reversibility of TEER decrease is gradual, owing to the fact that complete removal of the
polymer prior to recovery is unlikely without incurring some damage to the cells
(Borchard et al., 1996; Verheul et al., 2008).

Figure 7.10 TEER assessment of fTMC concentrations (0.2-0.6 w/v %) on Caco-2 cell
monolayers. C10 (0.1 % w/v) was used as a positive control. Error bars represent the
standard deviation of six measurements.

It has been established that Cs unmodified or TMC with DQ% less than 18 % is unable
to significantly reduce TEER. However, at DQ% of 40-60 %, a decrease in TEER of
Caco-2 cells and increased mannitol permeation at pH 7.4 can be achieved (Amidi et al.,
2010). This study concluded that the prepared fTMC was capable of transiently and
reversibly opening the tight junctions between Caco-2 cells and thus merits further
investigation as a PE.

270

7.4 Conclusion

In this work, CT has been extracted from A. bisporus with equivalent purity and DA% to
13

a commercial standard, as determined by

C NMR. The extracted CT was then

derivatised to Cs, the optimum method for production being identified as microwave
extraction. The Cs produced using this method showed equivalent purity and DDA% to
that of commercial fungal Cs purchased from Sigma Aldrich and that of ultrapure CL113
from NovaMatrix, as identified by 1H-NMR and FTIR spectroscopy. As Cs, a positively
charged polyelectrolyte, has shown promising potential as a drug delivery vehicle, this
may be an application for future use of the product. Lastly, fungal and commercial Cs
were then chemically modified to TMC and assessed for permeation enhancing effects
using TEER, showing its potential application as a PE. Based on the present knowledge
identified in this work, A. bisporus can be considered as a good source of CT that can be
easily isolated without aggressive treatments, subsequently deacetylated for the
production of Cs and chemically modified to TMC, showing these by-products have
potential use for many different practical applications.
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8 FUNGAL CHITOSAN NANOPARTICLES
COATED WITH ZEIN FOR IMPROVED
ORAL DELIVERY OF SELENOCYSTINE
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The work presented in this chapter contains the following elements of research:
An unpublished study of the validation of an extraction and characterisation of
selenoamino acids from Irish mushrooms with the objective of demonstrating the
availability of the species for supplement production in the Irish context (Sections 8.2.28.2.3 and 8.3.1-8.3.2).
A study of the formulation of SeCys2 into nanoparticles produced from A. bisporus origin
chitosan, using results from previous chapters to demonstrate the feasibility of a
supplement formulation containing using mushrooms origin ingredients. This work will
be submitted as:
Vozza, G., Khalid, M.D, Forde S, Byrne, H. J., Ryan, S and Frias, J. (2018). Fungal
chitosan nanoparticles coated with zein for improved delivery of selenocystine. To the
Journal of Innovative Food Science and Emerging Technologies (IFSET), May 2018.
Vozza, G., was the primary author, Khalid, M.D., helped develop the formulation process,
Forde, S, conducted experiments in Section 8.3.6 and Byrne, H. J., Frias, J. and Ryan S
contributed to layout, design and proofing.
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Abstract
Selenoamino acids (SeAAs), have been shown to possess antioxidant and anticancer
properties. SeAAs, especially selenocystine (SeCys2) and selenomethionine (SeMet)
have been shown to accumulate in mushroom bodies supplemented with Se during
cultivation. In this work, a Reverse phase, high performance liquid chromatography,
Photodiode Array Detector (RP-HPLC-PDA) method was validated to analyse the SeAAs
content of Se supplemented A. bisporus. The predominant species found was SeCys2, at
616 ± 23 µg/g dried mushroom powder (DMP), while 18 ± 9 µg/g DMP of SeMet was
identified, inferring that Se supplemented mushrooms may be a viable source for organic
Se (291±7 µg/g of Total Se). SeCys2, however, can be toxic above the recommended
nutritional intake level, and thus improved, targeted delivery methods are desirable.
SeCys2 was encapsulated into nanoparticles (NPs) composed of fungal derived chitosan
(fCs), via ionotropic gelation with tripolyphosphate (TPP), then coated by zein (a maize
derived prolamine rich protein). Optimum NP physicochemical properties for oral
delivery were obtained at a 6:1 ratio of Cs:TPP, with a 1:0.75 mass ratio of Cs:zein
coating (diameter ~300 nm, polydispersity index ~0.3, zeta potential >38mV). Scanning
electron microscopy (SEM) analysis showed spheroidal, well distributed particles. An
encapsulation efficiency of 84.4 % was achieved. Cytotoxicity studies of SeCys2 loaded
NPs elicited no decrease in cellular viability in Caco-2 (intestinal) cells after 4hrs
exposure, although a significant reduction was observed, when compared to pure SeCys2,
for all test concentrations in HepG2 liver cells, after 72 hr exposure. Accelerated thermal
stability testing of the NPs indicated good stability under normal storage conditions.
Lastly, the sustained release profile of the formulation showed that 32 ± 4.5 % of SeCys2
was released from the fCs NPs after 2 hr in simulated gastric fluid, followed by 30 ± 2 %
release in simulated intestinal fluid for 4 hr.
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Keywords
Agaricus bisporus, Fungal chitosan, selenium, zein, selenocystine, nanoparticles, oral
delivery.
Abbreviations
fCs, fungal chitosan; CL113, PROTASAN™ UP; DLS, dynamic light scattering; EE%,
Encapsulation efficiency; GRAS, Generally recognised as safe; LDV, laser doppler
velocimetry; MSC, methylselenocysteine; NP, nanoparticle; PDI, Polydispersity;
SeCys2, selenocystine; SeMet, Selenomethionine; TPP, Tripolyphosphate; ZP, Zeta
potential. CT, Chitin; DDA%, Degree of Deacetylation.

8.1 Introduction

Selenium is an essential micronutrient in human and animal nutrition (Rayman, 2000)
that exists in a wide array of different forms, both organic and inorganic. Selenite and
selenate salts are the most common inorganic forms, whereas selenoamino acids
(SeAAs),

such

as

selenocystine

(SeCys2),

selenomethionine

(SeMet),

and

methylselenocysteine (MSC) are the most commonly found forms in foods from the
Agaricus, Brassica and Allium families (Montes-Bayón, M. J D Molet, et al., 2006;
Maseko et al., 2013; Reilly et al., 2014). Health benefits of Se originating from MSC and
SeCys2 have been linked to the body’s endogenous antioxidant defence system,
protecting cellular components such as cell membranes, lipids, lipoproteins and DNA
from oxidative damage by free radicals, reactive oxygen and reactive nitrogen species
(Ponnampalam et al., 2009). As oxidative damage is linked to the development of
cardiovascular and neurodegenerative diseases as well as cancers, several experimental
in vivo studies of the effects of administration of Se compounds have been undertaken
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(Valko et al., 2007; Lobo et al., 2010; de Souza et al., 2014). SeCys2 has been shown to
reduce tobacco-derived nitrosamine-induced lung tumour growth and enhance hepatic
chemoprotective enzyme activities in mice (Fan et al., 2013), SeMet may have some
potential in degenerative disease by decreasing oxidative stress of small molecule
antioxidants used as a buffer for free radicals in brain tissue (Song et al., 2014; Reddy et
al., 2017), whereas MSC has been shown to offer selective protection against organ
specific toxicity induced by clinically active antitumor agents, cisplatin, oxaliplatin, and
irinotecan in rat models (Cao et al., 2014). A number of benefits regarding oncology
treatments due the modulation of the therapeutic efficacy and selectivity of anticancer
drugs has been reported for these SeAAs also (Evans, Khairuddin and Jameson, 2017).
Although essential, Se possesses a low therapeutic index, meaning that there is a fine line
between beneficial and toxic doses. Generally, organic Se shows a greater degree of
bioavailability than the inorganic forms, as well as a higher threshold for toxicity
(Amoako, Uden and Tyson, 2009). Despite the associated health benefits, Se intake in
Ireland is remarkably low, whereby, nearly 50% of females and 20% of males aged
between 18 – 64 years fail to meet the average recommended requirement (ARR) of 40
µg/day (Murphy and Cashman, 2002). This low Se intake in the Irish population has been
attributed to the drop in imports of high-protein wheat for bread-making flour from North
America and Canada (Barclay and Macpherson, 1992), which are Se-rich in comparison
to Irish flour varieties (Murphy and Cashman, 2001).
Selenium-fortified A. bisporus have demonstrated the ability to assimilate inorganic Se
(such as sodium selenite) from the growth substrate and convert it to organic forms, such
as SeMet, MSC and SeCys2 (Maseko et al., 2013) For this, mushrooms have been
proposed as a potential source of Se for Se deficient populations (Falandysz, 2008;
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Maseko et al., 2013). While A. bisporus generally contain an average of only >1 µg Se/g
dry weight (Savic et al., 2012), when cultivated in substrates containing Se in either
inorganic or organic forms, they exhibit much higher concentrations, ranging from 354 ±
0.19 µg/g to 707 ± 37.3 µg/g of Se (Gergely et al., 2006; Savic et al., 2012).
The predominant form of Se identified in A. bisporus is SeCys2 (Maseko et al., 2013),
which has been shown to exert similar toxicity as that of inorganic forms such as selenite
(Takahashi, Suzuki and Ogra, 2017). Additionally, Se from A. bisporus has been reported
to have poor bioavailability (Thiry et al., 2012), which is further retarded upon cooking
(Khanam and Platel, 2016). As such, the efficacy of SeCys2 can be limited by its potential
to reach the target site of the jejunum for therapeutic action, thus reducing its
bioavailability. To identify Se species present in A. bisporus, it is first necessary to isolate
fractions of Se from the fruiting bodies of the mushrooms and identify the species present.
However, to date, no robust method for complete extraction and analysis of Se from food
sources has been developed (Thiry et al., 2012). Careful optimisation of extraction
procedures is an essential requirement for Se speciation analysis of solid samples, in order
to achieve high extraction efficiencies that also mitigate interconversion of the original
species present (Dumont, Vanhaecke and Cornelis, 2006). It is generally recognised that
a single step extraction is insufficient for Se liberation due to the varied matrix
associations of Se in real samples (Pyrzyńska, 1996). For example, hot water extraction
has been employed as a Se leaching solution for three edible wild mushroom species
(Macrolepiota procera, Lepista luscina and Boletus luridus), although only 47% of the
total Se content present in the sample (present in water soluble proteins) could be
recovered (Huerta, Sánchez and Sanz-Medel, 2005). As many Se species are protein
bound, several authors have utilised strong acids in extraction procedures, in order to
increase liberation of Se from various matrices (Casiot et al., 1999; Wrobel et al., 2003).
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Additionally, proteolytic enzymes have been employed for extracting SeAAs
incorporated into proteins due to their ability to cleave peptide bonds (Montes-Bayón,
Maria José Díaz Molet, et al., 2006). Also, inorganic forms of Se have been found to
become entrapped physically or chemically into cell walls and as such, acids and nonproteolytic enzymes such as driselase have been used in Se extraction (Infante, Hearn and
Catterick, 2005).
A dedicated analytical approach must be adopted in all areas of interest in the field of Se
speciation, especially in the case of the separation technique preceding element or
molecule specific detection. A massive challenge to the analyst is the myriad of Se species
with different physicochemical properties present in biological systems. Se species must
be unambiguously separated, identified and correctly quantified after they are extracted
from a given matrix. However, interconversion amongst Se species upon extraction from
a food matrix is a common obstacle that needs to be overcome in speciation analysis
(Uden et al., 2004).
In this work, Se species were extracted from Se supplemented A. bisporus samples, using
protease enzymes or HCL (0.1 M), under microwave or sonic energy respectively. Se
species were then separated by Reverse phase, high performance liquid chromatography
(RP-HPLC) coupled to a Photodiode Array Detector (PDA) and subjected to a validation
protocol, based on approved guidelines (EMEA, 1995), to assess its suitability for routine
work.
All considered, an opportunity presents for developing a drug delivery system that
optimises SeCys2 bioavailability, whilst reducing its toxic side effects. One approach is
the use of colloidal drug carriers that can provide site specific or targeted bioactive (BA)
delivery combined with optimal BA release profiles. Nanoparticle (NP) delivery systems
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have shown a higher mobility and cellular uptake compared to systems of larger size
which may offer an advantage to the delivery of BA compounds. Mohanraj & Cheng
(2007) compared the uptake of 1 and 10 µm particles to that of 100 nm particles in in
vitro models, observing that an increase of 2.5-6 fold higher uptake respectively for the
smaller sized particles. Etheridge et al. (2013) observed that the effect of particle size on
cellular intake can also be influenced by the constituent material and the particle
geometry, a consequence of reduced intestinal clearance mechanisms and an increase in
the mass to surface ratio interaction with the biological support.
In recent years, a wide array of constituents, such as natural and synthetic polymers,
lipids, and proteins, have been employed to prepare BA containing nanocarriers (Puri et
al., 2009; Elzoghby, Samy and Elgindy, 2012; Pridgen, Alexis and Farokhzad, 2015).
Among the materials proposed for mucosal delivery, polysaccharides have received
increasing attention because of their physical and biological properties (Rampino et al.,
2013). The natural polymer chitosan (Cs) is a positively charged mucopolysaccharide,
closely related to cellulose and derived from chitin (CT), the second most abundant
polymer in nature (Kean and Thanou, 2010). Cs has been used for the development and
formulation of nanoparticles by ionotropic gelation due to its physicochemical and
biological properties (H. Zhang et al., 2015; Mohammed et al., 2017). This bioactivity
includes improved adherence to mucosal surfaces, increased drug residence time (Ryan
et al., 2012), and protection of the bioactive drug from intestinal proteases (Ryan et al.,
2013; Amaro et al., 2015). Cs can be dissolved in acidic media, due to protonation of the
amine residues present in the polymer backbone. Ionotropic gelation allows for the
formation of NPs from Cs via crosslinking with oppositely-charged electrolytes (such as
tripolyphosphate (TPP)) under mild conditions in which amino acids and peptides will
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remain reasonably stable (Janes, Calvo and Alonso, 2001; Wang et al., 2011; Chen et al.,
2013).
Typically, Cs is manufactured commercially on a large scale by alkaline N-deacetylation
of crustacean origin CT (Philibert, Lee and Fabien, 2017). However, the preparation of
Cs with controlled properties, by means of microorganisms such as fungi is of increasing
interest as it offers several advantages over its crustacean counterparts. For example,
fungal Cs (fCs) has significantly lower heavy metal association than that of crustaceans,
allowing for milder production methods in its isolation, and year-round growth that is not
seasonally dependant (Muzzarelli et al., 2012). In this context, production and
purification of Cs from the cell walls of waste fungal mycelium may offer the advantage
of being more sustainable with potential for a more consistent product.
To date, the vast majority of Cs research in a drug delivery context has used crustacean
derived Cs (Ryan et al., 2013; Umerska, Corrigan and Tajber, 2014; Diop et al., 2015;
Danish et al., 2017a), For example, PROTASAN™ CL113, an ultrapure commercial Cs,
derived from crustacean shells and sold by NovaMatrix, FMC Corporations, has been
previously promoted for its ability to encapsulate and deliver food derived BAs such as
Retinyl Palmitate (a vitamin A isomer) and possesses the following physicochemical
properties: MW of 110-150 kDa, DDA% ≥80 % and minimal metal contamination
(Fernández‐Gutiérrez et al., 2015). However, one drawback of NPs formulated with Cs
is that the ability of the BA to be encapsulated within the NP matrix is often limited by
the availability of its the ionisable groups (Lin, Liu and Ping, 2007). Additionally, they
can often display fast release rates in the stomach environment, due to the enhanced
solubility of Cs at acidic pH (Mohammed et al., 2017). To overcome these limitations,
coating of Cs NPs with anionic polyelectrolytes has been investigated (Banerjee et al.,
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2016). Zein a GRAS approved prolamine-rich protein derived from maize, has been used
in the formulation and coating of peptide oral delivery systems (Y. Zhang et al., 2015),
to increase encapsulation efficiency (Luo and Wang, 2014) and improve the control of
gastric release of labile bioactives (Luo et al., 2010; Paliwal and Palakurthi, 2014). By
exploiting the physical interactions between protein and polysaccharide (in this instance
zein and Cs), it is possible to improve and broaden the range of the physical and chemical
stability properties of the NP delivery systems (Benshitrit et al., 2012).
In the previous work of Vozza et al., (2018a, Chapter 5) a Design of Experiments (DoE)
approach was used to establish optimum formulation conditions that would produce
SeAA (SeMet) loaded NPs, via ionotropic gelation. DoE identified the conditions of mass
ratio 6:1 (Cs:TPP), with TPP dissolved in NaOH (0.1 M) and Cs dissolved in acetate
buffer (pH 3) prior to crosslinking, produced NPs with physicochemical properties (Size
~ 300 nm, PDI <0.5 and ZP >30 mV) suitable for oral delivery (des Rieux et al., 2006).
Additionally, by coating the produced NPs with zein, the encapsulation efficiency (EE%)
was significantly improved from < 65% to >80%.
In a further study, Vozza et al., (2018b, Chapter 6), employed the optimised formulation
conditions to encapsulate SeCys2 and MSC, based on the rationale that SeCys2 (with a
pKa of 4.7 (Lacourciere and Stadtman, 1999)), and MSC (with a pKa of 4.9 (Mishra,
Priyadarsini and Mohan, 2007)), contain comparably ionisable groups to SeMet. The
findings showed that, by employing the previously established DoE parameters, similar
formulations (e.g. physicochemical properties and EE%) to those achieved for the SeMet
loaded NPs could be produced.
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As the Cs employed for the NP formulations in Vozza et al., (2018a, 2018b, Chapters 46), was CL113, a further study by Vozza et al., (2018c, Chapter 7) looked at the extraction
of CT from the edible basidiomycete mushroom A. bisporus and its derivatisation to fCs,
with equivalent properties (DDA%, MW and purity) to that of CL113.
The aim of this study was to qualitatively and quantitatively identify SeAAs present in A.
bisporus as a potential source for organic Se and to build directly on the previous work
on encapsulation in Cs NPs. This was achieved by applying the optimum DoE
formulation conditions, detailed in Vozza et al., (2018a, 2018b, Chapters 4-6), to fCs,
produced as per Vozza et al., (2018c, Chapter 7) with synthetic SeCys2 (to avoid natural
variance from A. bisporus SeCys2). Once the encapsulating fCs NPs were prepared, they
were extensively assessed for their physicochemical properties, morphology, thermal
stability, cytotoxicity and in vitro controlled release, utilising the methods developed in
the previous studies (Vozza et al., 2018a, Chapter 5).
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8.2 Materials and Methods

8.2.1 Materials

Fungal Cs (fCs), with MW of 156±24 kDa and degree of deacetylation (DDA%) of 86 %
was derived as per Vozza et al., (2018c, Chapter 7), Seleno-DL-cystine (>98 % purity),
D (+) - Trehalose dihydrate, Sodium Tripolyphosphate (TPP), and zein, of ≥99 % purity,
were obtained from Sigma Aldrich, Ireland. Acetic acid, ACS reagent, ≥99.7%, sodium
hydroxide solution 50 wt % in H2O, hydrochloric acid (HCL) 37 wt % in H2O were
purchased from Fisher Scientific, Ireland. All other reagents, chemicals and solvents were
of analytical grade from Sigma Aldrich, Ireland. Deionised water (dH2O) ≥18 MΩcm
was obtained using Millipore Simplicity® Water Purification System and used for all
manipulations unless otherwise specified.

8.2.2 RP-HPLC-PDA Method Validation

RP-HPLC-PDA was employed to quantify the SeAAs present in the mushroom samples,
as previously described (Ward, Connolly and Murphy, 2012) with the following
modifications. Samples were analysed with a Waters 2998 HPLC coupled to a Photodiode
Array Detector, (Waters, USA), using a Pursuit 5 C18, 250 x 4.6 mm column, (Agilent
Technologies, UK). Isocratic elution was carried out at a flow rate of 0.8 mL/min, column
temperature 45.0 ± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid
(97.9:2.0:0.1). Samples were monitored according to their UV absorbance at 218 nm.

290

The chromatographic method was validated for linearity, precision, accuracy, limit of
detection (LOD) and limit of quantification (LOQ). To establish linearity, primary
standard stock solutions for SeMet, MSC and SeCys2 were prepared separately in aqueous
tris hydrochloride (10 mM) at 1 mg/mL concentration. Solutions were further diluted with
the mobile phase to obtain eight working standard solutions of 4-500 μg/ml and ran on
RP-HPLC-PDA, under the conditions denoted in Section 8.2.2. Assay precision was
estimated by analysing each standard compound in six replicates and expressed as
percentage of relative standard deviation (%RSD). All the samples were prepared freshly
at the same nominal concentration, injected on three separated days (inter-day precision)
and calculated based on retention time (RT) and peak area of each standard compound.
The accuracy of the method was validated based on determination of percentage recovery
of standard compounds after spiking the sample with known concentrations of standard
compounds. The limit of detection (LOD) and limit of quantification (LOQ) were
established by analysing the standard deviation (STD) of the calibration curve and its
slope (S) using the multipliers suggested by the International Conference on
Harmonisation guidelines (ICH, 2005), of 3.3 for LOD or 10 for LOQ and calculated
using Equations 8.1 and 8.2. All values were calculated as means ± standard deviation of
three replicates and repeated twice, (n = 6).
𝟑. 𝟑 × 𝑺𝑻𝑫
𝑺

𝑳𝑶𝑫 =

(Equation 8.1)

𝑳𝑶𝑫 =

𝟏𝟎 × 𝑺𝑻𝑫
𝑺
(Equation 8.2)
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8.2.3 Sample extraction

A. bisporus samples supplemented with sodium selenite (60 mg/L) on day 4 of
production, were provided by Monaghan Mushrooms (MM), Tyholland Farm,
Monaghan, Ireland. Mushroom bodies were freeze-dried, ground to a powder (DMP),
sieved through a 500 uM sieve and stored in a desiccator at room temperature for further
analyses. To identify SeAA species present, mushroom samples were subjected to acid
or enzymatic digestions. For acid extractions, HCL (1 mL,1 M) was added to DMP (40
mg), sonicated (55 ºC, 1 hr) in a Bransen 2200 water bath sonicator (Bransen Ultrasonics,
UK) and centrifuged (14,000 rpm, 15 min, 4 ºC) to obtain clear supernatant. The samples
were then diluted 1:2 with mobile phase, filtered (0.25 μm) and ran on RP-HPLC-PDA
as per Section 8.2.2, both with and without SeAA spike additions. In terms of enzymatic
extractions, Protease XIV (0.5 mL, 60 mg/mL) was added to DMP (40 mg) and vortex
mixed (1 min), then ultrasonicated for 30 s at 45 % amplitude and the probe tip washed
with 0.25 mL of protease solution to ensure maximum recovery of the analytes. Samples
were then placed into individual microwave vessels (EasyPrep™, CEM, UK) and
subjected to microwave irradiation (MARS5, CEM, UK), for 15 mins at 80 W, followed
by a 30 min cool down period. The resultant extracts were then centrifuged (14,000 rpm,
15 min, 4 °C) to obtain the clear supernatant and the pellet washed with H2O (1 mL). The
final volume was then made up to 5 mL using mobile phase, before removing an aliquot
(2 mL) for filtration (0.25 μm), dilution (1:2) and spike addition, prior to RP-HPLC-PDA
analysis.
Measurements of Se totals were conducted by an accredited third-party laboratory
(Eurofins, Ireland), using ICP-MS and used for comparison against the developed RPHPLC-PDA method.
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8.2.4 Preparation of Se loaded fCs nanoparticles, coated with zein Particle size, PDI and ZP
fCs (Vozza et al, 2018c, Chapter 7), SeCys2 loaded NPs were formed via the ionotropic
gelation method (Vozza et al, 2018b, Chapter 6) with small modifications from the
original method from Calvo et al., (1997). In Brief, aqueous TPP solution (3 mg/mL) was
prepared in NaOH (0.01 M), with a SeCys2 concentration of 400 ug/mL. and added in
equal volumetric proportions to stirring fCs solution (3 mg/mL, 700 rpm) prepared in
acetate buffer (pH 3). The NPs formed were left to stabilise for 30 min, after which
absolute EtOH (8 mL) was added whilst the stirring speed (700 rpm) of the solution was
maintained. Filtered zein (2 mL, 5.625 mg/mL), dissolved in aqueous EtOH (80% v/v),
was then added dropwise to the solution to yield zein:Cs NPs of mass ratio 0.75:1 and
left to stabilise for 30 min. NPs were isolated by centrifugation (3000 rpm, 30 min) using
a 20 kDa MWCO (Vivaspin 20, Sartorius) centrifugal filter. Filtered EtOH (80% v/v)
(equivalent in volume to the recovered supernatant) was added to the purified NPs and
subsequently sonicated at 35% amplitude for 30 s with 5 s pulse intervals. The NP
formulations were then concentrated under vacuum (175 mbar) at 40 °C until EtOH was
completely removed. To ensure stability of the optimised formulation after lyophilisation,
10 mL of the cryoprotectant trehalose 5 % w/v in H2O were added to each formulation
and they were lyophilised for 36 hr (Danish et al, 2017b)
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8.2.5 Physicochemical characterisation of SeCys2 loaded NPs

8.2.5.1 Particle size, PDI and Zeta potential

Dynamic light scattering (DLS) was used to determine the mean particle size and
polydispersity index (PDI) of the NP formulation. Laser doppler velocimetry (LDV) was
used to measure the zeta potential (ZP). Both DLS and LDV analysis were performed
with a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser (Malvern
Instruments Ltd., UK), using a folded capillary cuvette (Folded capillary cell-DTS1060,
Malvern, UK), at 25 °C. The values presented herein were acquired from three separate
experiments, each of which included three replicates. N=3 (Chapter 3, Section 3.2.1).
8.2.5.2 Scanning electron microscopy (SEM)

SEM analysis was used to visualise the morphology of the NPs formed at an accelerating
voltage of 20 kV, using a secondary electron detector (Hitachi, SU6600 FESEM, USA).
NP solutions were spin coated onto Si wafers, dried at room temperature and then sputter
coated with 4 nm Au/Pd prior to imaging (Mukhopadhyay et al., 2013), (Chapter 3,
Section 3.2.2).
8.2.5.3 Encapsulation efficiency of SeCys in Cs:TPP nanoparticles

The EE% of SeCys2 in the fCs NPs was determined by the separation and quantification
of SeCys2 left in the supernatant after ultracentrifugation isolation of the formed NPs,
using the RP-HPLC-PDA method denoted in Section 8.2.2.
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The encapsulation efficiency was calculated using Equation 8.3 (Xu and Du, 2003),
(Chapter 3, Section 3.2.3):
𝑬𝑬% =

𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕−𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕

𝑿 𝟏𝟎𝟎
(Equation 8.3)

8.2.6 Cytotoxicity

The potential cytotoxicity of pure SeCys2, unloaded and SeCys2 loaded fCs NPs, was
studied in Caco-2 human epithelial cells, and HepG2 human liver hepatocellular cells.
Both cell lines are routinely employed to assess the potential toxicity of orally delivered
compounds (Gleeson et al., 2015; Brayden et al., 2015). Caco-2 and HepG2 cells were
seeded at a density of 2 x 104 cells/well and cultured on 96 well plates in Dulbecco's
Modified Eagle Medium (DMEM) and Eagle's Minimum Essential Medium (EMEM)
respectively, supplemented with 10 % foetal bovine serum, 1 % L-glutamine, 1 %
penicillin-streptomycin and 1 % non-essential amino acids at 37 °C in a humidified
incubator with 5 % CO2 and 95 % O2. Time points were selected with the intention to
mimic in vivo conditions for each cell type. As the maximum time NPs will be exposed
to the intestine, a 4 hr exposure time was used in Caco-2 cell lines (Neves et al., 2016),
while to mimic the liver exposure, a 72-h exposure time was used for HepG2 cell lines
(Brayden et al., 2014). Triton X-100™ (0.05%) was used as a positive control. The
concentrations of the test compounds applied were 0.25, 2.5, 5, 10, 25, 50 and 100 uM.
After

exposure,

treatments

were

removed

and

replaced

with

MTS(3-(4,5-

dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium).
Optical density (OD) was measured at 490 nm using a microplate reader (TECAN
GENios, Grodig, Austria). Each value presented was normalised against untreated control
and calculated from three separate experiments, each of which included six replicates.
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8.2.7 Accelerated stability analysis

NPs were suspended at a concentration of 0.1 mg/mL, in aqueous KCl solution (10 mM)
and stored at accelerated conditions: 60 °C for 720 min, 70 °C for 300 min and 80 °C for
120 min (Danish et al., 2017a). The particle size, PDI and zeta potential were measured
using the Nanosizer ZS (Malvern Instruments Ltd, UK) over time intervals to determine
the degree of degradation. The generated data was then analysed via R software (R Core
Team, 2016). The temperature dependence of the kinetic parameters of SeMet-loaded
NPs stability was measured by calculating the observed rate constants. This was plotted
in an Arrhenius representation and apparent activation energy, Ea and reaction rate
constant, kref were calculated according to Equation 8.4:

𝑷 = 𝑷𝒐 + 𝒆

𝒍𝒏(𝒌)−

𝑬𝒂 𝟏 𝟏
( −
)
𝑹 𝑻 𝑻𝒓𝒆𝒇

𝒕
(Equation 8.4)

where P is the property (particle size, PDI or ZP) at time t, Po is the initial property
conditions, k is the apparent zero order reaction constant, Ea is the energy of activation,
R is the universal gas constant, T is the temperature of the experiment in Kelvin (K) and
Tref is the reference temperature (343 K).

8.2.8 In vitro controlled release studies

SeCys2 release from the NPs was carried out using a dialysis bag diffusion technique
(Hosseinzadeh et al., 2012) over 6 hr (Calderon L. et al., 2013; Yoon et al., 2014). Freeze
dried SeCys2 loaded fCs NPs, coated with zein, were suspended in 5 mL H2O and
sonicated at 35 % amplitude for 30 s with 5 s intervals and placed into a Float-ALyzer®G2 dialysis membrane with a pore size of 25 kDa (Spectrum Laboratories, USA).
The sample was placed into 40 mL of simulated gastric fluid (SGF) or simulated intestinal
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fluid (SIF) specified according to the British Pharmacopoeia (Pharmacopoeia, 2016).
SGF was composed of 0.1 M HCL and SIF was composed of 1 volume of 0.2 M trisodium
phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without
enzymes (British Pharmacopoeia Commission, 2016). Samples were placed in a
thermostatic shaker at 37 ºC and agitated at 100 rpm. At predetermined time points, 1 mL
of release fluid was analysed and replaced with simulated fluid to maintain sink
conditions.
SeCys2 release was measured by RP-HPLC-PDA (Section 8.2.5). Equation 8.5 was used
to determine the % drug release:

𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =

𝑫(𝒕)
∗ 𝟏𝟎𝟎
𝑫(𝒍)
(Equation 8.5)

where 𝐷𝑟𝑢𝑔𝑟𝑒𝑙 is the percentage of SeCys2 released, D(l) represents the concentration of
SeCys2 loaded and D(t) represents the amount of SeCys2 released at time t, respectively.
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8.3 Results and Discussion

8.3.1 RP-HPLC-PDA Method Validation

Most often, for Se speciation analysis in food samples, Liquid chromatography-tandem
mass spectrometry (LC-MS/MS) is the method commonly employed, owing to its
excellent sensitivity and short run time (Schaumlöffel and Tholey, 2011). However, the
apparatus is expensive and many analytical laboratories cannot support such equipment
because of the high maintenance costs (Capelo et al., 2006).
In this work, RP-HPLC-PDA was employed for the determination of SeAAs (SeCys2,
SeMet and MSC) in A. bisporus, supplemented with sodium selenite. The proposed
method was validated with respect to linearity, LOD, LOQ, recoveries and precision
according to the International Conference on Harmonization (ICH) guidelines for method
validation (ICH, 2005). The linearity of calibration curves was calculated using linear
regression analysis of area versus concentration, for eight concentration levels of each
standard compound, injected in triplicate. Table 8.1 shows the regression equation and
correlation coefficient relationship between concentrations and peak area. Over the range
tested (5-400 ug/mL), all the analytes exhibited a good linearity with correlation
coefficients ranging from 0.9995 to 0.9998. The LOD and LOQ were estimated from the
calibration curve and values subsequently ranged from 0.33 to 2.64 µg/L and 1–8 µg/mL,
respectively (Table 8.1). The precision of the method was assessed by the percent relative
standard deviation (%RSD) using retention times and peak areas of standard compounds.
The results suggest a satisfactory intermediate precision value (%RSD) which ranged
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from 0.5 to 4.43 and 2.87–3.78 with respect to retention time and peak-area, respectively
(Table 8.1).
Table 8.1 Precision of the method, linearity data for calibration curves and retention
time (RT) of reference SeAAs studied. LOD and LOQ calcula ted according to Equations
8.1 & 8.2. RSD (%): percentage relative standard deviation of mean recovery. N=6.

SeAA
SeCys2
MSC
SeMet
SeAA
SeCys2
MSC
SeMet

Linearity
range
(ug/mL)
4-500
4-500
4-500
Recovery
(%)
96
94
88

Retention
time (min)

Slope (m)

Intercept (c)

4.33
7.24
15.60
LOD
(ug/mL)
2.6
1.3
0.3

5.30±0.80
8.80±0.40
9.54±0.10
LOQ
(ug/mL)
8.0
4.0
1.0

12.95±7.42
16.81±12.86
11.80±27.59
RSD (%)
RT
0.52
2.45
4.43

Correlation
coefficient
(R2)
0.9998
0.9997
0.9995
RSD (%)
Peak area
3.78
2.87
3.40

For evaluation of the accuracy of the method, recovery assays were performed, whereby
mushroom extracts were spiked with a known amount of standard compound and the
percentage recoveries were determined to range from 88-96 % (Table 8.1). These findings
suggest that the proposed RP-HPLC-PDA method is sufficiently accurate and sensitive
for the determination of the SeAAs selected for assessment in in vitro studies, without
the use of expensive instrumentation setups such as LC-MS/MS.

8.3.2 Qualitative and Quantitative analysis of SeAAs in A. bisporus

The first part of this experiment focused on comparing the acidic and protease extractions
for the three SeAAs (SeCys2, SeMet and MSC) selected for study in the dried mushroom
powder (DMP) samples. As can be seen in Figure 8.1, significantly more SeCys2 and
SeMet (66-fold and 5-fold higher, respectively) was liberated from the DMP through use
of a proteolytic digestion when compared to that of acidic digestion. The enzymatic
hydrolysis was most likely better equipped to liberate SeMet and SeCys2 associated with
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high molecular weight compounds (such as proteins) from the mushroom matrix, due to
them being protein bound (Kápolna et al., 2007). Although MSC has been identified by
others in Se supplemented A. bisporus samples (Gergely et al., 2006; Maseko et al.,
2013), spike additions failed to identify MSC in the DMP investigated in this study. MSC
is a non-protein bound, water soluble SeAA and as such it was expected to be present in
the acid extractions (Gergely et al., 2006). However, as concentrations of MSC present
in Se supplemented mushrooms are reported to be ≈ 0.8 ug/mL (Maseko et al., 2013) and
the validated RP-HPLC-PDA method having an LOD of 1.3 ug/mL (for MSC), it is likely
that it is present in the DMP but not detectable by the RP-HPLC-PDA method employed.
(A)

(B)
30

700

SeMet ug/g DMP
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Figure 8.1 Comparison of acid and protease extractions for the liberation of SeCys 2 (A)
and SeMet (B) from DMP. N=3.

Table 8.2, shows the quantitative data for SeMet and SeCys2 identified in the DMP after
protease digestion, the latter being shown to be the predominant species, present at 616 ±
23 µg/g DMP, while a modest amount of 18 ± 9 µg/g DMP SeMet was identified. Se
equivalent values were then calculated for the identified SeAAs (40 and 45 % of SeMet
and SeCys2 exist as Se, respectively), tallied together, and compared to total Se values as
identified by the third party accredited lab Eurofins, Ireland (Table 8.2).
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Table 8.2 Concentration of Se species in DMP after protease extraction, determined by
RP-HPLC-PDA. N=6.

SeAA
SeCys2
SeMet
MSC
Sum of Speciesa
Total Seb

Se AA µg/g DMP
616.69 ± 23.64
18.97 ± 9.64
n.d
635.66 ± 16.64
-

Se equivalent µg/g DMP
283.68 ± 10.87
7.59 ± 3.85
n.d
291.27 ± 7.36
356.25 ± 61.87

n.d (not determined), a Sum of SeCys2 and SeMet as determined by RP-HPLC-PDA, b Total Se,
as measured by ICP-MS, Eurofins, Ireland.

The total Se identified using the RP-HPLC-PDA method developed was 291 ± 7 µg/g vs
356 ± 61 µg/g from Eurofins (Figure 8.2), showing that approx. 80 % of the total Se
content was identified using the current method. Several other SeAA species, such as
selenite, selenite, selenoethionine, have been reported to be present in Se supplemented
A. bisporus (Stefánka et al., 2001; Haberhauer-Troyer et al., 2003), which were not
targeted for identification in this study and could account for the discrepancy in Se totals.

Total Se ug/g DMP

500
400
300
200
100
0
ICP-MS (Eurofin)

HPLC Method

Se totals

Figure 8.2 Se totals, Eurofins vs developed RP-HPLC-PDA method. N=3.

Although Se totals for A. bisporus have been reported previously, there appears to be
several conflicting findings. For example, Maseko (2013), found total Se to be 137 ug/g
of dried stalks and mushroom caps. However, in that study, the Se provided to the
mushroom bodies during cultivation was as sodium selenite at a maximum of 40 mg/L,
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which is less than the 60 mg/L used in the A. bisporus provided by Monaghan
mushrooms. On the other hand, Gergely et al., (2006) reported the ability of A. bisporus
to accumulate 770.7 ± 37.3 μg/g after supplementation of mushroom compost with only
10 mg/kg of selenised yeast, and Werner and Beelman, (2002), demonstrated the ability
of A. bisporus to accumulate Se up to 1300 µg/g DMP, after supplementing cultivation
media with up to 300 mg/L. Perhaps the reason for the reported discrepancies in these
studies is related to the variances in the cultivation or extraction methods. Moreover, it is
worth noting that these studies did not test/validate the robustness of the employed
analytical methods for Se determination or use certified reference material as a reference
check point. The current study, however, did assess the suitability of the analytical
method for employment in Se determination, in addition to employing an independent
ISO accredited third party laboratory to assess the provided samples for Se content and
thus comparison with the proposed RP-HPLC-PDA method. Overall, given the high
concentrations of Se present in the fungal samples (291 µg/g DMP, equivalent to 23 ug/g
fresh weight), Se supplemented mushrooms may be a feasible source for Se in the diet.
To meet the Se recommended daily allowance (RDA) (40 ug/day), ingestion of just 2 g
fresh mushroom bodies would be required. However, it is worth noting that Se from A.
bisporus has been reported to have poor bioavailability (Thiry et al., 2012), which is
further retarded upon cooking (Khanam and Platel, 2016). As such, the efficacy of the
predominant Se species present in the supplemented mushroom bodies (SeCys2) may be
limited by its potential to reach the target site of the jejunum for therapeutic action, thus
encapsulating SeCys2 into a NP delivery system may offer an advantage.
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8.3.3 Characterisation of fCs NPs loaded with SeCys2 - Particle size,
PDI and surface charge
Table 8.3 displays the physicochemical properties of the SeCys2 loaded NPs produced
with the fCs developed in Vozza et al., (2018c, Chapter 7) For ease of comparison, the
properties of NPs produced with CL113 (Vozza et al., 2018b, Chapter 6) are displayed in
this table also. No significant difference between size and PDI of the fCs and CL113 NPs
was observed, although for ZP and EE%, NPs formulated with fCs were significantly
higher vs the CL113 NPs (ZP 38 vs 31 mV, EE% 84 vs 80 %) (Table 8.3).
Table 8.3 Physiochemical results for SeCys 2 loaded NPs, coated with zein. Size, PDI,
ZP and EE% are presented for each NP formulated with either fCs or CL113. N=3.

fCs SeCys2 NPs

Size (nm)

PDI

ZP

EE%

Average

299.5 ± 47.1

0.324 ± 0.176

38.7 ± 2.1

84.4 ± 1.2

CL113 SeCys2 NPs

Size (nm)

PDI

ZP

EE%

Average

262.1 ± 11.1

0.243 ± 0.061

31.5 ± 1.0

78.9 ± 1.5

Previous observations have shown the importance of the final Cs:TPP mass ratio, the
formulation media pH and zein coating mass ratio in determining the physicochemical
properties of ionotropic formed Cs NPs (Vozza et al., 2018a, Vozza et al., 2018b,
Chapters 4-6). Other variables which have been shown to affect Cs NP properties (e.g.
size, PDI, ZP and morphology) include the ionic strength of the formulation medium,
concentration of both polyelectrolytes prior to crosslinking and the degree of
deacetylation (DDA%)/MW of the employed Cs (Qinna et al., 2015). It is worth noting
that the latter two factors confer different properties to Cs, which can affect properties
associated with the NPs it produces:
•

Cs ability to complex with opposing charged polyelectrolytes is dependent on the
DDA% (Anitha et al., 2014)
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•

NP dimensions and ZP; larger size and higher ZP reported with higher MW and
DDA% Cs (Alameh et al., 2017)

•

NP toxicity; lower MW and DDA%, reported to have less toxicity than that of high
MW Cs (Kean and Thanou, 2010)

•

NP EE%; higher in NPs produced with high MW and DDA% Cs (Jelvehgari et al.,
2010)

•

Release kinetics; Slower for high MW Cs NPs (Gan and Wang, 2007)

The DDA% and MW of the Cs used to produce NPs play a significant role in their final
properties. Vozza et al., (2018b Chapter 7), 1H-NMR calculated the DDA% of CL113
and fCs, to be 85 ± 4% and 86 ±6 % respectively. As such, the variance between the ZP
and EE% values for the produced NPs is unlikely to be related to the DDA% of the Cs
used for their production. In this regard, for CL113 vs fCs NPs, the apparent difference
in ZP and EE%, may be a result of a difference in their MW (156±24 vs 110±6 kDa).Gan
and Wang, (2007), reported that the EE% of BSA in Cs NPs was increased from 61.1 to
69.9 and 78.2 % as a result of an increase in Cs molecular weight from low to medium
and high, indicating that the longer Cs chains could offer more reactive sites for the
formation of hydrogen bonds with the BSA protein molecules. Additionally, at low pH,
Cs is fully extended in solution and the higher the MW weight of Cs, the greater the
electrostatic repulsion between the primary amines on the backbone (thus reduced steric
hinderance), which would allow for increased interactions between opposing
polyelectrolytes and thus increased EE% (Almalik et al., 2013). With this in mind, it is
reasonable to suggest that the higher MW of the fCs used to produce the NPs in this work
allowed for higher EE% and ZP compared to their CL113 counterparts, which is
consistent with the findings of other authors (Ing et al., 2012).
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8.3.4 NP morphology - Scanning electron microscopy

Figure 8.3 shows the SEM images of SeCys2 loaded NPs formulated with fCs (A) or
CL113 (B). Spheroidal, well distributed particles with slightly irregular surface
morphology were observed for SeCys2 loaded CL113 NPs (8.3 B). This may be
attributable to the electrostatic interaction of the negatively charged carboxyl groups of
zein facilitating a thin layer membrane around the positively charged amines residues of
Cs (Luo et al., 2011) with variation in surface density of zein protein on the Cs NP surface
and porosity of Cs core (Pan et al., 2015). Additionally, low MW Cs NPs have been
reported to facilitate surface binding of negatively charged polyelectrolytes such as
hyaluronic acid, due to their less porous more compact dimensions (Almalik et al., 2013).
fCs NPs showed smooth, dense, spheroidal morphologies with higher polydispersity than
that of the CL113 NPs, which agrees with the DLS observations for PDI (Table 8.3). This
may be related to the distribution of the polymer chains of fCs in comparison to CL113,
which is certified to possess a MW of 110-150 kDa, and as such is likely fractionally
separated to this range prior to sale. The larger the spread of the Cs chain lengths, the
larger the variance in NP PDI to be expected. Additionally, hyaluronic acid has appeared
to diffuse more deeply into the bulk of high MW Cs NPs, reducing the observable surface
coating appearance via SEM and atomic force microscopy (Almalik et al., 2013), which
agrees with the observed properties of the higher MW fCs NPs. In terms of the particle
size, comparing SEM and DLS measurements, larger sizes were observed by SEM
imaging (approx. 90-150 nm larger), which may be due to the rapid evaporation of
residual ethanol (present in the final suspension media) during the spin casting process
and subsequent flattening of the particles on the grid (da Rosa et al., 2015).
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Figure 8.3 SEM image of (A) SeCys 2 fCs NPs and (B) SeCys 2 CL113 NPs coated with
zein.

8.3.5 Accelerated stability analysis of fungal derived fCs NPs loaded
with SeCys2
Figure 8.4 shows the kinetic behaviour of the SeCys2 loaded fCs NP properties: size (A),
PDI (B) and ZP (C), at temperatures ranging from 60-80 °C. The stability of the NPs
decreased with increasing temperature. Little change was detected for all properties at 60
°C, over the course of 720 min, whereas a more pronounced influence on size and PDI
and a decrease in ZP was observed at 70 °C after 300 min. At 80 °C, destabilisation of
the NP complexes was evident according to all properties, whereby size increased from
approximately 300 nm to > 700 nm, PDI from approximately 0.2 to >0.9 and ZP reduced
from approximately 36 mV to < 18 mV, indicating that aggregation of the NPs had
occurred (Wu, Zhang and Watanabe, 2011).
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Figure 8.4 (1) Particle size, (2) PDI and (3) ZP analysis of fCs SeCys 2 loaded NPs
exposed to (a) 60 °C, (b) 70 °C and (c) 80 °C, over time periods of 120, 300 and 720
min, respectively. N=3.

The one-step nonlinear regression analysis of the kinetic experiments shows that the
particle size and PDI of SeCys2 loaded fCs NPs fit to a zero-order kinetic behaviour, with
an Arrhenius dependence of ln (kref@70 °C) = 6.43 ± 4.12 min−1 and Ea = 291.35 ±
62.35 kJ/mol for size, and a ln (kref@70 °C) = 0.026 ± 0.007 min−1, and an Ea = 192.39
± 24.05 kJ/mol for PDI respectively (Figure 8.4). Regarding ZP, an apparent first order
mechanism fits the data better than an apparent zero order model, with an Arrhenius
dependence of ln (kref@70 °C) = 0.051 ± 0.004 min−1 and Ea = 148.10 ± 6.581 kJ/mol.
Lastly, a linear correlation is evident between 1/T and ln k, indicating that the
formulations will be stable under normal storage conditions (Figure 8.5).
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Figure 8.5 Arrhenius plots for the PDI, Size and ZP accelerated studies of SeCys 2
loaded NPs. N=3.

No significant difference in kinetic behaviour was observed between the SeCys2 loaded
CL113 and fCs NPs properties (size (A), PDI (B) and ZP (C)) at temperatures ranging
from 60-80 °C. As shown previously by Vozza et al., (2018a, 2018b, Chapters 5 & 6),
the SeAAs (SeMet, MSC or SeCys2) used to load the NPs did not have an effect on the
formulation stability, which lends weight to the argument that the contributing factors to
the formulation stability lies with the Cs:zein complex rather than the loaded SeAA. The
complexation of protein (in this instance zein) with polysaccharide (Cs) systems involves
non-covalent interactions that can change the interfacial behaviour and stability of food
colloids (Ghosh et al., 2012). When Cs is blended with a polymer, the miscibility between
their molecules is a very significant factor, especially for the mechanical properties of the
blend (Sakurai, Maegawa and Takahashi, 2000). For example, previous differential
scanning calorimetry studies have shown that pure zein has a transition temperature
around 150 °C, which was attributed to thermal denaturation of this protein (Neo et al.,
2013). By harnessing the thermal stability of Cs (transition temperature of 203°C) and
combining it with the aromatic side groups and double bonds of zein, it is possible to
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greatly increase the stability of labile nutraceuticals against thermal degradation and
oligomerization (Torres-Giner, Ocio and Lagaron, 2009; Luo et al., 2013).
Zein coated tablets exhibit stronger resistance to abrasion, high humidity and high
temperatures than a variety of commercial sugar-coated tablets (Y. Zhang et al., 2015).
Moreover, it has been reported that the bi-layer approach for encapsulation of BAs leads
to a better control of the NP interface structure, charge, thickness and permeability, and
substantially enhanced stability (Hu and McClements, 2014). Notably, the net attractive
and net repulsive strength character of protein–polysaccharide non-covalent physical
interactions can vary substantially, depending primarily on environmental conditions
such as pH, ionic strength, and temperature (Semenova et al., 2014). In this work, the
conditions (presence of salt) used to prepare the NPs, in addition to the strong bonding
between the zein and Cs complex, may have been a contributing factor to the enhanced
stability of the formulation and is consistent with our previous observations (Danish, et
al., 2017a; Vozza et al., 2018a, 2018b).

8.3.6 Cytotoxicity assessment of fungal derived Cs NPs loaded with
SeCys2
In the work of Vozza et al., (2018b, Chapter 6), the tested concentrations of native SeCys2
and loaded CLL3 NPs (25, 50 & 100 uM) where more reflective of supra-nutritional Se
levels, reported to be involved in the prevention of several types of cancer, including lung,
colorectal, and prostate cancers (Rikiishi, 2007; Suzuki et al., 2010; Bao et al., 2015). To
gain more insight into the potential cytotoxicity of SeCys2 as a basal nutritional
supplement (in native form and encapsulated within fCs NPs), additional test
concentrations for nutritionally low (0.25, 2.5 uM) and adequate (5, 10 uM), Se status,
were investigated (Hawkes et al., 2008). The supra-nutritional concentrations (25, 50 and
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100 uM), were also assessed, to maintain consistency in comparing the SeCys2 loaded
CL113 NPs to the fCs NPs, in Caco-2 human epithelial cells, and HepG2 human liver
hepatocellular cells, using the MTS assay. As the NPs will be exposed to the intestinal
epithelium following oral delivery (leading to its facilitated transport and uptake), time
points were selected with the intention to mimic in vivo conditions for each cell type, to
assess the potential cytotoxicity of the formulated NPs (Gleeson et al., 2015; Brayden et
al., 2015). Caco-2 cells were exposed for 4h (Figure 8.6, A, B)) and HepG2 cells for 72h
(Figure 8.7, A).
In Caco-2 exposures, no cytotoxicity was observed for SeCys2 native, unloaded or SeCys2
loaded NPs, in comparison to the negative control, across all tested concentrations (Figure
8.6 A, B). This is consistent with previous observations (Vozza et al., 2018b, Chapter6)
and in agreement with the works of others (Marschall et al., 2016; Takahashi, Suzuki and
Ogra, 2017).
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Figure 8.6 Cytotoxicity assessment of

SeCys 2 ,

unloaded fCs NPs and

SeCys 2 loaded fCs NPs, exposed for 4h in Caco2 cell lines at (a) low (0.25, 2.5 uM) and
adequate nutritional level (5-10 uM) and (b) supra-nutritional level (25-100 uM)
concentrations. Percentage (%) of MTS converted was compared to untreated control.
1-Way ANOVA with Dunnett’s post-test *** p< 0.001. Each value presented was
normalised against untreated control and calculated from three separate experiments,
each of which included six replicates. N=3.

Regarding native SeCys2 exposure to HepG2 cell lines, no significant toxicity was
observed for test concentrations ranging from 0.25-5 uM (≤94 % viability). However, a
dose dependant reduction in cell viability was observed for concentrations exceeding 5
uM, which levelled off at 50 uM test concentrations (≤40 % viability). As can be seen in
Figure 8.7 A, the encapsulation of SeCys2 within the fCs NP matrix conferred protection
to the HepG2 cells after 72 hr exposure, from 0.25-25 uM test concentrations. However,
this shielding effect was lost at concentrations >50 uM, showing equivalent toxicity to
that of the native SeCys2 (≤40 % viability). Nevertheless, the IC50 of native SeCys2 was
found to be 12.8 ± 3.6 uM vs 32.5 ± 1.4 uM for SeCys2 loaded fCs NPs, showing that the
cytotoxic effects of pure SeCys2 can be reduced with the applied formulation (Figure 8.7
B, C)
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Similar results for the toxicity of native SeCys2 were observed by Takahashi, Suzuki and
Ogra, (2017), who reported no significant change in the viability of Caco-2 cell lines after
6 hr, although significant toxicity to HepG2 cells was observed at 100 uM, comparable
to that of the inorganic form selenite, after prolonged exposure (48 hr). As the toxicity of
SeCys2 has been shown to be comparable to that of selenite, it has been proposed by
others that the cellular overload of metabolites (such as selenide moieties (-Se-) and (HSe) produced during selenoprotein formation or excretion (Rayman, Infante and Sargent,
2008; Marschall et al., 2016) is responsible for this affect. This is conceivable, as the
reduction of SeCys2 to SeCys in the cell would result in the generation of a highly reactive
and sensitive to oxidation selenyl group (-SeH), whose relatively low pKa of 5.2 would
promote the formation of (-Se-) at physiological pH (Iwaoka, 2014).
Lastly, the unloaded NPs showed a significant proliferative effect in HepG2 cells over
the range of 0.25-50 uM test concentrations, although at 100 uM, this effect was lost.
Previous studies have shown the combination of zeins demonstrated cytocompatibility
with NIH 3T3 and human liver cells (HL-7702) in terms of cell adhesion and proliferation
(Dong, Sun and Wang, 2004), and an increase in fibroblast production caused by the
presence of Cs (Rajam et al., 2011). Thus, it is reasonable to suggest that the observed
protective effects of the encapsulated native SeCys2 is attributable to the fCs:zein NP
matrix.
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Figure 8.7: (A) Cytotoxicity assessment of

SeCys 2 ,
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SeCys 2 loaded fCs NPs, exposed at test concentrations of 0.25 -100 uM, for 72 hr
in HepG2 cell lines. MTS converted was compared to untreated control. (B) Dose response curve was constructed by plotting cell viability versus log concentration of ( ●-) SeCys 2 and (-■-) SeCys 2 loaded fCs NPs, and (C) corresponding IC 50 values of
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and Students t-test (C). N=3.

8.3.7 In vitro release studies

Figure 8.8 shows the cumulative release profile of the SeCys2 loaded fCs NPs, coated
with zein, after subjection to 2 hrs in an SGF environment (pH 1.2) representative of the
stomach, followed by a compartmental change to SIF (pH 6.8), representative of the
intestine, for 4 hrs. For ease of comparison, the release of SeCys2 from NPs produced
with CL113 (Vozza et al., 2018b, Chapter 6) is displayed in this figure also. As can be
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seen, 32 ± 4.5 % of SeCys2 was released from the fCs NPs after 2 hr in SGF, followed by
30 ± 2 % release in SIF for 4 hr. In comparison, the release of SeCys2 from NPs
formulated with CL113 was significantly faster in SGF (45 ± 4 %) after 2 hr, with a
marginally slower release (24 ± 4 %), compared to fCs NPs, after subjection to a SIF
environment (4 hr).
Three basic mechanisms that are typically employed to describe the release of drugs from
polymeric particles are, swelling/erosion, diffusion, and degradation (Liechty et al.,
2010). The prominence of each can depend on the conditions of the environment.
Therefore, the release kinetics of SeCys2 loaded fCs NPs were monitored sequentially in
SGF and SIF controlled release experiments. As two different simulated fluids were used
for this study, representing the pH environment in the stomach (SGF) and the jejunum
target site in the intestine (SIF), their release profile was modelled using a swelling,
Peppas equation (8.6) and (8.7) (Siepmann and Peppas, 2011, Danish et al., 2017a).
For the SGF:
𝑴𝒕
= 𝒌𝒔𝟏 ∗ √𝒕𝒊𝒎𝒆 + 𝒌𝒔𝟐 ∗ 𝒕𝒊𝒎𝒆
𝑴∞
(Equation 8.6)
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at
infinite time, and ks1 and ks2 are the diffusive and relaxation rate constants respectively.
For the SIF:
𝑴𝒕 𝑴𝟏𝟐𝟎
−
= 𝒌𝒊𝟏 ∗ (√𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) + 𝒌𝒊𝟐 ∗ (𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎)
𝑴∞
𝑴∞
(Equation 8.7)
where M120 is the predicted diffused mass at the time of changing from SGF to SIF (120
min), ki1 and ki2 are diffusive and relaxation rate constants.
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Figure 8.8 Release kinetics of SeCys 2 loaded CL113 (–○–) and fCs (--●--) NPs, coated
with zein, after 2 hr in SGF (pH 1.2) and 4 hrs in SIF (pH 6.8). Lines indicate the model
predictions of Equations 8.6 and 8.7. N=3.

The release of SeCys2 from the CL113 and fCs nanoparticles was best fitted with a
combination of diffusion and relaxation mechanisms. The fits of the model are illustrated
by solid lines in Figure 8.8. Table 8.4 presents the fitted values for the rate constants in
SGF (ks) and SIF (ki) for both SeCys2 loaded (CL113and fCs) NPs, divided into diffusion
and relaxation mechanisms (1 and 2) (Equations 8.6 & 8.7).
For SeCys2 loaded fCs NPs, subjected to the simulated stomach environment (SGF, pH
1.2), no statistically significant ks1 parameter was found, indicating that the primary
mechanism for release in the stomach was via relaxation, i.e. slower release, approaching
zero-order kinetics. Conversely, after 2 hr subjected to the SGF environment, a
compartmental change was employed to mimic the movement of the SeCys2 fCs NPs to
the intestinal environment (SIF, pH 6.8), whereupon a diffusion (ki1) mechanism was
observed (p<0.05) indicating that the primary mechanism for release in the stomach was
via diffusion, i.e. slower release, approaching zero-order kinetics.
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In contrast, a combination of ki1 and ki2 mechanisms in the stomach (SGF) was observed
for the release of the SeCys2 loaded CL113 NPs and no statistically significant ki2
parameter was found for the intestinal compartment, indicating that, in the small intestine
(jejunum), at pH 6.8, relaxation is the primary mechanism of release for SeCys2.
Table 8.4 Swellable model parameters for kinetic release studies of SeCys 2 loaded fCs
or CL113 NPs, coated with zein. ks represents the stomach compartment and ki the
intestinal compartment, divided into diffusion and relaxation mechanisms ( 1 and 2 ). All
parameters listed where statistically significant, ( ∗ p < 0.05).

CL113 SeCys2 loaded NPs
Coefficients
Estimate (min-1/2)
ks1
2.29±0.68
ks2
0.22±0.07
ki1
1.15±0.20
fCs SeCys2 loaded NPs
ks2
0.24±0.05
ki1
1.98±0.16
As the only variable between these two formulations relates to the Cs used to produce the
NPs, which matched regarding DDA%, it is conceivable that the reduced release rate
observed for the fCs NPs may be related to the MW of the precursor fCs being higher
than that of CL113 (156±24 vs 110±6 kDa). On exposure to the dissolution fluids (SGF
and SIF), the Cs complex will become hydrated forming a viscous gel layer that slows
down further seeping-in of dissolution fluids towards the core of the NP (Miladi et al.,
2015). The subsequent Cs swelling under these conditions allows for the drug release to
follow a diffusion oriented mechanism, which is then typically trailed by the mechanical
erosion of the swollen Cs hydrogel (Mohammed et al., 2017). In tandem, subsequent
hydration and swelling of the system is heavily dependent upon whether the Cs erodes
further. With this in mind, it was observed that the release of SeCys2 from both Cs:zein
NPs was pH dependent, indicative of Cs solubility in acidic media (Yuan et al., 2013),
although the slower release observed for the fCs NPs was most likely attributed to its
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higher MW. For example, Gan and Wang, (2007), showed that the release kinetics of
BSA from Cs NPs decreased significantly upon increasing molecular weights. The
reduction observed in that study was postulated to arise from the protein requiring
increased swelling and degradation of the NPs which was hindered by a greater crosslink
density of TPP with high MW, causing increased chain packing and rigidity, as well as
increased inter-chain bonding. Additionally, the higher the MW, the larger proportion of
(-NH2) residues, allowing for the encapsulated drug to be associated multiple sites on the
Cs polymer, thus reducing the overall release from the system (Dash et al., 2011). Overall,
despite the high-water solubility of SeCys2 there was good control of drug release in the
simulated physiological environment of stomach and small intestine for both fCs and
CL113 NPs, with fCs displaying the most optimum release profile, most likely a
consequence of higher MW.
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8.4 Conclusion

A RP-HPLC-PDA method was validated to analyse Se supplemented A. bisporus. The
predominant species was SeCys2 at 616 ± 23 µg/g DMP, with modest amounts of SeMet
identified also, inferring that Se supplemented mushrooms may be a feasible source for
organic Se. fCs was then used to formulate SeCys2 loaded NPs, with optimum properties
for oral delivery formed by coating the produced NPs at a 1:0.75 mass ratio of Cs:zein,
resulting in sizes of 299.5 ± 47.1 nm, PDI 0.324 ± 0.176, ZP 38.7 ± 2.1, and EE% of 84.4
± 1.2. SEM analysis showed smooth spheroidal, well distributed particles were produced.
MTS cytotoxicity studies on SeCys2 loaded NPs showed no decrease in cellular viability
in Caco-2 (intestinal) cells after 4 hr exposures across all test concentrations. However, a
significant reduction was observed when compared to pure SeCys2, across all test
concentrations in HepG2 liver cells after 72 hr exposure. Accelerated thermal stability of
the produced NPs indicated good stability under normal storage conditions. After 6 hr
exposure to simulated gastrointestinal tract environments, the sustained release profile of
the formulation showed that 62.0 ± 2.5 % SeCys2 was released. By encapsulating SeCys2
into a NP delivery system, improved oral administration of this molecule may be
achieved, which could be of beneficial use for the supplementation of food products with
these essential nutrients. All assessments on the fCs NPs properties were compared
against SeCys2 CL113 NPs developed in previous work by Vozza et al., (2018b, Chapter
6), showing that equivalent NPs formulations could be produced. This study provides
robust methods to formulate and assess SeCys2 fCs NPs, in addition to the speciation
analysis of SeAAs in supplemented A. bisporus, inferring that the encapsulation of
SeCys2 into a NP delivery system can be achieved using food-derived components whilst
also providing a viable approach to oral administration of this molecule.
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9 CONCLUSIONS AND FUTURE
PERSPECTIVES
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9.1 Overview

Nanotechnology has been touted as the next revolution in many industries, including the
pharmaceutical and food industry (Srinivas et al., 2010; Safari and Zarnegar, 2014;
Divya, 2015). It is not surprising that the nutraceutical industry has expanded within the
past two decades (DeFelice 1995; Verbeke 2005; Lagos et al. 2015) given that consumers
now acknowledge the ability of certain foods to reduce disease risk or improve health
(Hasler, 2000). Aqueous solubility and permeability of BA compounds have been
highlighted among the major challenges in early and late product research and
development (R&D), affecting up to 40 % of drugs on the pharmaceutical market (Censi
and Di Martino, 2015). Attrition of many molecules in the pharmaceutical R&D program
can be ascribed to lack of efficacy and the onset of secondary effects (Basavaraj and
Betageri, 2014). The oral route, being the most popular, can be particularly challenging
due to the harsh environment of the associated biological fluids found in the GIT, leading
to limited absorption and limited bioavailability, (Sosnik, das Neves and Sarmento,
2014). That considered, an opportunity presents itself for development of a drug delivery
carrier system that can optimise stability and bioavailability, whilst reducing its toxic side
effects. One approach is the use of colloidal drug carriers that can provide site specific or
targeted BA delivery, combined with optimal BA release profiles (Joye, Davidov-Pardo
and McClements, 2014).
This project was carried out at the food and pharma interface, to produce oral
formulations of nutraceutical SeAAs, which have been reported to possess narrow
therapeutic indices and to be poorly absorbed in the small intestinal epithelium (Amoako,
Uden and Tyson, 2009). Pharmaceutical drug delivery formulation techniques, such as
ionotropic gelation, were employed to produce NP delivery systems that could potentially
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improve the permeation, bioavailability and toxicity of the SeAAs. In tandem, process
techniques common to the food industry, such as DoE (statistical experimental designs),
were used to develop optimum NP formulations for oral delivery. The precise conditions
identified through efficient estimation of process parameters enabled the production of
NPs with target physicochemical properties (size, PDI and ZP), as identified by DLS. In
vitro evaluation of the produced NPs was then conducted to assess the likelihood of oral
compatibility in terms of stability, cytotoxicity and release profiles. Lastly, mushroom
by-products were isolated and purified for the formulation of these NP systems.

9.2 Research Findings

In Chapter 4, a CCD and mathematical modelling approach was employed to assess the
method of ionic gelation between the biopolymer chitosan (Cs) and tripolyphosphate
(TPP), for production of NPs with physicochemical properties suitable for oral delivery.
The mass ratio of Cs:TPP is one of the most influential variables that determines the size,
PDI, ZP and morphology of ionotropically formed Cs NPs. The results of the CCD design
identified that, at approximate concentrations of Cs (1.68 - 1.8 mg/mL) and intermediate
concentrations of TPP (0.20 - 0.37 mg/mL), a feasible region was identified in which NP
target properties could be achieved. The physicochemical properties of the NPs produced
from the validation of the CCD study were assessed by DLS, showing that, under
optimum conditions of Cs:TPP (6:1), NPs with sizes of 161 ± 43 nm, PDI of 0.39 ± 0.02
and ZP of 42 ± 3 could be produced. The information acquired from the CCD enabled
further development and understanding of the model variables for NP production.
In Chapter 5, the main variables which affect EE%, particle size, PDI and ZP were
optimised by use of a BBD. The SeAA, SeMet, was used as a prototype encapsulant, and
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increasing the EE% of SeMet in the formulation was one of the driving targets for study.
It was in this work that the importance of ionisable groups present on the BA to be
encapsulated was highlighted, and a fundamental understanding of the formulation
variables was gained. Through modulation of the formulation media pH, it was possible
to induce higher protonation of Cs and ionisation of SeMet and thus electrostatic
interactions between the two. This modification resulted in an increase of the EE% of the
NPs from 39 ± 3 % to 66 ± 1 %, whilst their physicochemical properties remained within
the target range for oral delivery. To further increase the EE%, the NPs were coated with
the prolamine rich protein zein, which resulted in a final EE% of >80%, with NP
diameters of 377±47nm, whilst the PDI and ZP values were maintained. Once satisfactory
NPs for oral delivery were attained, it was necessary to then assess their suitability as a
delivery system in vitro. Techniques were developed to evaluate their stability,
cytotoxicity and release profiles and overall, the NPs performed well, showing high
colloidal stability and thermal resistance over prolonged periods of time and no decrease
in cellular viability in either Caco-2 or HepG2 cells after 4 and 72 hr exposures,
respectively. Lastly, after 6 hr exposure to simulated intestinal buffers, the cumulative
release profile of SeMet from the NPs showed that ≤ 60% of the drug had been released,
indicating that degradation of the NP was slow and thus the mechanism may be
diffusion/relaxation oriented. Overall, the findings inferred that it was possible to use
DoE for the encapsulation of SeMet into a NP delivery system comprising food-derived
components and that the oral administration of this molecule was plausible.
The strength of the DoE methodology was then tested in Chapter 6, in which the
optimised formulation conditions, as previously identified, were employed to encapsulate
the SeAAs SeCys2 and MSC. The rationale for this approach was based on the fact that
SeCys2 and MSC contain comparable ionisable groups to SeMet and, as such, similar
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formulations (e.g. physicochemical properties and EE%) as those achieved for the SeMet
loaded NPs could be achieved. It was here that the reliability and usefulness of DoE was
evidenced, as the responses that were estimated using the derived quadratic polynomial
equations in Chapter 5, produced SeCys2 and MSC loaded NPs, with equivalent
physicochemical properties to those of SeMet. Differences between the encapsulated
SeAAs were then identified by the in vitro techniques developed previously, whereby
SeMet and MSC were shown to elicit little to no toxicity at test concentrations of 25100uM in Caco-2 and HepG2 cell lines after 4 and 72 hr exposures. Although native
SeCys2 mirrored SeMet and MSC in terms of no apparent toxicity to Caco-2 cell lines, it
elicited significant toxicity in HepG2 cells, across all tested concentrations. The
feasibility of the formulation was then evidenced, as the encapsulation of SeCys2 within
the Cs:zein NP matrix conferred protection to the HepG2 cells after 72 hr exposure,
indicating that, at the test concentrations used in the study (25-100 uM), the cytotoxic
effects of pure SeCys2 could be reduced. Interestingly, variances in the release profiles of
the SeAAs were identified in this work, appearing to be intrinsically linked with their
pKa values. A slower release in the stomach was observed for SeAAs with increasing
pKa (SeCys2,

pKa=4.66

< MSC,

pKa=4.93

< SeMet,

pka= 5.53)

and it was postulated that this

systematic variance was attributable to their chargeable properties and interactions with
the protonated 1º amines of Cs. In terms of stability, all formulations displayed high
colloidal stability and thermal resistance over prolonged periods of time, independent of
the encapsulated SeAA, with evidence that the Cs:zein matrix was responsible for this
stability.
In Chapters 4-6, all the NPs developed were produced using PROTASAN™ UP (CL113),
a well-known commercially pure Cs derived from crustaceans. Chapter 7 then looked at
extracting chitin (the precursor to Cs) from the edible basidiomycete mushroom A.
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bisporus and its subsequent derivatisation to Cs using microwave radiation. The target of
that study was to reduce the time taken for the production of Cs compared to traditional
methods and to produce a product with equivalent properties (such as DDA% and MW)
to CL113, that could be potentially used in future NP formulations. The study indicated
that fungal Cs (fCs) could be produced with equivalent DDA% to that of CL113 (86±6
vs 85±4 %). Notably, the produced fCs possessed a higher MW (180±19 vs 110±4 kDa),

although it still fell within the medium molecular range suitable for oral delivery (110225 kDa) (Bowman and Leong, 2006)). Once Cs with satisfactory properties was
produced from the A. bisporus samples, a further modification was investigated, whereby
the free amine groups present on the polymer backbone, were subjected to exhaustive
methylation to give rise to trimethyl-chitosan (TMC). TMC was then assessed in vitro
and showed potential application as a permeation enhancer. Based on the findings of
Chapter 7, A. bisporus can be considered as a good source of chitin that can be easily
isolated without aggressive treatments, subsequently deacetylated for the production of
Cs and chemically modified to TMC, showing these by-products have potential use for
many different practical applications.
Lastly, in Chapter 8, fCs was used to formulate NPs loaded with synthetic SeCys 2 by
employing the optimised formulation conditions previously identified (Chapter 5). Once
again, the robustness of the DoE formulation model was evidenced, as although fCs was
used in place of CL113, NPs with equivalent physicochemical properties (sizes of 299.5
± 47.1 nm, PDI 0.324 ± 0.176, ZP 38.7 ± 2.1, and EE% of 84.4 ± 1.2) were produced.
The effect of Cs MW on NP production was also highlighted in this study, whereby the
higher MW fCs NPs showed increased EE% / ZP values and a slower controlled release
profile, most likely attributable to the larger proportion of ˚1 amines present on the
polymer backbone available to interact with the ionised groups of SeCys2. No apparent
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toxicity to Caco-2 cell lines was observed after 4 hr exposure, although, for HepG2 cells,
the IC50 of native SeCys2 was found to be 12.8 ± 3.6 uM vs 32.5 ± 1.4 uM for SeCys2
loaded fCs NPs, showing that the cytotoxic effects of pure SeCys2 can be reduced with
the applied formulation. Finally, a preliminary study to assess the feasibility of Irish
mushrooms providing Se species for supplementation purposes was conducted. In that
study, a RP-HPLC-PDA method was validated to analyse Se supplemented A. bisporus
and the predominant species identified was SeCys2 at 616 ± 23 µg/g DMP. Modest
amounts of the SeAA, SeMet were also identified, at 18 ± 9 µg/g DMP. These findings
infer that, Se supplemented mushrooms may be a feasible source for organic Se
supplementation purposes and warrant further investigation.

9.3 Considerations and Future Perspectives

The work in this thesis raises several important points for consideration. Firstly, the
physicochemical properties of the carrier system are critical considerations and
ultimately, the desired targets (e.g. size, PDI, ZP) will rely heavily on the desired delivery
route. Time spent on achieving these target properties can be substantially reduced, by
employing a DoE approach, to develop optimum processes, via efficient screening of
process parameters. In this work, a robust formulation model was produced using SeMet
as a prototype encapsulant, which allowed for the subsequent encapsulation of
structurally similar SeAAs, in a fraction of the time it would take compared to a OFAT
approach, proving the benefits of a systematic approach to NP carrier design. While for
the food industry, DoE has become standard practice for R&D of improved
manufacturing processes (Carneiro and Azevedo, 2017), in comparison, the
pharmaceutical industry has been late in adopting these paradigms (Politis et al., 2017).
The FDA, have recognised that “quality cannot be tested into products, i.e. quality should
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be built in by design” (Ich.org, 2009) and the benefits of a DoE approach have started to
become apparent to the industry (Politis et al., 2017). The work in this thesis shows that
an experimental planning approach together with a knowledge of the physical chemistry
phenomena involved can enable the achievement of formulation target properties with
application to similar targets/cargo successfully.
Further exploration of the application of other DoE strategies might increase research
efficiencies, for example with the extension from laboratory experiments in this thesis to
industrially oriented experiment DoE such as Taguchi methodology. The Taguchi method
utilises orthogonal array (OA), signal-to-noise ratios (𝑆/𝑁), main effects, and analysis of
variance (ANOVA) (Fei, Mehat and Kamaruddin, 2013). OA provides a set of wellbalanced (minimum experimental runs) experiments and 𝑆/𝑁, which are logarithmic
functions of desired output, which serve as objective functions for optimisation (Datta,
Bandyopadhyay and Pal, 2008). The approach provides an easy to interpret set of results
that help experimenters determine the appropriate set of factor levels to create a robust
system that performs on target. Static mixers are composed of several tortuous motionless
elements, that allow for rapid combination of flow streams through mixers with low
energy requirement, low cost, compact space requirement and continuous operation
(Dong et al., 2013). As such, coupling of a static mixer system with a Taguchi DoE
method may offer a future approach for industrial scale up of the NPs developed in this
work.
Regarding the use of these SeAA loaded NPs for supplementation purposes, this current
work optimised physicochemical properties (size, PDI, ZP and morphology) suitable for
oral delivery, in addition to ensuring high enough encapsulation of the cargo for
commercial applications. These formulations were then screened in vitro to assess their
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stability, release profiles and potential cytotoxicity for suitability for oral delivery. The
findings of this work indicate that the formulation will be orally compatible and suitable
for supplementation purposes.
The role of selenocompounds as potent cancer chemopreventive agents has been
evidenced in several epidemiological studies, preclinical investigations and clinical
intervention trials. However, these reports have often conflicted (Novotny et al., 2010;
Mandair et al., 2014) and accumulated evidence suggests that the important determinants
of the chemopreventive activities of Se compounds are both dose and chemical species
dependant (El-Bayoumy, Sinha and Richie Jr, 2015). Additionally, the metabolic
products from the various Se forms present in food and Se supplements, aimed at
increasing selenium body status, are typically based on the indirect analysis of
selenoproteins such as glutathione peroxidase (GPX) and selenoprotein P, as they are the
major forms of Se present in the body (Kieliszek and Błażejak, 2013). The question,
however, regarding what happens to selenium, from when it is ingested until it is excreted
from the body, largely remains open (Kokarnig et al., 2015). The antioxidant properties
of the GPX selenoproteins, have been presumed to be the main factor in preventing
carcinogenesis, largely based on animal and cellular studies (Chen, Prabhu and Mastro,
2013). However, this is likely to be an oversimplification, and emerging evidence
suggests that certain forms of Se might exclusively elevate the level of Se-binding protein
(SBP) (suggested to play a role in tumour suppression) rather than GPX (Mandair et al.,
2014). Amoako et al., addressed the issue of stability of un-encapsulated Se species in
selenium supplements (comprising multiple complex species in yeast-based and nonyeast-based supplements), exposing their predisposition to interconvert at the expense of
long-term stability (Amoako, Uden and Tyson, 2009). No other work has focused on the
encapsulation of organic Se species prior to their assessment as either supplementary,
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chemo-preventative or therapeutic agents. The evidence provided in this thesis presents
a formulation cargo system that can be used in future research in Se
supplementation/therapy which may prevent biases in this research area and possibly lead
to industrial applications.
Lastly, the SeCys2 fCs NPs formulation developed in this work, may warrant a future
investigation as a potential chemotherapeutic, based on literature evidence and the ability
of the formulation to provide stability against Se degradation. Over the last decade,
chemotherapy and targeted therapy combinations have helped to significantly improve
patient outcomes (Kemp et al., 2016). Although chemotherapeutic agents can be highly
effective, small biological differences in the host and cancer cells makes treatment more
challenging (Hoelder, Clarke and Workman, 2012). Often, antineoplastic agents are toxic
chemicals and biologics designed to destroy cancer cells. However, while exerting their
desired pharmacological effects, they can often precipitate severe toxic effects. Nausea,
hair loss, compromised immune system, cardiotoxicity, are some of the adverse physical
effects of these agents (Keefe and Bateman, 2012). As such, strategies are evolving to
reduce or eliminate these unfavourable side effects by targeted delivery of the
chemotherapeutic agent to the specific areas of cancer (Byers et al., 2016). Molecular
targeting for cancer chemoprevention has recently been focused on intracellularsignalling cascades (Wada, 2012). The anticancer activity of Se has been postulated to
include inhibition of cell proliferation, modulation of redox state, detoxification of
carcinogen, stimulation of the immune system, inhibition of angiogenesis and induction
of cell apoptosis (Sanmartín et al., 2011; Narayan et al., 2015; Wrobel, Power and
Toborek, 2016). In an in vitro study, SeCys2 was identified as a novel agent with a broadspectrum of antitumour activity, whereby a panel of eight human cancer cell lines was
shown to be susceptible to SeCys2, with IC50 values ranging from 3.6 to 37.0 μM (Chen
338

and Wong, 2009). More specifically, SeCys2 has been reported to induce normalisation
of the tumour vasculature, and a 4-fold increase in intra-tumoral doxorubicin levels, upon
oral administration in mouse models, indicating its selective uptake by tumour tissues in
vivo (Fernandes and Gandin, 2015). Studies by Estevez et al., assessed the effects of Cs
stabilised, elemental Se (Se0) NPs on cell proliferation, apoptosis and cell cycle pattern
in HepG2 cells and compared their peformance to other Se species. They found that the
Se0 NPs, stabilised with Cs, modestly inhibit a key enzyme known as CDK1, which is
responsible for cell division and postulated that Se could be used as a chemotherapeutic
by causing cell cycle arrest in cancer cells through CDK1 inhibition. Interestingly, they
observed that native SeCys2 induced a more potent inhibitory effect on CDK1, but argued
that strong inhibition of this enzyme would likely be toxic to both cancerous and healthy
cells (Estevez et al., 2014). It is worth noting that, in that study, the authors neglected to
stabilise the SeCys2 with Cs for use as a control, so a true conclusion cannot be drawn on
whether the Se0 NPs were solely responsible for the observed effects and not the synergy
between the Cs and Se0 complex.
A challenge in the use of Se as a cancer therapeutic is to deliver redox active selenium,
preferentially directly to the tumour and/or metastatic cells (Misra et al., 2015).
Interestingly, a significant number of Cs-based NPs have been reported to be selectively
accumulated into tumour sites, primarily owing to the enhanced permeability and
retention (EPR) effect (Prabaharan, 2008; Na et al., 2011; Maeda, Nakamura and Fang,
2013). The EPR affect relates to the defective tumour vasculature and disorganised
endothelium with poor lymphatic drainage at the tumour sites, allowing for the selective
accumulation of macromolecular drugs in tumour tissues (Wolinsky and Grinstaff, 2008).
As Cs is biodegradable and easily metabolised from the body, it has become quite
clinically attractive for use in drug delivery applications (Kumari, Yadav and Yadav,
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2010). Moreover, the biocompatibility of Cs is dependent on its purity, MW, and DDA%
and, as this work evidenced, can be modulated accordingly, given the right production
conditions. Considering the apparent selective cancer targeting properties of both SeCys2
and Cs and the reported antitumour activity of SeCys2, in addition to the observed ability
of Cs to confer protection to non-cancerous cells, it seems reasonable to suggest that the
SeCys2 loaded fCs NPs, as described in this work, may warrant investigation as anticancer
formulations.
Crustacean derived Cs is dependent on the source itself, whereby, to yield a product with
reproducible properties, the same species must be harvested, at the same time
(seasonally), in the same geographical location and at the same life stage cycle and
different batch materials require different processing conditions (Weinhold et al., 2009).
fCs offers several advantages over its crustacean counterparts, owing to the highly
controlled environments in which it is cultivated, year-round growth that is not seasonally
dependant and significantly lower heavy metal association than that of crustaceans
(Muzzarelli et al., 2012). The present work shows the reproducibility of laboratory based
fCs production as well as the ability to match industry standards. However, to make fCs
sustainable and competitive in the market, especially for pharmaceutical applications, the
assessment of reproducibility of fCs product batches is imperative. Currently, there are
two companies that are actively selling enzymatically derived fCs for weight-loss
products (Kiytozyme, Belgium) and for R&D applications (Mycodev, Canada) at a cost
range of €177-213 per gram (www.sigmaaldrich.com). There are many potential reasons
for this apparent high cost, which may relate to the enzymes being employed, the initial
investment cost of the scale-up instrumentation and their subsequent energy
consumption. Although it is difficult to provide an exact comparison of cost of the fCs
produced in this small-scale work, with that of commercially available products, a crude
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estimate can be made. For instance, the initial investment of a MARS 6, 40 vessel
turntable microwave, as used in this project, is €15,000 and it can process 10 g of chitin
at a time, using > 400 mL of NaOH (30 % w/v, ≈ €15) with a 15 min reaction time in a
600W microwave at a cost €23.79 per Kwh (www.energyusecalculator.com, accessed in
May 2018). The weight yield of fCs using this method is 5.5g, with a DDA% of 86 ± 6 %
and MW of 180±19 kDa. Excluding the initial €15,000 investment of the microwave, the

apparent cost of fCs using the method developed in this research is ≈ €6.2/g, showing
considerable potential for a mark-up that would quickly recover the initial investment
cost and offer a significantly more competitive price compared to the current market
providers.
Consumers may see purchasing non-animal products as an ethical obligation, whilst
others trade it off against price and other product attributes (Vanhonacker et al., 2007;
Vanhonacker and Verbeke, 2014). Varying preferences and perceptions may also stem
from norms and values within specific subcultures, such as those linked to religious (e.g.
pigs in Muslim and cows in Hinduism countries) and cultural differences at the national
level (Van Riemsdijk et al., 2017). Regardless, with the rise in consumer demand for nonanimal constituents in food (Bord Bia Insight Centre, 2016), cosmetic (Hennigs,
Karampournioti and Wiedmann, 2016) and pharmaceutical (Murtaugh et al., 2017)
products, industrial companies are very interested in fungal-based alternatives, (Martin
Zaki, Lambson Ltd, private communication) for use in product formulations. As such,
fCs, produced as per this current work, may be well placed to address this demand and
would warrant further investigation.
Additionally, in this thesis, the Cs derivative TMC, which is a permeation enhancer
presently used in both academic and pharmaceutical research and development (Kulkarni
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et al., 2017), was produced from fungal chitosan. A recommendation for future work
regarding further optimisation of TMC production from fCs would be the employment of
parallel synthesis for potential optimisation of the DDQ % and further reduction in the
extent of O-methylation. For example, variation of the alkylhalides (e.g. chloromethane,
bromomethane), bases (e.g. KOH, K2CO3), and/or aprotic solvents (e.g. DMF, DMSO)
employed may identify improved synthetic routes. It would also be interesting to employ
a CCD to investigate the use of microwave irradiation for the synthesis of TMC, which
would allow for both optimisation and comparison to the conventional method employed
in this research, as it may result in a significantly reduced production time, similar to that
attained for the fCs.
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food derived antihypertensive tri-peptides, Isoleucine-Proline-Proline and LeucineLysine-Proline encapsulated into a chitosan based nanoparticle system. Innovative Food
Science

&

Emerging

Technologies,

https://doi.org/10.1016/j.ifset.2017.07.002
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44,

139–148.

Conference Presentations
Innovations in Encapsulation, Royal Society of Chemistry (RSC) conference, Dec 2017,
London, UK. Giuliana Vozza, Minna Khalid, Hugh J. Byrne, Sinead Ryan and Jesus
Frias. Oral presentation – “Methylselenocysteine loaded chitosan:zein nanoparticles:
Formulation, characterisation, and in vitro evaluations”
American Association of Pharmaceutical Scientists (AAPS) conference, Nov 2017, San
Diego, California. Poster presentation – “Formulation, characterisation and in vitro
assessment of Selenocystine loaded chitosan nanoparticles for oral delivery”
The European Federation of Food Science & Technology (EFFoST) conference, Nov
2017, Sitges, Spain. Giuliana Vozza, Hugh J. Byrne, Sinéad Ryan and Jesús Frías Poster
presentation – “Isolation and characterisation of chitin and chitosan from the cultivated
mushroom Agaricus bisporus”
The International Union of Food Science and Technology (IUFoST) conference, Aug
2016. Dublin, Ireland. Giuliana Vozza, Minna Khalid, Hugh J. Byrne, Sinéad Ryan and
Jesús Frías Poster presentation – “Protein-polysaccharide delivery systems: A
systematic approach for the formulation and optimisation of selenomethionine-loaded
chitosan: zein nanoparticles”
United Kingdom and Ireland Controlled Release Society (UKICRS) symposium, April
2016. Giuliana Vozza, Minna Khalid, Hugh J. Byrne, Sinéad Ryan and Jesús Frías Poster
presentation - “Preparation, optimization and characterization of selenium-loaded
chitosan nanoparticles for oral delivery”
The European Federation of Food Science & Technology (EFFoST) conference, Nov
2015, Athens, Greece. Giuliana Vozza, Minna Khalid, Hugh J. Byrne, Sinéad Ryan and
Jesús Frías Oral presentation - “Encapsulation efficiency and physicochemical
properties of a selenomethionine-loaded chitosan nanoparticles formulation for oral
delivery”
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Delivery of Functionality in Complex Food Systems (DOF), July 2015, Paris, France.
Giuliana Vozza, Minna Khalid, Hugh J. Byrne, Sinéad Ryan and Jesús Frías Poster
presentation - “Preparation and characterisation of selenomethionine-loaded chitosan
nanoparticles for oral delivery”
43rd Institute of Food Science and Technology of Ireland (IFSTI), Nov 2014. Dublin,
Ireland. Giuliana Vozza, Minna Khalid, Hugh J. Byrne, Sinéad Ryan and Jesús Frías
Poster presentation - “Preparation and characterization of selenomethionine loaded
chitosan/TPP nanoparticles for oral delivery”.
Modules
•

PGD (Postgraduate Demonstrator) Training (Sept 2014)

•

Applied Modelling in Environment, Food and Health (Sept 2015)

•

Thesis writing group workshop (July 2015)

•

PhD (and beyond) master class (Feb 2016)

•

Science Writing and Presenting Skills (April 2016)

•

Statistics for the Agri-Food Researcher (Aug 2017)

•

Agri-Food Career Management (Dec 2017)

•

Leadership Skills for the Agri-Food sector (Jan 2018)
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